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Thesis Outline 
 
 
Elucidating the mechanism by which nerve endings can achieve quantal release of 
neurotransmitters into the synaptic cleft is of fundamental importance. Release occurs via 
Ca2+-regulated exocytosis which involves a highly complex series of steps. It is dependent 
on the membrane excitability of the nerve endings controlled by voltage-sensitive cation 
channels, and can also be modulated by way of pre-synaptic receptors. Naturally-occurring 
neurotoxins from diverse sources such as snakes and micro-organisms have been found to 
facilitate or inhibit transmitter release and, in doing so, helped the identification of pre-
synaptic proteins responsible for neuro-exocytosis and its regulation. Both over- and under-
active transmitter release cause significant clinical symptoms and, therefore, compounds 
that restore normal function would be of great value as therapeutics for such conditions 
(Dolly, 2005). The work described in this thesis relates to the regulation of exocytosis; both 
overactive (Section A) and underactive (Section B).  
 
Botulinum neurotoxins (BoNTs) produced by Clostridium botulinum, are very specific 
blockers of acetylcholine release from peripheral nerve endings. This action has been 
exploited to explore the process of regulated exosytosis including the vital part played by 
the target of these toxins, SNARE proteins, leading to their use as theraputic agents for 
disorders due to over-active skeletal muscle. BoNT complex (serotype A) is used for 
treating dystonias and spasticity and has also been proved useful for smooth muscle 
disorders (Dolly, 2005). Interestingly, it has been observed that the toxin alleviates pain 
associated with various conditions with or without accompanying excess muscle 
contractions (Aoki, 2001). These anti-nociceptive effects have been demonstrated in a 
number of applications including the treatment of tension-associated headaches, and 
chronic pain, active areas of research (Aoki, 2001). As early indications suggest that the 
toxin is effective in the treatment of refractory joint pain associated with chronic arthritis 
(Mahowald et al., 2006), Section A of this thesis explores its possible mechanism of action 
in this application. 
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In contrast to the blocking activity of BoNTs, dendrotoxins isolated from the venoms of the 
green and black mamba snakes, facilitate acetylcholine (Ach) release at the neuromuscular 
junction due to a potent and selective inhibition of some members of the Kv1 family of 
voltage-activated K+ channels. Blockade of their outward hyper-polarising current increases 
transmitter efflux leading to repetitive firing and even some epileptic-like activity. Through 
selective inhibition of channel subtypes, their specific roles in neurons can be better 
understood (Dolly, 2005). Dysfunction of Kv1 channel subtypes underlie several human 
diseases including Episodic Ataxia I and some types of epilepsies (Lehmann-Horn and 
Jurkat-Rott, 1999; Manganas et al., 2001; Zuberi et al., 1999) and their blockade in 
experimental models of multiple sclerosis has been shown to improve inefficient nerve 
impulse conduction (Smith et al., 2000). Specific blockers of K+ channels could act as 
potential therapeutics for certain conditions, returning under-active neurotransmitter release 
back up to normal levels. Understanding the interactions of a range of Kv1 channel 
blockers with heteromultimeric Kv1 channels mimicking those found in mammalian brain 
is the focus of Section B of this thesis. 
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Section A 
 
An exploration of the possible mechanism 
of action of BOTOX® in the treatment of 
chronic pain and inflammation resulting 
from arthritis 
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Chapter 1 
 
1.1 Introduction 
 
1.1.1 Pathogenesis of rheumatoid arthritis 
Rheumatoid arthritis (RA) is the most common auto-immune disease (Nishimoto and 
Kishimoto, 2004), affecting 1% of the population (McInnes and Schett, 2007). Despite this, 
there is no evidence yet for a specific auto-antigen (Fox, 1997) and the etiopathogenesis 
(cause and development) of the disease remains far from clear (McInnes and Liew, 1998). 
Without doubt though, this is a chronic inflammatory condition (Beeton et al., 2003; 
Keeble and Brain, 2004; McInnes and Liew, 1998; McInnes and Schett, 2007) typically 
affecting distal synovial joints, characterised by “flare ups” and periods of remission 
(Keeble and Brain, 2004; McInnes and Schett, 2007), where dysregulation of the cellular 
immune system and cytokine network results in severe pain (Beeton et al., 2003; Keeble 
and Brain, 2004). This, coupled with associated extra-articular disease, significantly 
impacts morbidity and mortality (Beeton et al., 2003; McInnes and Schett, 2007). 
Synoviocytes (cells of the synovial membrane) proliferating uncontrollably attach to the 
surface of the joint causing infiltration of mononuclear cells (e.g. lymphocytes, dendritic 
cells, macrophages) which produce pro-inflammatory cytokines. These cytokines induce 
further synoviocyte propagation and activation resulting in the formation of invasive and 
destructive pannus. Eventually oedema forms in the joint, the pannus invades the joint and 
along with chondrocytes (cells of the cartilage), produce proteolytic enzymes causing 
destruction of adjacent cartilage and release of more pro-inflammatory cytokines (Kay and 
Calabrese, 2004). The function of osteoclasts (responsible for bone resorption) is also 
dysregulated, altering the balance of normal bone turnover and resulting in overall 
resorption (Kay and Calabrese, 2004; McInnes et al., 2003). These processes lead to the 
classical symptoms of RA: swollen, painful joints with loss of mobility leading ultimately 
to joint erosion and deformity. Hence, there is loss of movement and further pain as well as 
systemic effects [caused by release of cytokines from inflamed joints (McInnes and Schett, 
2007)] such as inflammation of the lining of organs (Kay and Calabrese, 2004).   
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1.1.2 The role of inflammatory mediators  
As a specific auto-antigen trigger or alternative cause of RA remain unknown, potential 
therapeutics have tended to focus on the increased levels of pro-inflammatory cytokines in 
affected joints, and the immune cells responsible for their production. Cytokines play a role 
in every stage of the pathogenesis of RA from contributing to auto-immunity, to 
maintaining chronic inflammation in joints, to the destruction of cartilage and bone 
(McInnes and Schett, 2007). However, as there are many cytokines over-expressed in 
affected joints including interleukin (IL)-1β, IL-6, IL-15 and tumour necrosis factor alpha 
(TNFα) (McInnes and Schett, 2007), elucidating which are the most important was 
imperative (Feldmann et al., 2005). TNFα is crucial in controlling inflammatory and 
immune reactions resulting from disease and IL-1β [the secreted form of IL-1 typically 
considered more important as it acts on neighbouring cells (Kay and Calabrese, 2004)] is 
implicated in conditions that result in chronic inflammation (Kaneyama et al., 2005). IL-1 
and TNFα are involved in the communication between cells in affected joints and, 
importantly, each cytokine up-regulates production of the other (Kay and Calabrese, 2004). 
Examination of cytokine interactions in cultured synovial cells from rheumatoid joints 
found that blockade of TNFα reduced not only the synthesis of IL-1 but all pro-
inflammatory cytokines found in diseased joints (Feldmann et al., 2005), thereby, revealing 
a central role for TNFα in the regulation of synovial inflammation (McInnes and Liew, 
1998) and, therefore, the pathogenesis of RA (Grimsholm et al., 2005). The streptococcal 
cell wall arthritis model in IL-1 and TNFα-deficient mice has gone some way to 
distinguishing the roles of these 2 cytokines revealing TNFα to be important in the 
inflammatory process and implicating IL-1 in pathways that result in joint damage (Kay 
and Calabrese, 2004). IL-6 is another cytokine over-expressed in rheumatoid joints 
(McInnes and Schett, 2007) that has a pivotal role in the disease pathogenesis (Nishimoto 
and Kishimoto, 2004). It is produced by a variety of cell types and regulates immune plus 
inflammatory responses to infection or injury (Kaneyama et al., 2005; Nishimoto and 
Kishimoto, 2004). Despite the array of factors implicated in RA, the crucial functions of 
these 3 cytokines have not only been demonstrated in vitro but also in vivo. Various 
therapies attenuating the actions of these cytokines are in widespread clinical use; TNFα 
(Feldmann et al., 2005; McInnes and Schett, 2007), licensed for clinical use; IL-1 (Kay and 
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Calabrese, 2004; McInnes and Schett, 2007), and in late stage clinical trials; IL-6 (McInnes 
and Schett, 2007; Nishimoto and Kishimoto, 2004).  
 
1.1.3 Immune cells and rheumatoid arthritis 
Given the undeniable importance of cytokines in RA, the cells that produce them as a 
means of communication (Kay and Calabrese, 2004) are also under scrutiny. The role of T-
cells was once thought to be central to disease pathogenesis given not only their presence in 
large numbers in diseased joints (Fox, 1997; McInnes and Schett, 2007), but the fact that 
specific subsets accumulate (Fox, 1997). A possible genetic involvement in RA involving 
specific class II MHC (major histocompatibility complex) alleles implies that CD4 T-cells 
responding to specific antigens are necessary for development of the disease. Onset of 
arthritic symptoms in animal models has also been shown to depend on T-cells (Fox, 1997; 
McInnes and Schett, 2007). However, disappointing results with therapeutics aimed at 
decreasing T-cell numbers have called into question their central role (Beeton et al., 2003; 
McInnes and Schett, 2007). Additionally, neutrophils are implicated in inflammatory and 
immune events; in RA, once activated (Kontny et al., 2002), they infiltrate affected joints 
accounting for 90% of the cells found in the synovial fluid (SF) (Beeton et al., 2003; Kay 
and Calabrese, 2004). They are concentrated at sites of erosion (Beeton et al., 2003) and 
destroy connective tissue via release of proteolytic enzymes and oxygen free radicals 
(Kontny et al., 2002). When neutrophils are activated they release hypochlorous acid 
(which contributes to the destruction of bacteria). Taurine is a dominant free amino acid in 
the cytoplasm of neutrophils and is a scavenger for hypochlorous acid.  The two 
compounds react together to form taurine chloramine, which has potent anti-inflammatory 
activity. In neutrophils from patients with RA the formation of taurine chloramine is 
impaired (Kontny et al., 2002). Furthermore, the normally short life-span of these cells is 
extended from hours to days once they enter the site of inflammation (Beeton et al., 2003; 
Kay and Calabrese, 2004). This is coupled with the release of inflammatory mediators 
including IL-1β, TNFα and IL-6 (Beeton et al., 2003; Kasama et al., 2000; Kontny et al., 
2002; McInnes and Schett, 2007). Despite this, studies on possible RA therapies that would 
target these cells are lacking (Beeton et al., 2003). B-cells produce auto-antibodies and 
immunoglobulins that can form complexes which trigger not only local inflammation, but 
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also release of IL-1 and TNFα by macrophages (see below) (Kay and Calabrese, 2004; 
McInnes and Schett, 2007). They are a further source of the pro-inflammatory cytokines 
key in the arthritic diseased state: Il-1β, TNFα and IL-6. Hence, the use of B-cell depleting 
therapies have produced some significant and sometimes long-term positive results 
(McInnes and Schett, 2007). Arguably the primary source of inflammatory mediators in 
affected joints [including among many others Il-1β, TNFα and IL-6 (McInnes and Schett, 
2007)] is macrophages (Kay and Calabrese, 2004). These are found in close proximity to T-
cells and may act as antigen presenting cells and, in doing so, continue the immune 
response (Kay and Calabrese, 2004). While other cell types are involved in cartilage and 
bone erosion, they are less important in the production of the inflammatory factors 
described here. 
 
1.1.4 The neural influence 
While the immune system undoubtedly has a huge role to play in the development and 
continuation of RA, there is evidence for involvement of the nervous system. Inflammation 
of symmetrical joints suggests a neural influence and neurogenic inflammation, which is 
involved in the onset and progression of joint disease, has been shown by several groups to 
be involved in RA (Keeble and Brain, 2004). Stimulation of sensory nerves and a 
subsequent release of neuropeptides, mediates this type of inflammation which is 
characterised by oedema formation, increased blood flow, extravasation and inflammatory 
cell recruitment (Grimsholm et al., 2005; Keeble and Brain, 2004). It was, therefore, 
important to identify the neuropeptide(s) responsible. Substance P (SP) is the best 
characterised and evidence for its role in RA is plentiful. Following release from sensory 
neurons, and subsequent binding to the neurokinin 1 (NK1) receptor, SP exerts its pro-
inflammatory effects; increased microvascular permeability leading to inflammatory 
swelling as well as inflammatory cell accumulation resulting in vasodilation (Keeble and 
Brain, 2004). Levels of SP are increased in SF from RA affected joints, where it is 
responsible for increased synoviocyte proliferation, enhanced release of pro-inflammatory 
mediators and destructive enzymes including collagenase, presumably due to the presence 
of NK1 receptors on rheumatoid synoviocytes (Grimsholm et al., 2005). Not only are SP-
positive nerve fibres found in rheumatoid synovium and SP-sensitive cells occur on blood 
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vessels in the joint (contributing to vasodilation and inflammatory cell accumulation), but 
SP-containing neurons in the bone marrow communicate with the synovium (Keeble and 
Brain, 2004). As well as a pro-inflammatory role, SP is also involved in central pain 
pathways as a chief mediator in “wind up” which leads to central sensitisation, a feature of 
chronic pain conditions. Neurons in the dorsal horn of the spinal chord develop increased 
sensitivity and enlarged receptive fields (Keeble and Brain, 2004) as a result of peripheral 
inflammation (Ji et al., 2003). Indeed, spinal NK1 receptors are vital for the persistence of 
arthritic pain (Keeble and Brain, 2004). Calcitonin gene related peptide (CGRP) is another 
neuropeptide involved in pain signalling and occurs at elevated levels in SF from RA joints 
(Grimsholm et al., 2005). Like SP, it also causes neurogenic inflammation (Helyes et al., 
2006). 
 
1.1.5 Interactions between the immune and nervous systems 
The immune controlled reactions in RA do not work in isolation from the neural processes. 
The nervous and immune systems are known to interact in a reciprocal fashion (Freidin and 
Kessler, 1991) not only by secretion of neuropeptides at the site of inflammation during 
immune responses but via the production of these mediators by immune cells (Grimsholm 
et al., 2005). Conversely, cytokines can function as growth and differentiation factors in the 
nervous as well as the immune system (Shadiack et al., 1993). Some studies have found 
correlations between SF levels of SP and various pro-inflammatory cytokines such as IL-6 
and TNFα in long-standing (greater than 1 year) RA as well as a correlation between SP 
levels and joint inflammation (Grimsholm et al., 2005). However, there are claims that 
serum levels of SP do not correlate with disease activity (Keeble and Brain, 2004). 
Undoubtedly though, IL-1β induces SP expression in cultures of superior cervical 
ganglionic neurons (SCGN) and SP increases IL-1 production in B-cells (Freidin and 
Kessler, 1991) and modulates release of IL-1, TNFα and IL-6 from blood monocytes 
(macrophage precursors) (Grimsholm et al., 2005).  
Another cytokine with a role in the “cross-talk” between the nervous and immune systems 
is leukaemia inhibitory factor (LIF). It is an IL-6 type cytokine named for its ability to 
induce terminal differentiation in myeloid leukaemia cells. It also has several other 
functions including regulating blood cell development and T-cell maturation in the immune 
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system, and gene expression and neuronal response to injury in the nervous system 
(Patterson, 1994). Levels are increased in inflammatory conditions such as RA (and 
osteoarthritis) although the source is not clear (Patterson, 1994). However, LIF has been 
shown to be produced by IL-1β, and the former acts to induce the production of SP 
(Shadiack et al., 1993) in SCGN cultures; this process is dependent on the presence of non-
neuronal cells in the cultures, implying that glial cells are the source of LIF not only in 
events concerning solely the nervous system but those involving the immune system also 
(Patterson, 1994; Shadiack et al., 1993). So inflammation (and the presence of 
inflammatory mediators) induces LIF which, in turn, triggers production of neuropeptides 
(including SP and CGRP) in sensory neurons that do not usually express them, and through 
the induction of neurogenic inflammation, these neuronal mediators contribute directly to 
the inflammatory process (Patterson, 1994).  
 
1.1.6 Osteoarthritis 
Osteoarthritis (OA), the most common joint disease, chiefly affects the hands, spine, hips 
and knees. Changes in bone below the cartilage and loss of cartilage in the joint lead to pain 
and disability. It is thought that various processes, with a variety of causes or origins, 
potentially coupled with existing pre-dispositions, result in this joint disease. Cartilage 
integrity, vital for healthy joints, is maintained by the balance between cytokine-controlled 
anabolic and catabolic processes. However, the contribution of cytokines to joint 
destruction is not as well understood in OA as it is in RA. Despite this, it seems that the 
cytokine profile of SF from OA patients is the same as that of RA, although individual 
factors are present at lower concentrations. It is thought, therefore, that either OA joints are 
more sensitive to cytokines and damage occurs at lower concentrations or the cytokines 
themselves are not responsible for joint damage (Westacott and Sharif, 1996).  
Joint cartilage is composed of collagen, water and proteoglycan (PG). IL-1 is an inducer of 
cartilage degradation acting by suppressing production of collagen, increasing destructive 
enzyme levels and interfering with the ability of chondrocytes to produce PG. Despite this, 
IL-1 in the SF of OA joints cannot always be detected. An increase in the number of IL-1α 
and β secreting macrophages in OA compared to non-arthritic joints demonstrates that 
diseased areas can produce IL-1. Furthermore IL-1 receptor numbers are increased on OA 
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chondrocytes suggesting that cartilage in these joints could be more sensitive to damage by 
IL-1 compared to healthy joint cartilage. TNFα also degrades cartilage although less 
potently than IL-1 and, similarly, its detection in OA SF is not consistent. Interestingly, 
there is no correlation between IL-1 and TNFα levels demonstrating that in OA, at least, 
these cytokines are not produced by the same cells in response to a common stimulus (the 
opposite is thought to be the case in RA). Like IL-1, there are increased TNFα receptor 
levels on OA chondrocytes, perhaps conferring increased sensitivity of cartilage to this 
cytokine thereby enhancing destruction. High levels of IL-6 in diseased joints have been 
hypothesised to indicate disease activity. Both IL-1 and TNFα induce IL-6 production 
which is necessary for IL-1 mediated inhibition of PG synthesis, a contributing factor to 
cartilage damage (Westacott and Sharif, 1996). As well as a role in RA, LIF has also been 
found in SF from OA patients (Patterson, 1994; Westacott and Sharif, 1996). It is thought 
to be involved in the degradation of joint cartilage, possibly by stimulating the loss of PG 
(Westacott and Sharif, 1996). However, a role for LIF in immune and nervous system 
communication in OA joints has not been investigated.  
 
1.1.7 Botulinum neurotoxins and their mechanism of inhibition of SNARE-mediated 
exocytosis 
There are seven distinct serotypes of BoNT (A-G) which are produced by the bacterium 
Clostridium botulinum. The disease caused by these toxins, botulism, is characterised by 
flaccid paralysis caused by inhibition of synaptic transmission resulting from blockade of 
Ach release at peripheral nerve endings (Dolly and Aoki, 2006; Humeau et al., 2000). The 
toxin is produced as a single chain, 150 kDa polypeptide, but cleavage one-third of the way 
from the N-terminus into a 100 kDa heavy chain and 50 kDa light chain is necessary for 
full biological activity. However, the 2 resultant chains remain connected by a disulphide 
bridge and non-covalent interactions. Following binding of the toxin to high affinity sites 
on pre-synaptic motor nerve endings, acceptor-mediator endocytosis results in 
internalisation followed by reduction of the inter-chain bridge and the light chain is 
released into the cytoplasm (Humeau et al., 2000). BoNT light chains have zinc-dependent 
protease activity and cleave SNARE proteins, with serotypes targeting only specific 
SNAREs (Dolly and Aoki, 2006; Humeau et al., 2000). SNARE (soluble NSF (N-
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ethylmaleimide sensitive factor) attachment protein receptor)-mediated exocytosis is 
required for Ach release and SNARE cleavage by BoNTs prevents this process (Humeau et 
al., 2000). For exocytosis to occur, vesicles containing Ach must contact the target 
membrane (i.e. the plasma membrane) through docking. The vesicle membrane is then 
integrated completely into the target membrane in a multi-step process - priming and fusion 
(Rizo and Sudhof, 1998). This is dependent on the interaction of SNARE proteins on the 
vesicle and target membranes, v-SNAREs and t-SNAREs, resulting in the formation of a 4-
helix bundle and fusion of the two membranes. The energy released from the formation of 
the very stable SNARE complex is thought to be sufficient to fuse the membranes allowing 
efflux of the vesicle contents (Jahn and Scheller, 2006; Rizo and Sudhof, 1998). At the 
neuromuscular junction, the v-SNARE is vesicle-associated membrane protein (VAMP) 
and the t-SNAREs are SNAP-25 (synaptosomal-associated protein, with molecular mass 25 
kDa) and syntaxin (Dolly and Aoki, 2006; Rizo and Sudhof, 1998). VAMP is cleaved by 
BoNTs /B, /D, /F and /G, SNAP-25 by BoNTs /A, /C1 and /E and syntaxin by BoNT/C1 
(Dolly and Aoki, 2006; Humeau et al., 2000). Many homologues of these proteins exist in 
various tissues and some are cleaved by the BoNTs. Cleavage can also be species specific. 
In almost all cases, alterations in toxin potency on various homologues/species are due to 
mutations in amino acid sequence of the SNAREs in question although occasionally it is 
due to an absence of receptors to a given BoNT serotype in a particular species (Humeau et 
al., 2000).  
 
1.1.8 Aims of the study 
BOTOX®, a pharmaceutical preparation containing BoNT/A complexed with 
haemagglutinin (Dolly and Aoki, 2006), has proved successful in the treatment of severe, 
chronic pain associated with joints affected by both RA and OA (Mahowald et al., 2006). 
BoNT/A can inhibit SNARE-mediated exocytosis of neuropeptides from sensory nerves – 
C and Aδ fibres – preventing “wind-up” and central sensitisation (Aoki, 2001; Dolly and 
Aoki, 2006), processes that have been shown to be involved in RA (Keeble and Brain, 2004) 
(see above). Notably, LIF in the pancreas has been shown to cause an alteration in the 
phenotype of sympathetic neurons; the transmitter released changes from norepinephrine to 
Ach – an affect that can be replicated in cultured sensory neurons (Patterson, 1994; 
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Shadiack et al., 1993). Given that the toxin has a high affinity for cholinergic neurons, 
conferred by receptors present at nerve endings (Aoki, 2001; Dolly and Aoki, 2006), 
perhaps, the presence of LIF in arthritic joints can influence the phenotype of the 
innervating neurons resulting in heightened toxin sensitivity. Furthermore, there is much 
evidence that the release of cytokines implicated in the pathogenesis of these diseases is 
SNARE-mediated (Chai et al., 2006; Martin-Martin et al., 2000; Mollinedo et al., 1999; 
Murray et al., 2005b; Pagan et al., 2003), and provided the cells can mediate their uptake, 
BoNTs could selectively cleave these proteins preventing exocytosis of the inflammatory 
mediators. It is, therefore, reasonable to hypothesise that the mechanism of action of 
BOTOX in the treatment of chronic pain is related to SNARE inactivation in cytokine-
releasing cells. Demonstrating reduction by BoNTs of neuropeptide and cytokine release 
and associated SNARE cleavage in cells would confirm the ability of BoNTs to act directly 
on immune cells. Substantiating this hypothesis is a crucial step in defining the action of 
BOTOX® and, hence, characterising the target(s) of this therapeutic in the treatment of 
arthritis. 
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1.2 Materials and Methods 
 
1.2.1 Materials 
SF samples were provided by Dr. M. Mahowald, Minnesota Medical School, MN, USA. 
The Bioresources Unit at Dublin City University provided Sprague-Dawley rat pups. 
BoNT/B, /C1, /D, /E and /F were purchased from Metabiologics. List Laboratories 
provided BoNT/A in fully active di-chain form. Anti-syntaxin antibody (HPC-1, 
demonstrated in house to react with mouse, rat and human proteins) as well as alkaline 
phosphatase (AP) and horseradish peroxidase (HRP) conjugated secondary antibodies were 
purchased from Sigma. SMI-81 antibody (anti-SNAP-25, reactive with mammalian protein) 
was bought from Sternberger Monoclonals. Anti-VAMP-2 and anti-SNAP-23 antibodies 
(both reactive with human, rat and mouse proteins) were from Synaptic Systems. The pan 
VAMP antibody (HV62, reactive with mammalian proteins) was produced in-house. 
Fluorescently conjugated secondary antibodies were bought from Molecular Probes [Alexa 
Fluor (AF) 488] and Jackson Immunoresearch [Indocarbocyanine 3 dye (Cy3)]. 
SuperSignal West Pico Luminol/Enhancer solution was from Pierce. ELISA kits for TNFα, 
IL-1β, IL-6, LIF and SP, and CGRP were purchased from R&D Systems and SPIbio, 
respectively. Leibovitz’s (L15) medium, trypan blue, RPMI-1640 medium (RPMI), L-
glutamate, phosphate buffered saline (PBS) used for tissue culture and 
antibiotic/antimicotic (ab/am) solution were from Gibco. Other tissue culture reagents and 
all other chemicals were sourced from Sigma.  
 
1.2.2 Details of synovial fluid donors and sample preparation for analysis 
As part of a double blind, randomised, placebo-controlled clinical trial, SF samples were 
taken from arthritic patients before and after intra-articular (IA) injection with BOTOX® or 
placebo as detailed in Table 1.1 and stored at -80°C until used. In preparation for ELISA 
analysis, samples were thawed on ice and sonicated.   
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1.2.3 ELISA of synovial fluid samples and cell supernatants of botulinum neurotoxin-
treated macrophages  
ELISAs were carried out using kits, according to the manufacturers’ instructions. For all 
factors tested, levels in test samples were calculated from standard curves produced from 
absorbance readings of wells containing known concentrations of standard solutions. 
 
1.2.3a TNFα, IL-1β, IL-6 Samples and standards were incubated overnight at 4°C in 96-
well plates pre-coated with the relevant capture antibody. After thorough washing, plates 
were incubated with a second biotinylated antibody for 2 h at room temperature. Following 
another washing step, plates were incubated with streptavidin-HRP for 20 min at room 
temperature in the dark, washed, and substrate added for 20 min in the dark. Stop solution 
was then applied and the plate read using a microplate reader set to 450 nm with a reference 
wavelength of 570 nm.  
1.2.3b LIF Standards and samples were reacted overnight at 4°C in 96-well plates pre-
coated with a monoclonal antibody against LIF. After thorough washing, plates were 
incubated with a second antibody conjugated to HRP for 2 h at room temperature. Plates 
were developed with substrate solution for 20 min, in the dark, at room temperature, and 
after the addition of stop solution, read using a microplate reader as above. 
1.2.3c Substance P SP levels in test samples were determined using a competitive enzyme 
immuno-assay. Samples, standards and controls were placed in a 96-well plate pre-coated 
with a polyclonal antibody. Primary antibody (for SP) solution and SP conjugated to HRP 
were added to the wells and the plate was incubated overnight at 4°C. After washing, 
substrate solution was added to the wells and the plate incubated for 30 min, at room 
temperature, in the dark. Following the addition of stop solution, the absorbance at 450 nm 
of each well was determined using a microplate reader, with a reference wavelength as 
before. 
1.2.3d CGRP A 96-well plate pre-coated with a monoclonal antibody for CGRP was rinsed 
with wash buffer. Samples, standards and controls were placed into the plate; an anti-CGRP 
tracer was added and the plate incubated overnight at 4°C. The plate was washed again and 
incubated with Ellman’s reagent [5, 5'-dithiobis-(2-nitrobenzoic acid)] in the dark, at room 
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temperature for 30 min. Absorbance of wells at 405 nm was determined using a microplate 
reader. 
 
1.2.4 Isolation and culture of superior cervical ganglionic neurons; treatment with LIF and 
quantification of SNARE cleavage by botulinum neurotoxins 
Culturing of SCGNs was performed as discussed in (Mahanthappa and Patterson, 1998). 
Rat pups (1–3 day old) were killed with a lethal injection of Dolethal (50 mg/kg body 
weight). The animals were then placed on their backs and pinned through the front paws 
and snout. Using a dissection microscope, the trachea was exposed and cut through to 
reveal the oesophagus. Once the latter and the tongue were removed, the carotid artery was 
visible and ganglion (found at the artery branch) could be dissected out. Dispersal of 
ganglia was achieved with 1 mg/ml collagenase in L15 buffered for a 5% CO2 atmosphere 
(L15-CO2), for 30 min, with periodic agitation. Following trituration with a glass pipette, 
centrifugation, and resuspension in L15-CO2 to remove the collagenase, neurons were 
plated in wells previously coated with rat tail collagen. Typically, 10 ganglia were used per 
48-well plate. The following day, the antimitotic agent cytosine arabinoside (AraC), was 
added to the medium to prevent proliferation of non-neuronal cells. AraC was removed at 
day 2 after plating and replaced again on day 3. At this stage LIF (10 ng/ml) was added to 
some of the cells. Next day, AraC was removed but LIF was retained in test cultures. 
Medium (with and without LIF) was changed on day 9 after plating. Cells cultured for 12 
days were exposed to toxins (BoNT/A, /B, /C1 and /E), diluted in L15-CO2 to the 
concentrations detailed in Fig. 1.2 and 1.3, with 2 wells used for each concentration. The 
following day, the toxin containing medium was removed and cells harvested in lithium 
dodecyl sulphate (LDS) sample buffer, with pooling of wells for each concentration. After 
samples were heated to >80°C for 5 min, they were run on NuPAGE 12% Bis-Tris gels in 
MOPS buffer (50 mM Tris, 50 mM MOPS, 0.1% SDS, 1 mM EDTA, pH 7.7) for 2 h at 
175 volts. Gels were layered onto nitrocellulose membranes, sandwiched between several 
sheets of blotting paper, all previously soaked with transfer buffer [25 mM Tris, 192 mM 
glycine, 30% (v/v) methanol]. Wet transfer was carried out for 2 h at 25 volts. The resultant 
membranes were blocked with 3% TBS-T (20 mM Tris, 300 mM NaCl and 0.1% Tween 20, 
pH 7.5)/milk for 1 h at room temperature. After blocking, membranes were incubated with 
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mouse HPC-1 (1:2000), mouse SMI-81 (1:4000) and rabbit anti-VAMP-2 (1:200) diluted 
with 3% TBS-T/milk. After 1 h, three 10 min washes were performed with TBS-T and the 
membranes incubated for 1 h with the anti-mouse and anti-rabbit secondary antibodies 
conjugated to AP, made up in 3% TBS-T/milk. Membranes were washed twice for 10 min 
with TBS-T and once with AP buffer (200 mM Tris, 200 mM NaCl, 20 mM MgCl2, pH 9.5) 
before addition of substrate solution (40 mM BCIP/10 mM NBT in AP buffer). This was 
left for 5 – 30 min depending on colour development before a TBS-T wash and, finally, a 
rinse with TBS-T containing EDTA (20 mM) to stop the enzymic reaction. Band 
densitometric analysis was performed using GeneTools software to determine the amount 
of intact relative to cleaved protein. Where cleavage products were not detectable by 
antibodies, densities of the diminishing intact protein band were compared to that of an 
internal standard i.e. VAMP-2 was compared to syntaxin-1. 
 
1.2.5 Culture of lymphocytes and macrophages 
DG75 (an Epstein-Barr Virus-negative B cell line from a patient with Burkitt's lymphoma) 
cell line was cultured in RPMI medium supplemented with 10% foetal calf serum (FCS), L-
glutamate and ab/am solution. Cells were maintained in flasks as suspension cultures and 
grown to a density of 1x106 cells/ml before harvesting by centrifugation in a sterile tube at 
1000 g, for 5 min, at room temperature. When further cell propagation was required, a 
suitable volume of cells was returned to a culture flask containing fresh medium.  
Murine macrophages (J774 cell line) were also grown in RPMI supplemented with 10% 
FCS. Once confluent, they were detached from the base of the flask that they loosely attach 
to, by tapping the sides. Medium containing the cells was collected and cells were pelleted 
by centrifugation at 200 g for 5 min at room temperature. For continuation of cultures, cells 
were resuspended in 7 ml of fresh medium and 1 ml was used to seed a 75 cm2 flask 
containing 14 ml of RPMI. Cells were maintained for 3-4 days before splitting again.  
 
1.2.6 Treatment of murine macrophages with botulinum neurotoxins 
Macrophages cultured as previously described were plated in 6-well plates at a density of 4 
million cells/well. Medium was removed the following day and replaced with one 
containing 1 or 10 nM of BoNT/A, /B (1 nM only), /D, /E or /F in both the presence and 
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absence of 1 µg/ml lipopolysaccharide (LPS). After 24 h incubation, supernatants were 
collected and analysed using ELISAs. 
 
1.2.7 SNARE profiling of membranes prepared from cultured lymphocytes and 
macrophages 
Cells previously pelleted (at least 1x108 cells) were resuspended in ice-cold PBS and 
centrifuged at 200 g for 5 min; this was repeated twice before the cells were resuspended in 
5 ml of ice-cold distilled H2O. At this stage, a protease inhibitor cocktail was added at a 
1:1000 dilution (according to manufacture’s instructions, Sigma). Cells were then lysed by 
three freeze/thaw cycles; the tube containing cells was alternated between a beaker 
containing -80°C IMS and water at 37°C. The lysate was passed through a pre-cooled 25 
gauge needle 10 times, adjusted to 0.32 M sucrose and centrifuged at 1000 g for 10 min at 
4°C. The resultant supernatant was centrifuged at 105,000 g for 1 h at 4°C, the pellet 
solubilised in LDS sample buffer and heated to >80°C for 5 minutes once it had been 
passed through another 25 gauge needle. SDS-PAGE and Western blotting were performed 
as described previously. Antibodies used were as in section 1.2.4 with the inclusion of 
rabbit anti-SNAP-23 (diluted 1:1000), and in this case a HRP-conjugated secondary 
antibody. For development, three ten min washes with TBS-T were performed after the 
secondary antibody incubation, before substrate solution (SuperSignal West Pico 
Luminol/Enhancer solution) was added. After an appropriate incubation, according to the 
manufacturer’s instructions, excess liquid was removed and the membrane covered with a 
plastic sheet. Visualisation was with a G:BOX (Syngene) gel documentation system.   
 
1.2.8 Isolation of neutrophils from whole blood 
Human heparinized whole blood (30 ml) was separated into 4 tubes and diluted 1:2 with 
Hank’s balanced salt solution (HBSS). Each aliquot of diluted blood was layered over 10 
ml of ficoll-paque and centrifuged at 400 g for 30 min at room temperature. The plasma 
and ficoll-paque were aspirated off leaving a red blood cell pellet containing the neutrophils. 
The pellet was resuspended in 15 ml HBSS (twice the original volume of whole blood) and 
6% dextran (w/v in 0.85% NaCl solution) added to a final concentration of 1%. Red blood 
cells were left to settle out for 1 h at room temperature. The neutrophil-rich supernatant was 
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removed, diluted 1:2 with HBSS and centrifuged at 600 g for 10 min. Sometimes, red blood 
cell contamination was still present in the resultant pellet so, on these occasions, the red 
blood cells were briefly lysed with 2 ml ammonium chloride lysing buffer (168 mM NH4Cl, 
7.2 mM KHCO3, 1 mM EDTA, pH 7.3). HBSS (20 ml) was then added and another 
centrifugation step (at 600 g for 10 min) performed. The neutrophil pellet was resuspended 
in RPMI and cell number/viability ascertained using trypan blue and a haemocytometer. 
Typically in the region of 3 million cells were collected, with greater than 98% viability.     
 
1.2.9 Immuno-staining of isolated neutrophils 
All steps were performed with cells in suspension, as described in (Tapper et al., 2002). 
Neutrophils were pelleted out of RPMI and fixed in 1.5% paraformaldehyde (PFA) for 30 
min at 4°C then 1 h at room temperature, washed twice by centrifuging (at 1000 g for 3 min) 
and resuspending in 50 µl PBS. Following fixation, cells were permeabilised with 0.1% 
Triton-X 100 (TX-100) for 5 min before being washed again. Cells were then resuspened in 
25 µl of rabbit anti-SNAP-23 or guinea pig HV62 made up in 5% FCS/PBS for 2 h at room 
temperature, with constant agitation to avoid settling. Following another wash step, cells 
were incubated with 25 µl of the appropriate, fluorescently-conjugated, secondary antibody 
(anti-rabbit AF 488 or anti-guinea pig Cy3), for 1 h at room temperature, in the dark, again 
with agitation. After washing, cells were incubated with 30 µl 4',6-diamidino-2-
phenylindole (DAPI) stain for 10 min, washed a final time, and resuspended in 15 µl of 
PBS. Glycerol (45 µl of 100%) was added and the cells resuspended. This mixture was then 
placed onto a slide (taking care not to form bubbles). A coverslip was placed on top, and 
nail varnish used to seal the edges, once all excess liquid was removed with tissue. After 
the nail varnish had hardened, slides were stored overnight at 4°C before being examined 
with a fluorescent microscope, using the appropriate filter sets. 
In some experiments, permeabilised neutrophils were intoxicated with tetanus toxin (TeTX) 
light chain before and after fixation. In such instances, cells were incubated in HEPES 
buffer (50 mM HEPES-NaOH (pH 7.4), 2 mM dithioreitol (DTT), 0.2 mg/ml bovine serum 
albumin (BSA), 50 µM ZnCl2) containing 400 nM toxin light chain for 1 h at 37°C, washed, 
then stained as described above. 
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1.3 Results 
 
1.3.1 Comparison of cytokine profiles of arthritic patients pre- and post- BOTOX® 
administration failed to reveal a trend that can be attributed to this treatment 
As part of a clinical trial involving patients suffering from chronic pain associated with RA 
or OA, SF samples were taken pre- and at various times post-IA injection with BOTOX® or 
placebo (Table 1.1). Samples were analysed for levels of various inflammatory cytokines 
(TNFα, IL-1β and IL-6), as well as the neuropeptides SP and CGRP and, also, LIF. Despite 
its key role in the pathogenesis of RA (Grimsholm et al., 2005), TNFα was only detectable 
in 1 of the 2 RA patients tested (Fig. 1.1a). Where TNFα was present in RA patient RFS 
(Fig. 1.1a inset), there was no substantial decrease 1 month after IA BOTOX®. However, 3 
months post the 2nd BOTOX® treatment, the patient’s SF cytokine concentration had nearly 
tripled compared with initial baseline levels before any toxin was administered. In line with 
previous studies (Westacott and Sharif, 1996), TNFα was detectable in 3 out of 4 SF 
samples from OA patients (Fig. 1.1a). TNFα-containing sample sets were not available to 
track the effect of BOTOX® on cytokine levels within the expected duration of action of the 
treatment. Instead, SF was only taken when a patient presented for another BOTOX® 
injection, presumably once the effects of the previous dose had worn off. In this instance, 
there were similarities between RA and OA patients (RFS and CMO) in that TNFα 
concentrations had again nearly tripled compared with baseline (Fig. 1.1a). Cytokine levels 
were unchanged in samples from patients who received a placebo.  Despite the fact that in 
RA TNFα and IL-1β upregulate each other (Kay and Calabrese, 2004) and are produced by 
the same cells, presumably in response to the same stimulus (Westacott and Sharif, 1996), 
IL-1β was measurable in one RA patient’s SF, TAH, where no TNFα was detected (Fig. 
1.1b). In the other RA patient, RFS, differences in concentrations of both factors over time 
were consistent (Fig. 1.1a,b and insets). Where TNFα was detected in OA SF, IL-1β was 
also present (Fig. 1.1b). However, TNFα concentration changes in patient CMO were not 
mirrored in IL-1β levels. 
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Patient Diagnosis Patient ID Knee Study Visit Treatment 
  
   
 
TBB OA TBB #1  left Baseline - pre IA placebo placebo 
  TBB #2  left  1 mo blind - after IA placebo  placebo 
  TBB #3  left 1 mo OL - after IA BOTOX®  BOTOX® 
  TBB #4  left 3 mo OL - after IA BOTOX®   
  TBB #5  left 6 mo OL - after IA BOTOX®  
      
CMO OA CMO #1  left Baseline - pre IA BOTOX® BOTOX® 
  CMO #2  left 6 mo OL - after second IA 
BOTOX® 
 
      
RJO OA RJO #1 left Baseline - pre IA placebo placebo 
  RJO #2  left 1 mo blind - after IA placebo placebo 
      
MCS OA MCS #1  right Baseline - pre IA placebo placebo 
  MCS #2  right 1 mo blind - after IA Placebo  placebo 
      
TAH RA TAH #1  right Baseline - pre IA BOTOX® BOTOX® 
  TAH #2 right 1 mo blind - after IA BOTOX® BOTOX® 
      
RFS RA RFS #1  left Baseline - pre IA BOTOX® BOTOX® 
  RFS #2  left 1 mo blind - after IA BOTOX® BOTOX® 
  RFS #3 left 3 mo OL - after second IA 
BOTOX®  
BOTOX® 
Table 1.1│Details of SF samples taken from patients involved in a clinical trial assessing the 
effect of BOTOX® for the treatment of refractory joint pain associated with arthritic joints. 
Information relates to the patients, their treatments and time course of sample collection. (OA – 
osteoarthritis, RA – rheumatoid arthritis, IA – intra-articular injection, OL – open label, mo – 
month) 
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Figure 1.1│ Effect of BOTOX® on cytokine levels in SF samples from arthritic patients. 
Graphs show cytokine profiles of SF taken from patients with OA and RA before and after 
treatment with BOTOX® or a placebo. SF was taken at various time points and individual 
cytokine concentrations (a-e) were determined by ELISA. Samples were grouped according 
to patient; with each bar representing a different SF sample, plotted chronologically. Sample 
details are given in Table 1.1. Patient “RFS” shows inflammatory cytokine levels 
approximately 10 times higher (insets) than others. Results are averages (± S.D.) from 
ELISAs performed (n=4) on at least 2 different days. Error bars are sometimes encompassed 
by the bars. 
 
a 
c 
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Surprisingly, a greater than 50% drop in IL-1β was observed in patient MCS following 
treatment with a placebo. Consistent with the proposed correlation of IL-6 with disease 
activity in both RA (Nishimoto and Kishimoto, 2004) and OA (Westacott and Sharif, 1996), 
this cytokine was detected in all SF samples (Fig. 1.1c). Furthermore, where appropriate 
samples were available, in all patients treated with BOTOX® a decrease (albeit minimal in 
some cases) in cytokine concentration was observed (TBB, TAH and RFS). Levels 
increased again some months after BOTOX® administration in some patients (CMO 6 
months and RFS 3 months – Table 1.1) corresponding to the expected duration of action of 
the treatment. The neuropeptide SP was also present in all the samples tested (Fig. 1.1d). 
Disappointingly, the concentration of SP in SF appeared unaffected by BOTOX® treatment, 
while placebo treatment appeared to alter SP levels; both an increase and decrease were 
observed. LIF was also present in SF from both OA and RA joints (Fig. 1.1e). Interestingly, 
RA patient TAH had an appreciable increase in SF LIF following IA BOTOX®. In contrast 
with results from other studies (Grimsholm et al., 2005), CGRP was undetectable not only 
in OA SF but RA samples also (data not shown). For all the factors measured, there were 
no obvious concentration differences between the RA and OA samples. While patient RFS 
had appreciably higher levels of inflammatory cytokines than the others (Fig. 1.1a,b,c 
insets), this was the only trend seen between individuals. 
 
1.3.2 LIF enhanced botulinum-neurotoxin mediated SNARE cleavage in superior cervical 
ganglia neurons  
BoNT cleavage of SNARE proteins in cultured SCGNs, in the presence and absence of LIF, 
was quantified by SDS-PAGE, Western blotting and band densitometric analysis. Cleavage 
of SNAP-25 by BoNT serotypes /A, /C1 and /E, and VAMP-2 proteolysis by BoNT/B were 
analysed. BoNT/C1 also has proteolytic activity against syntaxin-1 but it was not analysed. 
Membranes resulting from Western blotting appeared to show enhanced cleavage of 
SNARE proteins in neurons cultured with 10 ng/ml LIF (Fig. 1.2). Thus, cleavage products 
of SNAP-25 were visible in LIF-treated cells where lower doses of BoNT/A, /E or/C1 had 
been administered. In the case of BoNT/B cleavage of VAMP-2, the intact VAMP band 
was reduced at lower concentrations of toxin compared with neurons cultured in the 
absence of LIF.  
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  0       1       10   100  1000  10,000 
pM BoNT              - LIF 
 0       1      10   100   1000 10,000 
pM BoNT              + LIF 
Syntaxin-1 
SNAP-25 
VAMP-2 
BoNT/A 
BoNT/B 
BoNT/C1 
BoNT/E 
Figure 1.2 │Botulinum neurotoxin-mediated SNARE cleavage in superior cervical 
ganglia neurons – visualisation. The effect of 12 days of 10 ng/ml LIF treatment on 
cleavage of SNARE proteins in SCGNs by various BoNT serotypes. SCGNs, cultured 
for 12 days with and without LIF were exposed to BoNT/A, /B, /C1 or /E (1 – 10,000 
pM) for 24 h, SNARE cleavage was then revealed by SDS-PAGE and Western 
blotting. Membranes were probed with antibodies against syntaxin-1 (HPC-1), SNAP-
25 [including BoNT/A, /C1 and /E cleavage products] (SMI-81) and VAMP-2, 
developed with AP and photographed with a G:BOX documentation system.     
 24 
Densitometry analysis of the protein bands revealed by AP development of the Western 
blots, performed as described in the figure legend (Fig. 1.3), confirmed the visualised effect 
of LIF treatment, i.e. that it resulted in more extensive SNARE cleavage with lower doses 
of toxin (Fig. 1.3). Repetition of these experiments will be necessary in order to ascertain 
the significance of cleavage differences. 
 
1.3.3 SNARE protein profiles in immune cells 
Membranes were prepared from cultures of human lymphocyte and murine macrophage 
cell lines and subjected to Western blotting using antibodies against the SNARE proteins 
syntaxin-1, VAMP-2, SNAP-25 and SNAP-23. Rat brain membranes were also included to 
provide positive controls for the neuronal SNAREs (Table 1.2, Fig. 1.4). Neither syntaxin-
1 nor SNAP-25 were detectable in either of the membrane preparations but were found in 
the brain membranes, as expected. VAMP-2 was visualised in murine macrophages but not 
in human lymphocytes which both contained SNAP-23. The detected molecular mass for 
the latter, though greater than 23 kDa, corresponds with the 29 kDa size previously reported 
and estimated for both human and mouse SNAP-23 respectively (Martin-Martin et al., 
2000). 
Neutrophils were isolated from human heparinized whole blood and immuno-staining was 
performed to determine the SNARE profile of these non-neuronal cells (Table 1.2). SNAP-
23 was identified (Fig. 1.5a) but, as human SNAP-23 is resistant to cleavage by all 
serotypes of BoNT, cleavage assays were not attempted. 
 
 Neuronal tissue  
(BoNT sensitivities) 
Non-neuronal tissue 
(BoNT sensitivities) 
v-SNAREs VAMP 1 (/B, /D, /F, /G) VAMP 3 (/B, /D, /F, /G) 
 VAMP 2 (/B, /D, /F, /G)  
   
t-SNAREs SNAP-25 (/A, /E) SNAP-23 (none) 
 syntaxin 1A, 1B (/C1) syntaxin 2, 3, 5, 6 (/C1*) 
  syntaxin 4 (none) 
 Table 1.2│ Human SNAREs – location and toxin sensitivities. Adapted from (Humeau et al., 
2000). * expected 
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Figure 1.3│ Botulinum neurotoxin-mediated SNARE cleavage in superior cervical 
ganglia neurons – quantitation. Analysis of SNARE cleavage by BoNT serotypes /A, 
/B, /C1 or /E in SCGNs with and without LIF treatment. Densitometric analysis of 
protein bands was performed on AP developed Western blots (Fig. 1.2) using 
GeneTools software. In the case of SNAP-25 (a, b, c), the density of the intact 
protein band in each lane was expressed as a % of the total (intact and cleaved). For 
VAMP-2 (d) where the cleavage product was not visualised, band density was 
compared to the syntaxin band as it is not cleaved by BoNT/B and served as an 
internal control for the amount of protein in each lane.     
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Figure 1.4│SNARE proteins of lymphocytes and macrophages. Membranes prepared 
from human lymphocyte (ly) and murine macrophage (mc) cell lines were subjected to 
SDS-PAGE and Western blotting (AP conjugated secondary antibodies were used for 
syntaxin-1, VAMP-2 and SNAP-25 and HRP for SNAP-23) and their SNARE profiles 
determined. Rat brain membranes (rb) were included as a positive control for neuronal 
SNAREs. Syntaxin-1 (→) and SNAP-25 (→) were only found in the rat brain 
membranes, VAMP-2 was present in murine macrophages and rat brain membranes (→) 
and SNAP-23 only in the immune cells (→). M, (◄) denotes mobilities of standard 
proteins (kDa). The apparent molecular weight of SNAP-23 was as expected from 
previous studies – see section 1.3.3. 
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Figure 1.5│ SNARE profile of neutrophils. These cells were isolated from human 
heparinized whole blood and SNAREs fluorescently labelled. a, SNAP-23 (rabbit anti-
SNAP-23 and anti-rabbit AF 488); b, VAMP (guinea pig HV62 and anti-guinea pig Cy3). 
DAPI staining revealed distinct multi-lobed nuclei of neutrophils (insets). Incubation with 
400 nM TeTX light chain (c) did not attenuate the VAMP signal (b compared with c) in 
fixed and permeabilised cells. Permeabilised, toxin treated, un-fixed neutrophils 
disintegrated during processing and could not be assessed. Omission of the primary 
antibody, with DAPI included to demonstrate the presence of cells, gave only background 
fluorescence: d, AF 488 and e, Cy3. 
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The HV62 antibody which recognises VAMPs -1, -2 and -3 labelled these cells (Fig. 1.5b). 
Omission of either of the primary antibodies resulted in only background signals (Fig. 
1.5d,e). VAMP proteins are cleaved by BoNT/B, /D, /F and /G and also by TeTX. For 
safety reasons and for ease of working, cleavage of VAMP in neutrophils was attempted by 
incubation with TeTX light chain rather than with a VAMP-cleaving BoNT serotype (Fig. 
1.5c). However, the fluorescent signal was not eliminated when fixed neutrophils were 
treated with TeTX light chain and labelled with HV62. Attempts were made to cleave 
protein in permeabilised, unfixed samples but due to the very delicate nature of the cells 
and their inability to survive outside the body for more than a few hours, neutrophils 
disintegrated before the staining process could be completed. Therefore, cleavage of 
VAMP and demonstration of the presence of toxin-sensitive VAMP in these immune cells 
could not be confirmed within the confines of working with such delicate cells (Fig. 1.5b,c). 
 
1.3.4 Various serotypes of botulinum neurotoxin act on LPS-activated macrophages to 
reduce release of inflammatory cytokines 
Murine macrophages were treated with different serotypes of BoNT (/A, /B, /D, /E or /F) 
overnight, in the presence and absence of LPS. After 24 h, cell supernatants were collected 
and inflammatory cytokine compositions analysed by ELISA. In the absence of LPS, 
BoNTs /B, /E and /F caused a small but significant increase in the release of IL-1β from the 
macrophages at 1 nM (Fig. 1.6a) (p=0.0447, 0.0025 and 0.0276 respectively). At a higher 
concentration (10 nM), BoNTs /E and /F continued to exert this significant effect with 
p<0.0001 in both cases (BoNT/B wasn’t tested at the higher concentration). In the presence 
of LPS some toxin serotypes reduced IL-1β release; /A, /B and /E having significant effects 
at the concentrations tested. BoNT/D only reduced IL-1β release significantly (p=0.0091) 
when 10 nM was applied to the LPS treated cells. In the case of TNFα, BoNT/A, /B, /E and 
/F significantly increased release in the absence of LPS at 1 nM, with an even greater 
response from 10 nM BoNT/E and especially BoNT/F. Conversely, the higher dose of 
BoNT/A did not result in a significant increase in TNFα release from non-activated cells 
(Fig. 1.6b). BoNT/D, which did not affect cytokine release in the absence of LPS, was able 
to reduce TNFα levels in its presence, but not significantly and only at the lower dose of 1 
nM. IL-6 release from LPS-activated macrophages was not significantly suppressed by any  
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Figure 1.6│ Cytokine release from botulinum neurotoxin-treated macrophages. Some 
serotypes of BoNT can attenuate the release of various cytokines from LPS-treated murine 
macrophages. Macrophages were treated with 1 or 10 nM toxin for 24 h in the absence (a-
c upper panels and d left hand panel) and presence (a-c lower panels and d right hand 
panel) of LPS (1 µg/ml) before cell supernatants were collected and cytokine levels 
measured by ELISA. Control supernatants from cells not exposed to toxin, with and 
without LPS, were similarly analysed. Data is plotted as mean (n=3) ± S.D. Significance 
values refered to in the text were calculated using unpaired t-tests, where control release 
was compared individually, to that in the presence of the various serotypes tested. 
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of the BoNT serotypes tested regardless of concentration (Fig. 1.6c), but 1 nM of /B 
(p=0.0233), /E (p=0.0311) and /F (p<0.001) cause significantly increased levels in the 
absence of LPS, an effect that was increased by a higher dose of BoNT/E and especially 
BoNT/F (p<0.0001) as seen with other cytokines where 10 nM BoNT/F causes release in 
the non-activated macrophages similar to that seen in the LPS-treated control. Given that 
LIF is produced by cells in arthritic joints, the affect of BoNTs on its release were also 
studied (Fig. 1.6d). Treatment with both 1 and 10 nM of the BoNT serotypes did not 
significantly increase or decrease LIF release from macrophages which had not been 
exposed to LPS. Only BoNT/A significantly attenuated LIF levels, and at both 
concentrations tested (1 nM, p=0.0129; 10 nM, p=0.0235). In summary, BoNT treatment 
had differing effects on the various cytokines examined. While increased (compared to 
control) release was usually the case when toxin was added to non-activated cells, this did 
not seem to have any bearing on results from LPS-treated cells, with the exception of 
BoNT/F which not only triggered cytokine release in the absence of LPS but also failed to 
reduce release in its presence. 
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1.4 Discussion 
 
Despite the success of BOTOX® IA injections in treating the chronic pain associated with 
both RA and OA (Mahowald et al., 2006), the mechanism of action of the toxin in this 
application has yet to be deciphered. This preliminary study was designed to begin to 
investigate potential targets for BOTOX® in the arthritic joint and the possible actions of 
other BoNT serotypes in such a condition, taking into account both the neural and 
inflammatory contributors. The first step in this exploration was to analyse SF taken from 
arthritic joints before and after BOTOX® treatment, administered during a clinical study. It 
was hoped that changes in the concentrations of various inflammatory mediators would 
reveal the potential site(s) of action of this treatment. 
 
In the SF samples investigated, from both RA and OA joints, only IL-6 levels consistently 
appeared to be affected by BOTOX® treatment, with levels reducing post treatment and 
increasing again when further treatments were required, which would be expected given the 
role IL-6 is thought to play in indicating disease activity in both conditions (Nishimoto and 
Kishimoto, 2004; Westacott and Sharif, 1996). However, a correlation between SP and IL-6 
levels in RA previously demonstrated was not revealed here (Grimsholm et al., 2005), nor 
was there a relationship between the other inflammatory cytokines tested and SP, as might 
be expected given previous observations (Grimsholm et al., 2005). Furthermore, a link 
between TNFα and IL-6 SF concentrations which have been seen in SF samples from 
patients with temporo-mandibular joint disorders including OA (Kaneyama et al., 2005) 
were not revealed in this study. While it is unwise to draw too many conclusions from such 
a small sample, some of the discrepancies between the results obtained in this study and 
others could be due to the well documented lack of reproducibility between such 
measurements made with various assay systems (Westacott and Sharif, 1996) in different 
Institutions (Kaneyama et al., 2005). So it is necessary to primarily compare results only 
within individual studies. 
Despite this, there is value in this investigation if limitations in both SF samples and factors 
analysed are addressed. Firstly, there were a very small number of samples available with 
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insufficient time points post BOTOX® administration. Age and disease stage matching 
would also be important in a more comprehensive study as well as information on the 
clinical outcomes for treated patients. Since SF volume can distort outcomes (Kaneyama et 
al., 2005), it is important to ensure that aspirated infusions are consistent in volume 
between patients. In this initial exploration, the number of factors investigated was limited. 
Assuming sufficient SF volume, it would be interesting to compare inflammatory mediators 
and their soluble receptors which act as antagonists (Grimsholm et al., 2005) as an excess 
of cytokine compared to such receptors is necessary (Kaneyama et al., 2005) for a factor to 
exert its effect. Where large excesses of inflammatory cytokines or alterations in their 
levels following treatment are not found, investigating anti-inflammatory cytokines could 
reveal whether an imbalance between the 2 groups is indicative of symptoms, or, 
deficiencies in compounds capable of counteracting inflammation are causal. Monitoring 
other factors more directly implicated in joint destruction such as receptor activator of 
nuclear factor-κΒ (RANK) ligand (RANKL) which is important for osteoclast 
differentiation (McInnes and Schett, 2007) could also reveal further information. 
 
LIF, a cytokine with many functions, has been found in SF from both RA and OA joints 
both in this study and elsewhere (Patterson, 1994). While it is thought to have a destructive 
role in the joint (Westacott and Sharif, 1996), it can also induce a cholinergic phenotype in 
neurons in vitro and in vivo (Patterson, 1994; Shadiack et al., 1993). Given the high affinity 
of BoNT serotypes for ecto-acceptors on cholinergic nerve endings (Aoki, 2001; Dolly and 
Aoki, 2006), experiments were performed to test the hypothesis that the presence of LIF 
enhances the sensitivity of sensory nerve endings in arthritic joints to BOTOX®. To this 
end SNARE cleavage by various serotypes of BoNTs was quantified in control and LIF-
treated cultured SCGNs. Incubation with LIF gave evidence of SNARE cleavage at lower 
toxin doses not just in the case of BoNT/A, the serotype used clinically, but for BoNT/B, 
/C1 and /E also. It is worth noting that LIF-treated cultures often appeared to be somewhat 
sparser with fewer processes. This corresponded to weaker bands on blots developed under 
the same conditions as control cultures, an effect particularly clear when analysing the 
already quite faint VAMP-2 bands. This made densitometry analysis of this protein 
somewhat more challenging; furthermore, as cultures were plated on collagen, protein 
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quantitation of samples before analysis was not possible. While this result is certainly 
promising, it is unwise to assume that such enhancements in SNARE cleavage would result 
in altered exocytosis of neuropeptides. A pertinent next step would be to compare the 
exocytosis of factors such as SP from cultures grown with and without LIF and to attempt a 
correlation of SNARE cleavage and release. This may also provide confirmation of the 
individual proteins contributing to the SNARE complex in the exocytosis of neuropeptides 
from these cells.     
 
Many studies have been performed to establish the SNARE proteins present in a variety of 
immune cells. A few examples include (Chai et al., 2006; Feng et al., 2001; Martin-Martin 
et al., 2000; Mollinedo et al., 1999; Murray et al., 2005a; Murray et al., 2005b; Pagan et al., 
2003; Pitzurra et al., 1996), some of which have established that exocytosis mediated by 
these SNAREs is the mechanism of release of the pro-inflammatory cytokines IL-1β and 
TNFα from immune cells (Chai et al., 2006; Murray et al., 2005a; Murray et al., 2005b; 
Pagan et al., 2003). It is, therefore, very plausible that BOTOX® injected into arthritic joints 
is acting on such cells, and that clinical benefits of this treatment, are at least in part, due to 
a reduction in inflammatory factors due to BOTOX®-mediated SNARE cleavage resulting 
in attenuation of their release. While BoNT/D has been shown to prevent release of TNFα 
from human monocytes (macrophage pre-cursors) activated by LPS (Imamura et al., 1989), 
the substrate for the toxin was not identified; therefore, no evidence of BoNT-mediated 
SNARE cleavage was sought. Conversely, where SNARE cleavage has been demonstrated 
in these cells, it was either by micro-injection or in permeabilised cells. VAMP proteins 
were cleaved by TeTX micro-injected into neutrophils (Mollinedo et al., 1999); likewise, 
the same toxin cleaved VAMP in macrophages following a perforation procedure (Pitzurra 
et al., 1996). As TeTX shares the same cleavage site as BoNT/B on VAMP (Humeau et al., 
2000), it is reasonable to hypothesise that at a minimum, VAMP in immune cells will be 
sensitive to BoNT/B if not other VAMP cleaving serotypes. In identifying SNARE proteins 
in immune cells in this study, the aim was to then cleave those proteins following 
application of the toxin in intact cells, one step further in demonstrating that BoNTs can 
target immune cells.  
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In contrast to their abundance in neurons, SNARE proteins are present in much smaller 
amounts in immune cells, especially in cell lines (like the lymphocyte and macrophage 
lines used here). Therefore, it was necessary to grow many flasks of cells and prepare 
membranes before Western blot analysis could be attempted. Although identification of 
SNAREs was possible, the number of cells and consequently the volume of culture medium 
that toxin would have to be applied to before cleavage experiments were attempted made 
this approach unworkable. The decision was then made to label SNARE proteins in isolated 
neutrophils, the benefit being that work was being conducted with native tissues. Due to 
limitations in the volume of blood available for extracting of such cells, immuno-
fluorescence rather than Western blotting was employed to identify SNAREs. While this 
was successful, the frailty of the neutrophils made cleavage experiments very difficult. 
Attempts were made to treat unfixed, permeabilised neutrophils with TeTX light chain 
(used rather than BoNT as it is much safer and, therefore, easier to work with) but, 
unfortunately, the cells disintegrated and immuno-staining could not be completed. TeTX 
was applied to fixed cells but no alteration in the fluorescent signal of labelled VAMP was 
observed. This is likely due to the fact that the target protein was fixed. So the low levels of 
SNARE proteins expressed in immune cells and the frailty of neutrophils made cleavage 
experiments very difficult.  
 
Even without demonstrating BoNT ability to cleave target proteins in immune cells, the 
effect of toxins on exocytosis from such cells was investigated. Control and LPS-activated 
macrophages were treated with BoNT/A, /B, /D, /E or /F and effects on the release of 
arthritis-pertinent cytokines measured. While taking into account that these experiments 
were performed in vitro, it is promising that cytokine release was affected by BoNT 
application. In the case of non-activated cells it is not surprising that, in some instances, 
toxins elicited cytokine release greater than that of control cells given that BoNT is a 
protein foreign to these cells. It is noteworthy that exposure to different serotypes resulted 
in release of different cytokines from non-activated cells but, in the main, BoNT/F 
triggered release greater than that from control cells and BoNT/B did not. More striking 
effects were seen from the LPS-activated macrophages, which more closely mimic the state 
of the cells as they would be in the arthritic joint. Again, attenuation of cytokine release 
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differed between the various serotypes tested indicating a specificity in response, perhaps a 
result of the many different combinations of SNARE proteins responsible for exocytosis 
from immune cells (Chai et al., 2006; Martin-Martin et al., 2000; Murray et al., 2005a; 
Murray et al., 2005b; Pagan et al., 2003). SNAP-25 cleaving BoNT/A, and BoNT/D which 
cleaves VAMP were most effective in this study. As BoNT/A is the serotype present in 
BOTOX®, it is encouraging that it was able to reduce IL-1β release. Furthermore, as IL-1β 
and TNFα up-regulate each other (Kay and Calabrese, 2004) and IL-1β increases SP release 
in neurons (Freidin and Kessler, 1991), attenuating release of just one factor could have 
several knock-on effects. However, while human SNAP-23, the non-neuronal homologue 
of the BoNT/A target SNAP-25, is insensitive to all BoNTs, the murine form is cleaved by 
BoNT/E and to a lesser extent by BoNT/A (Humeau et al., 2000). Therefore, actions seen 
in this murine in vitro model may not be replicated in the human joint. Despite this, 
BoNT/A was most effective at 1 nM and this dose may not be strong enough to overcome 
the reduced susceptibility of SNAP-23 to this toxin. Perhaps, though unlikely, there is as 
yet unidentified SNAP-25 in these cells, or the toxin is acting on a different target. 
 
In a search for the mechanism of action for IA administration of BOTOX® for the treatment 
of chronic pain in arthritic joints, there is some evidence from a small number of SF 
samples that IL-6 levels are reduced after toxin treatment. Evidence has been gathered that 
suggests that culturing neurons in the presence of LIF increases the sensitivity of SNARE 
proteins to cleavage by BoNT, although whether this would in turn alter neuropeptide 
release from such cells remains to be established. Although SNARE cleavage in immune 
cells could not be demonstrated, evidence was obtained that various BoNT serotypes, 
including the clinically-used BoNT/A, can alter SNARE-mediated cytokine release from 
activated macrophages. To take this study further it will be necessary to repeat the 
experiments measuring the effect of LIF treatment on SCGN SNARE cleavage by various 
serotypes of BoNTs. This will the establish the significance of the data achieved thus far as 
well as provide an opportunity to investigate the effect of both LIF and BoNT treatment on 
the release of SP from the cultured neurons thereby establishing if enhanced SNARE 
cleavage does result in reduced exocytosis from the SCGNs. It would also be appropriate to 
look for cholinergic markers in the neurons cultured with LIF to add weight to the 
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hypothesis that LIF causes a cholinergic phenotype which in turn leads to enhanced 
SNARE cleavage. As visualisation of cleaved SNAREs in cultured immune cells is 
challenging, fluorescence-activated cell sorting (FACS) could be employed to examine any 
effects of BoNT serotypes on the surface markers of cultured macrophages and thus 
demonstrate a direct action of BoNTs on these cells. Lastly an animal arthritis model e.g. 
rat adjuvant or rat and mouse type II collagen RA models could be employed to provide 
tissue and fluids from diseased, BOTOX® treated and untreated joints. Synovial membranes 
could be analysed for SNARE cleavage and SF for alterations in cytokine levels (assuming 
sufficient volume, therefore the larger the animal used the better). While there are still 
questions to be answered, this preliminary study has certainly yielded areas for further 
exploration and demonstrated the value in this line of approach.  
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Section B 
 
 
Defining the pharmacology of 
heteromeric Kv1 channels mimicking 
those in mammalian brain 
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Chapter 2 
Introduction 
 
 
2.1 K+ currents and K+ channels 
Neuronal action potentials are electrochemical signals that transmit information from one 
end of a cell to the other, triggering neurotransmitter release at synapses, resulting in cell to 
cell communication. These impulses are initiated and propagated by the movement of 
charged ions across usually impermeable cell membranes, through ion conducting channels 
(Li et al., 2006). K+ currents are responsible for returning the membrane potential to a 
resting state, thereby governing the resting membrane potential of a cell (Li et al., 2006). 
These currents vary in many respects including kinetics, voltage dependency and 
pharmacology. Various types of currents can be found in the same cell and similar currents 
arise in different cells indicating that diversity is not due to cell type. Single channel 
recordings have shown that the observed current diversity is likely to be due to different 
types of K+ channel. In fact, K+ channels are the largest and most prevalent group of ion 
channels, and are present in almost all eukaryotic cells (Rudy, 1988). In non-excitable cells 
they have roles in hormone secretion, cell proliferation, cell volume regulation and 
lymphocyte differentiation (Xu et al., 1995). While the number of K+ channel genes is large, 
the diversity of current phenotypes that exists across excitable cells is greater as alternative 
splicing, post-translational modifications and heterologous assembly of pore-forming 
subunits into tetramers all contribute to the functional diversity of K+ channel gene 
products (Li et al., 2006). Co-assembly with accessory subunits enhances this multiplicity 
resulting in channels with altered properties including assembly, trafficking, gating and 
conduction (Li et al., 2006). There are many types of K+ channel including Ca2+-activated 
(KCa), inward-rectifying (KIR) and two-pore (K2P) but the voltage-gated (Kv) family is the 
biggest consisting of several sub-families (Gutman et al., 2003a). 
 
2.2 The voltage-gated, Kv, family of K+ channels 
The lack of discovery of a K+ channel rich tissue hampered early research (pre-1980s) in 
the K+ channel field. Studying the genetics of Drosophila melanogaster provided an 
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alternative approach. Flies were isolated due to a mutation that caused their legs to shake 
when anaesthetized with ether. From 1983-87, voltage-clamp experiments in pupal and 
larval muscle showed that this “Shaker” mutation affects a K+ current. The fact that other 
currents are not affected suggested that the Shaker gene encodes a structural component of 
the current i.e. the channel (Papazian et al., 1987). Next, in 1987-88, protein sequences 
from 2 cDNAs of the Shaker gene complex were shown to have properties of integral 
membrane proteins containing 6 identical, potentially membrane-spanning segments as well 
as a topology and amino acid sequence very similar to vertebrate voltage-dependent Na+ 
channels (Pongs et al., 1988). Such channels were known to have 4 internal repeats, but this 
was not the case for the Shaker proteins leading to the hypothesis that 4 Shaker products 
aggregate to form a channel (Pongs et al., 1988).   
Using information gained from cloning the Shaker gene, 3 further K+ channel genes were 
isolated based on their similarity to Shaker viz. Shab, Shaw and Shal (Jan and Jan, 1992). 
All 4 members of this gene family encode peptides with conserved organisation, suggesting 
common function (Wei et al., 1990). While voltage-gating and K+ selectivity are features 
shared by the family, their kinetic and voltage sensitivities differ. Variations in lengths of 
domains at the N and C termini result in differences in size of the peptides: Shaker ~71 kDa, 
Shab ~100 kDa, Shaw ~56.5 kDa and Shal ~56 kDa. Despite this, there is a conserved core 
region encompassing the 6 potentially membrane spanning domains, which varies little 
(Wei et al., 1990), resulting in about 40% amino acid identity between any pair of genes 
(Jan and Jan, 1992). 
The 4 members of the Drosophila gene family, Shaker, Shab, Shaw and Shal, have 1 or 
more mammalian homologues and therefore each defines a subfamily (Kv1 – 4) of K+ 
channel genes (Jan and Jan, 1992; Wei et al., 1990): Shaker-related, Kv1; Shab-related, 
Kv2; Shaw-related, Kv3 and Shal-related, Kv4 (Gutman et al., 2003a; Gutman et al., 2005). 
These mammalian and Drosophila proteins are more closely related (regardless of species) 
than the subfamily members of a single species, sharing roughly 70% amino acid identity in 
the core region (Jan and Jan, 1992; Wei et al., 1990) [compared with 40% between 
subfamilies (Xu et al., 1995)]. This demonstrates that the individual structural features of 
the subfamilies evolved before vertebrate/invertebrate separation (Wei et al., 1990). Despite 
the similarity in products from the gene subfamilies, heteromultimerisation of subunits into 
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channels is family specific. N terminal domains control this assembly ensuring that cells 
maintain several distinct K+ current systems (Xu et al., 1995). 
 
2.3 The structure of Kv1 channels 
Kv1 channels are large (Mr ~ 400 kDa) sialoglycoprotein complexes (Parcej et al., 1992) 
composed of 4 pore-forming α subunits (Kv1.1-1.6) and 4 auxiliary, cytoplasmically-
associated β subunits (Dolly and Parcej, 1996; Orlova et al., 2003; Parcej et al., 1992; 
Rettig et al., 1994; Scott et al., 1994a).  
2.3.1 The α subunits The α subunits have several conserved features including 6 putative 
membrane-spanning segments (α helices S1-S6) and with both the N and C termini located 
intracellularly (Fig. 2.1a,b). A functional channel consists of 4 α subunits arranged around 
a central axis forming the ion conduction pathway (Fig. 2.1c). α helices S1-4 are 
responsible for voltage sensing, and wrap around the pore of the adjacent subunit (Long et 
al., 2005b) (Fig. 2.1c). The S4 helix contains a positively charged amino acid (arginine) at 
every third residue, interspersed with hydrophobic residues, and is generally thought to 
function as the main voltage-sensor (see below) (Jan and Jan, 1992). The ion conduction 
pore consists of S5, the S5-S6 loop and S6 (Long et al., 2005b).The S5-S6 loop contains a 
conserved sequence which acts as a K+ selectivity filter (see below) (Li et al., 2006). The 
S4-S5 linker connects the pore and voltage sensing components of the α subunits (Long et 
al., 2005a). 
2.3.2 The T1 domain Preceding S1, the first membrane spanning helix of an α subunit, the 
N-terminus forms the T1 domain (within the cell). These domains (1 from each α subunit) 
form a tetrameric complex at the intracellular membrane providing a docking platform for β 
subunits (Long et al., 2005a) (Fig. 2.2a). The T1-S1 linker maintains separation between 
the pore of the channel and the intracellular regions. A wide space between the T1 domain 
and pore is achieved by the radial direction of the linkers, allowing the inner pore helices to 
undergo large movements during pore opening (see below) without interference (Fig. 2.2a). 
This also results in diffusion pathways, called side portals, between the cytoplasm and pore 
entrance which provide a means for communication and allows the flow of K+. The 4 side 
portals of a complete channel attract cations due to negatively charged amino acids on their  
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Figure 2.1│Kv channel α subunit arrangement and structural model. a, A simple 
topographical model common to all Kv channels predicted by amino acid sequence. 
There are six membrane spanning segments (cylinders, S1-S6) with N- and C-termini 
arranged intracellularly. The fourth membrane spanning segment contains evenly 
spaced charged residues and comprises the membrane voltage-sensor. b, Side view of 
ribbon diagram of one subunit of Kv1.2 based on crystal structure (Long et al., 
2005a). K+ ions are shown as purple spheres. Transmembrane helices are labelled. The 
fourth transmembrane segment is shown in gold. c, Tetrameric arrangement of Kv1.2 
as viewed above from the extracellular surface. The 4 subunits are coloured 
differently. Taken from (Li et al., 2006) (a,b) and (Long et al., 2005a) (c). 
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rims and surface (Fig 2.2c). They also have a role in inactivation (see below) (Long et al., 
2005a). 
2.3.3 The β subunits β subunits act as accessory proteins, mainly for Kv1 channels (Li et al., 
2006; Parcej et al., 1992), and interact with them via the T1 domain (Long et al., 2005a) 
(Fig. 2.2a,b). There are several Kvβ family members with well conserved C-termini but 
differing N-termini (Leicher et al., 1998; Li et al., 2006; Scott et al., 1994b). These subunits 
also form tetramers, and are related to the aldo-keto reductase enzymes having both 
catalytic and substrate binding domains (Li et al., 2006). The active site contains an NADP+ 
cofactor and catalytic residues for hydride transfer but the function of this is as yet 
undeciphered. It has been suggested that the enzyme may act as a sensor for Kv1 channels 
in such a way that the redox state of the cell could have an influence on electrical activity at 
the membrane (Long et al., 2005a). Through their N-terminal domain, β1 subunits confer 
fast inactivation when co-expressed with Kv1 α subunits that usually produce non-
inactivating channels (Rettig et al., 1994) (see below). As other β subunits do not share this 
property it is likely they have other functions. Enhanced surface expression of channels co-
expressed with β subunits indicates a possible role as channel chaperones (Manganas and 
Trimmer, 2000). 
 
2.4 The pore-forming region of Kv1 α subunits. 
All K+ channels share a highly conserved pore region encoded by a critical amino acid 
sequence called the K+ signature sequence from which the structural elements of the pore 
are formed (Doyle et al., 1998; MacKinnon, 2003). In Kv1 α subunits, this is a short stretch 
of amino acids between the S5 and S6 transmembrane domains. This pore region consists 
of the turret, pore helix and selectivity filter (Doyle et al., 1998). In a fully assembled 
channel, 4 pore regions, 1 from each of the α subunits, assemble together to form an ion 
conduction pathway (MacKinnon, 2003), with 4-fold symmetry around the pore. The 
“turrets” from each monomer jut into the extracellular solution above the centrally-located 
pore entrance (Imredy and MacKinnon, 2000) (Fig. 2.3a). The transmembrane α helices are 
tilted with respect to the membrane resulting in a broad vestibule at the entrance of the pore 
(Doyle et al., 1998), which dips into the membrane and tapers into the selectivity filter at 
the centre of the vestibule (Hopkins et al., 1996).  
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Figure 2.2│Views of a Kv1.2-β2 subunit complex. a, Ribbon representation with the 
extracellular solution above and the intracellular solution below. Each α subunit, 
including the T1 domain and its associated β subunit, is coloured differently. TM 
indicates the membrane component of the channel. b, A single α and β subunit of the 
channel viewed from the side. The transmembrane S1-S6 helices, proline-valine-proline 
(PVP) sequence of S6, and the N and C termini of the Kv1.2 and β2 subunit are labelled. 
The N terminus of the β subunit is on the side furthest from the viewer. c, Surface 
representation of the Kv1.2-β2 complex. Negatively charged glutamate and aspartate 
residues are coloured red and positively charged arginine and lysine residues in blue. 
The large hole above the T1 domain depicts the side portal which connects the 
cytoplasm to the pore. Taken from (Long et al., 2005a). 
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2.4.1 Ion selectivity The selectivity filter is responsible not only for the 1000-fold greater 
selectivity of these channels for K+ over Na+ but, also, allows rapid diffusion through the 
pore. The selectivity filter separates the cavity of the channel from the extracellular solution. 
It is so narrow that it causes K+ to shed its hydrating water molecules in order to enter 
(Doyle et al., 1998). A single layer of threonine hydroxyl oxygen atoms and 4 evenly 
spaced layers of carbonyl oxygen atoms from the K+ signature sequence create 4 K+ 
binding sites along the selectivity filter numbered 1 to 4 from the extra to intracellular side 
(Fig. 2.3b,c). Dehydrated K+ binds to these sites taking 8 carbonyl oxygen atoms, 4 from 
above and 4 below the ion, which act like surrogate water taking the place of water oxygen 
atoms and in doing so compensate for the energetic cost of dehydration (Doyle et al., 1998; 
MacKinnon, 2003). In this way, a queue of K+ binding sites is formed and the ions can 
diffuse from water into the selectivity filter (MacKinnon, 2003). Na+ has a smaller radius 
than K+ meaning that it cannot get close enough to the carbonyl oxygen atoms to 
compensate for the energetic cost of dehydration. This prevents them from passing through 
the channel, thereby, ensuring such impressive K+ selectivity (Doyle et al., 1998). At most 
times, there are 2 ions in the selectivity filter. The repulsion between them overcomes the 
affinity that each has for its binding site so they are not too tightly bound, resulting in rapid 
diffusion through the pore. If the internal K+ concentration is too low, only 1 ion occupies 
the selectivity filter and, hence, binds too tightly preventing the flow of ions (MacKinnon, 
2003). 
 
2.5 Gating of Kv1 channels 
Ion channels gate (open and close) in response to external signals. Kv1 channels (as well as 
all voltage-gated K+, Na+ and Ca+ channels) open (activate) in a voltage dependent manner 
in response to membrane depolarization, i.e. changes in voltage across the cell membrane, 
and then spontaneously shut (inactivate), usually independently of voltage (Long et al., 
2005b; MacKinnon, 1991). The membrane electrical field exerts a force on charged amino 
acids (arginines in the S4 helix), called the gating charges, which move through the 
membrane, ultimately altering channel conformation. The gating charge is very large, 
resulting in channels that are very sensitive to small voltage changes (Long et al., 2005b). 
The gating charge of a Kv channel is the equivalent of almost 14 electrons moving across 
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Figure 2.3│The ion conduction pore of K+ channels. This is a representation of a 
KcsA channel from Streptomyces lividans. While each subunit consists only of 2 
helices as opposed to the 6 found in eukaryotic Kv1 channels, it shares close sequence 
homology in the pore region. a, View of a tetrameric channel, each subunit being 
distinguished by a different colour. b, Two of the four subunits of the pore are shown 
with the extracellular side on top (Zhou et al., 2001). The selectivity filter is depicted 
in gold. The blue mesh illustrates the electron densities of K+ and water along the 
pore. c, Close-up view of the selectivity filter with dehydrated K+ at positions 1 
through 4 (external to internal) inside the filter and a hydrated K+ in the central cavity 
below the filter. This figure was taken from (Doyle et al., 1998) (a) and (MacKinnon, 
2003) (b,c). 
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the transmembrane voltage difference. These charges are attributed to 4 arginine residues 
per α subunit – resulting in a total of 16, with each arginine residue having approximately 1 
electron charge (MacKinnon, 2003). The membrane electric field works on the charged 
residues, pushing them outwards when the inside of the membrane is positive, and pulling 
them inwards when the inside of the membrane is negative (Long et al., 2005b). S6 helices 
(1 from each subunit of a tetrameric channel) line the pore on the intracellular side of the 
selectivity filter, forming the inner helix bundle – an expandable constriction for opening 
and closing the pore. It is called the activation gate. The S6 helices have a conserved 
proline-X-proline (Pro-X-Pro) sequence (where X is any amino acid; valine in Kv1.2), 
which curves them so they run almost parallel to the membrane near the intracellular 
surface (Long et al., 2005a) (Fig. 2.2b). The S4-S5 linker (which connects the voltage 
sensing and pore channel components) runs parallel to the membrane inside the cell, 
crosses over the top of the S6 helix and forms amino acid contacts with it. The curved 
nature of S6, imbued by the conserved Pro-X-Pro sequence, enables it to act as a platform 
for the linker. Hence, the movement of the voltage sensor domain is transmitted to the 
activation gate, via the S4-S5 linker, resulting in the mechanical opening and closing of the 
pore (Long et al., 2005b).   
2.5.1 Inactivation Diversity of Kv channels is based mainly on differences in the kinetics of 
activation and inactivation (Pongs, 1992). Indeed, the firing pattern and wave forms of 
action potentials in a neuron is determined to a large extent by the inactivation properties of 
the K+ channels present in that particular cell (Jan and Jan, 1992). A refractory period 
follows inactivation when, through a series of conformational changes, the channel returns 
to its resting state. Channel inactivation can occur at the intra or extracellular entrance of 
the pore, and be imbued by the N or C terminus, respectively. Channels inactivated at the 
extracellular entrance to the pore reactivate rapidly compared with the slow reactivation 
resulting from intracellular inactivation (Pongs, 1992).  
Fast inactivation of Kv1 channels is mediated by the N-terminus, resulting in spontaneous 
closure of channels which occurs over tens of milliseconds (MacKinnon, 1991). The 
process occurs in some members of the Kv1 family, e.g. Kv1.4. The N terminus 
“inactivation gate” of the α subunit of these channels enters the side portals, blocking 
access of the intracellular K+ ions to the pore, thereby inactivating the channel. A very 
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specific N terminus sequence is required to produce an N terminal inactivation gate: 
approximately 10 hydrophobic amino acids followed by a mixture of hydrophilic and 
positively charged residues. The hydrophobic stretch enters the side portal, and reaches into 
the inner pore which is lined with hydrophobic amino acids. Positively charged amino acids 
from the hydrophilic sequence make electrostatic interactions with the negatively charged 
amino acids on the surface of the T1 domain and linkers to S1 (Fig. 2.4) (Long et al., 
2005a). The N terminus of the β1 subunit also has inactivation gate properties, with 70 
extra N terminal amino acids compared with other β subunit family members. This extra 
length allows the inactivation gate to reach to the side portal of the α subunit. Co-
expression of β1 subunits with Kv1 channels other than Kv1.4, confers them with N-type 
inactivation (Rettig et al., 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4│Hypothetical model for the binding of an inactivation peptide to 
the Kv1.2-β2 channel. A portion of the T1 and transmembrane components 
are shown. The inactivation peptide is modeled on the 22 N terminal residues 
of β1. Three positive residues (+) at positions 13, 15 and 20 from the N 
terminus were placed at the site of interaction with negatively charged 
residues on T1 (*) and the hydrophobic residues at the N terminus were 
placed at the inner pore where they are known to bind and block the flow of 
K+ ions. Taken from (Long et al., 2005a). 
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C-type inactivation is slower than N-type and is sensitive to external cations and the amino 
acid composition of the K+ channel pore as all 4 α subunits of the channel participate co-
operatively. The mechanism for inactivation is not as clear though it is likely that the outer 
mouth of the channel constricts, decreasing the inter-subunit distance across the outer 
vestibule of the channel pore (Panyi et al., 1995). 
 
2.6 The toxin approach to studying the biochemistry of K+ channels  
While studying the genetics of a Drosophila mutant was very successful for identifying Kv 
channel genes, the simultaneous discovery of Kv channel blockers in the early 1980s lead 
to isolation and characterisation of K+ channel proteins (Black et al., 1988; Rehm and 
Lazdunski, 1988). Several neurotoxins isolated from the venom of Dendroaspis 
angusticeps and polylepis (green and black mamba snakes, respectively) were found to 
facilitate neurotransmitter release at both peripheral and central synapses, an effect that was 
explained by the toxins’ blockade of voltage-sensitive K+ currents in these neurons (Dolly 
and Parcej, 1996; Halliwell et al., 1986). Toxin binding and affinity chromatography 
resulted in the purification of a subset of Kv channels from mammalian brain, revealed by 
cloning to be from the Kv1 family, identifying the dendrotoxins (DTXs) as blockers of 
some members of this set of proteins (Dolly and Parcej, 1996). Similarly, Noxiustoxin 
(NxTX) isolated from the venom of the Mexican scorpion Centruroides noxius (Carbone et 
al., 1982), was shown to increase neurotransmitter release from synaptosomes by 
decreasing K+ permeability (Sitges et al., 1986). This and other toxins isolated from 
scorpion venoms proved to be high affinity selective probes for K+ channels including 
those from the Kv1 subfamily and as such were, like DTXs, used to purify channels from 
native tissues [for example (Koschak et al., 1998)]. Despite the success of molecular 
cloning techniques, the subunit compositions of channels in native tissues was unknown. 
Importantly, the use of DTX to purify channels from native tissue resulted in the discovery 
of the β subunit and the α(4) β(4) stoichiometry of Kv1 channels (Parcej et al., 1992). In 
addition, scorpion toxins were used to identify the pore region of the Shaker channel, 
determine the tetrameric composition of K+ channels and investigate the role of Kv1 
channels in T cell function (Garcia et al., 2001; Garcia et al., 1998). Crucially, both DTXs 
and scorpion toxins were employed to define the subunit compositions of Kv1 channels in 
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native mammalian brain tissue (Koch et al., 1997; Koschak et al., 1998; Scott et al., 1994a; 
Wang et al., 1999b). 
 
2.7 Kv1 inhibition by peptide toxins 
2.7.1 Dendrotoxins DTXs are isolated from mamba venoms; αDTX, βDTX, γDTX and 
δDTX from Dendroaspis angusticeps, DTXI and DTXk from D. polylepis and DV14 from 
D. viridis (Benishin et al., 1988; Dolly, 1992; Hopkins et al., 1996). The toxins for which 
sequence data is available can be placed into 2 subfamilies (Table 2.1) which show 
approximately 60% amino acid identity. βDTX and γDTX have only been partially 
sequenced and while they are members of the DTX family, it is not clear to which 
subfamily they belong (Harvey, 1997; Hopkins et al., 1996).  
 
 
 
 
 
 
 
 
  
 1                      10                       20                         30                       40                       50 
 
δDTX 
 
       AAKYCKLP VRYGPCKKKI PSFYYKWKAK QCLPFDYSGC GGNANRFKTI EECRRTCVG 
 
DTXk 
 
       AAKYCKLP  LRIGPCKRKI  PSFYYKWKAK QCLPFDYSGC GGNANRFKTI EECRRTCVG 
 
DV14 
 
       AAKYCKLP VRYGPCKKKI PSFYYKWKAK QCYPFDYSGC GGNANRFKTI EECRRTCVG                       
  
 1                    10                        20                        30                        40                       50 
 
αDTX 
 
pEPRRKLCILH RDPGRCYDKI PAPYYNQKKK QCERFDWSGC GGNSNRFKTI EECRRTCIG 
 
DTXI 
 
pEP IRKLCILH RDPGRCYQKI PAFYYNQKKK QCEGFTWSGC GGNSNRFKTI EECRRTCIRK                               
  
1                   10                       20                       30                        40                         50 
 
BPTI 
 
    RPDFCLEP PYTGPCKARI  IRYFYNAKAG  ICQTFVYGGC  RAKRNNFKSA EDCMRTCGGA 
Table 2.1│Sequences of dendrotoxin subfamilies, and a homologous protease inhibitor. 
The single letter amino acid code is: A=alanine, R=arginine, N=asparagine, D=aspartic acid, 
C=cysteine, Q=glutamine, E=glutamic acid, G=glycine, H=histidine, I=isoleucine, 
L=leucine, K=lysine, M=methionine, F=phenylalanine, P=proline, S=serine, T=threonine, 
W=tryptophan, Y=tyrosine, V=valine, pE=pyroglutamate. Taken from (Hopkins et al., 
1996), (Katoh et al., 2000) and (Swaminathan et al., 1996). 
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After initial findings that they facilitated neurotransmitter release at the neuromuscular 
junction, it was determined that DTXs act by blocking Kv channels (Halliwell et al., 1986). 
DTXs are arguably the most specific of venom peptide toxins, with activity against only a 
few of the Kv1 α subunits. As a group they inhibit Kv1.1, 1.2 and 1.6 (Hopkins et al., 1996) 
but the specificities of individual homologues differ as detailed in Table 2.2. They are 
single chain polypeptides of low molecular weight (around 7 kDa), 57 – 60 residues long 
with 3 conserved disulphide bonds (Fig. 2.5b). Specifically, DTXk consists of a 310-helix 
(residues 3–7), a β-hairpin (residues 18-35) and an α helix (residues 47-56) (Smith et al., 
1997) (Fig. 2.6a). The DTXs also have sequence homology to Kunitz serine protease 
inhibitors such as bovine pancreatic trypsin inhibitor (BPTI) (Table 2.1), but the most 
potent toxins have negligible protease inhibitor activity and the inhibitors do not block K+ 
channels (Dolly and Parcej, 1996; Harvey, 1997). 
 
 
 
 
 
 
 
 
 
 
 
c a b 
Figure 2.5│Three-dimensional models of dendrotoxink and dendrotoxinI. a, main chain 
folding of DTXk side-chain positions of some the residues vital for Kv1.1 channel 
binding affinity. b, ribbon structure of DTXI with the three disulphide bonds, highly 
conserved among the DTXs, shown as yellow ball and stick models. c, positions of the 
two putative K+ channel binding triads on DTXI. Taken from (Smith et al., 1997) and 
(Katoh et al., 2000). 
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However, conserved patterns of disulphide bridging result in similar backbones of the 
DTXs and serine protease inhibitors, though there are differences in the detailed structures 
(Smith et al., 1997). Comparison of the 2 groups of homologues suggested that conserved 
lysine residues in the DTXs may be responsible for their channel blocking ability (Harvey, 
1997). These positively charged amino acids are concentrated in the lower part of the 
structure, the cationic domain, formed by the N- and C-terminal regions and residues 27-30 
of the β-turn (Katoh et al., 2000). In fact, studies involving site-directed mutagenesis of 
DTXk revealed the areas of the toxin that interact with Kv1.1 channels [the specific target 
of the toxin (Table 2.2)] both in synaptic plasma membranes from rat cerebral cortex and 
recombinantly expressed in Xenopus oocytes (Smith et al., 1997; Wang et al., 1999a). 
Mutants were chosen on the basis that a positively charged region of DTXk (the cationic 
domain) interacts with a negatively charged area on the channel (negatively charged amino 
acids in the S5-S6 domain). The multiple lysines and/or arginines (positive) conserved on 
DTXk as well as other channel blocking homologues, coupled with the fact that removing 
glutamate (negative) from the toxin binding domains of α subunits decreases DTX affinity, 
provided evidence for the theory. Furthermore, it was shown that for scorpion toxins 
interacting with Kv1.3 channels, there are electrostatic interactions between the toxin 
residues (similar to those on DTXs) and acidic (negative) amino acids in the channel mouth 
(Smith et al., 1997). Altering positively charged lysine residues (K24, 26 and 28) to alanine 
in the β hairpin decreased the binding affinity with the K26 mutant giving the largest 
decrease. Mutating a tryptophan residue (W25) to the less hydrophobic alanine also 
reduced binding affinity demonstrating that both positively charged and hydrophobic 
residues in the β-hairpin are important for toxin/channel interaction. Altering residues K3 
and 6 in the 310-helix also reduced toxin binding affinity, thus also demonstrating the 
importance of this region (Fig. 2.5a). Interestingly, mutating positively charged amino 
acids in the C terminal α helix did not influence binding, highlighting the selectivity of the 
identified residues. The studies concluded, therefore, that the 310-helix and β-hairpin 
domains are important for channel interaction with alterations of some residues in these 
structural elements reducing binding affinity (Smith et al., 1997; Wang et al., 1999a). A 
later study of DTXI comfirmed that residues in the N-terminal half of the molecule are 
mainly responsible for binding of the toxin although there was evidence that 
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Toxin Abbre-
viation 
Source Organism 
 
Animal Channels known to be 
sensitive 
Refs. 
Agitoxin-1 AgiTX
-1 
Leiurus quinquestriatus var. 
herbraeus 
Scorpion Kv1.1, 1.3, 1.6 (Garcia et al., 
1994; Suarez-
Kurtz et al., 
1999) 
Agitoxin-2 AgiTX
-2 
Leiurus quinquestriatus var. 
herbraeus 
Scorpion Kv1.1, 1.3, 1.6 (Garcia et al., 
1994; Suarez-
Kurtz et al., 
1999) 
(Cayabyab et 
al., 2000) 
Agitoxin-3 AgiTX
-3 
Leiurus quinquestriatus var. 
herbraeus 
Scorpion Kv1.3 (Garcia et al., 
1994) 
Charybdo-
toxin 
ChTX Leiurus quinquestriatus var. 
herbraeus  
Scorpion Kv1.2, 1.3 (Grissmer et al., 
1994) 
αDendrotoxin αDTX Dendroaspis angusticeps Snake Kv1.1, 1.2, 1.6 (Grissmer et al., 1994; Grupe et 
al., 1990) 
βDendrotoxin βDTX Dendroaspis angusticeps Snake Kv1.1, 1.2 (Hopkins et al., 1996) 
γDendrotoxin γDTX Dendroaspis angusticeps Snake Kv1.1, 1.2 (Hopkins et al., 1996) 
δDendrotoxin δDTX Dendroaspis angusticeps Snake Kv1.1, 1.6 (Hopkins, 1998; 
Imredy et al., 
1998) 
Dendrotoxin I DTXI Dendroaspis polylepis Snake Kv1.1, 1.2 (Hopkins, 1998) 
Dendrotoxin 
K 
DTXk Dendroaspis polylepis Snake Kv1.1 (Shamotienko et 
al., 1997) 
Hongotoxin HgTX Centruroides limbatus Scorpion Kv1.1, 1.2, 1.3, 1.6 (Koschak et al., 1998) 
Kaliotoxin KTX Androctonus australis Scorpion Kv1.1, 1.3 (Grissmer et al., 1994) 
Margatoxin MgTX Centruroides margaritatus Scorpion Kv1.1, 1.2, 1.3 (Garcia-Calvo 
et al., 1993) 
(Suarez-Kurtz 
et al., 1999) 
Mast Cell 
Degranulating 
Peptide 
MCD Apis mellifera Bee Kv1.1, 1.2, 1.6 (Grissmer et al., 1994; Grupe et 
al., 1990; 
Stuhmer et al., 
1989) 
Noxiustoxin NxTX Centruroides noxius Scorpion Kv1.2, 1.3 (Grissmer et al., 1994) 
Stichodactyla 
toxin 
ShK Stichodactyla helianthus. Sea 
anemone 
Kv1.1, 1.2, 1.3, 1.4, 1.6, (Kalman et al., 
1998; 
Middleton et al., 
2003; Suarez-
Kurtz et al., 
1999) 
Tityustoxin 
Kα 
TsTX-
Kα 
Tityus serrulatus Scorpion Kv1.2, 1.3 (Hopkins, 1998; 
Rodrigues et al., 
2003) 
Table 2.2 │ Details of toxins known to block Kv1 channels  
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there are some functional residues in the C-terminal of the DTXI molecule (Katoh et al., 
2000). The study went on to examine the possibility of the toxin possessing a functional 
diad or triad of residues crucial for channel binding, as have been discovered in sea 
anemone and scorpion toxins (Honma and Shiomi, 2006). Two putative triads were 
identified; Lys19/Tyr17/Trp37 and Lys5/28/29 (Fig. 2.5c). Conversely, binding of αDTX 
(the DTXI angusticeps homologue, see Table 2.1) only depends on residues at the N 
terminus for binding, with those in the β-hairpin (the location of the DTXI 
Lys19/Tyr17/Trp37 triad) being unimportant. In fact, three residue differences between 
αDTX and DTXI at positions 18, 34 and 36 result in large changes in the electrostatic 
potential of the domain. Thus, the more acidic residues surrounding Lys19 of αDTX are 
suggested to disturb interactions between it and negatively charged residues of the K+ 
channel pore (Katoh et al., 2000). It had been suggested that the fact that DTXk has two 
areas of residues vital for binding (in the β-hairpin and the 310-helix) compared with only 
one for αDTX (those at the N-terminus and not the β-hairpin) could be responsible for the 
very selective nature of DTXk (blocking only Kv1.1 channels) compared to αDTX (inhibits 
Kv1.1, 1.2 and 1.6), as a larger proportion of the toxin molecule interacts with the channel 
pore therefore requiring a higher degree of pore sequence specificity (Table 2.2) (Gasparini 
et al., 1998; Wang et al., 1999a). However, if DTXI does in fact have two binding triads, 
this does not translate into α subunit specificity as DTXI inhibits Kv1.1 and 1.2 channels 
(Table 2.2). It could though account for the higher binding affinity to rat brain membranes 
of DTXI over αDTX (Katoh et al., 2000). 
A study of the energetic and structural interactions between δDTX and the Shaker K+ 
channel, with the pore region mutated to resemble that of Kv1.1 (Imredy and MacKinnon, 
2000) found that a triangular patch of 7 amino acids formed the interaction surface of the 
toxin. In agreement with results gathered for subfamily member DTXk, the vital residues 
for δDTX binding are in the 310-helix and the β-hairpin (Imredy and MacKinnon, 2000). 
The authors propose that the asymmetric ligand binds off-centre to the pore, interacting 
predominantly with the turret region of one α subunit and contacting the 2 adjacent subunits, 
therefore, not interacting with all 4 subunits equally (see Fig. 2.6 for schematic). Assuming 
that a single toxin molecule binds per channel, the result is 4 possible orientations involving 
different combinations of the channel forming subunits. Such an interaction would render a  
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channel with bound DTX not completely, physically blocked, conveniently explaining the 
residual flow of current through certain channels even in the presence of very high toxin 
doses. The authors put forward 2 possible explanations for the mechanism of inhibition of 
the channels; that the positively charged toxin acts as a K+ repellent or, more likely, that a 
DTX molecule attached to a turret results in a more rigid pore structure which could then 
negatively influence the flow of ions (Imredy and MacKinnon, 2000). 
 
2.7.2 Scorpion toxins Scorpion toxins that inhibit K+ channel activity have homologous 
primary amino acid sequences (Garcia et al., 2001; Garcia et al., 1998). There have been at 
least 26 subfamilies identified as of 2008 (α-KTx1-26) (Shijin et al., 2008), with the isolation 
b a 
Figure 2.6│ Hypothetical binding orientation of snake and scorpion toxins. a, 
δDTX bound to the mutant Shaker K+ channel. The channel is shown looking 
directly down the pore from the extracellular side. Lys6 of δDTX is shown in 
purple. b, Binding orientation of agitoxin 2 on the K+ channel based on mutant 
cycle analysis of its interaction with the Shaker channel (MacKinnon et al., 1998; 
Ranganathan et al., 1996). The channel is in the same orientation as in a. The 
purple residue on AgiTX-2 is Lys27 which interacts with the external K+ binding 
site of the channel and, thus, acts as a “plug”' in the pore (Park and Miller, 1992; 
Ranganathan et al., 1996). The toxin backbones are shown as a black line. Taken 
from (Imredy and MacKinnon, 2000). 
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of scorpion toxins being a very active field [some examples include: (Abbas et al., 2008; 
Abdel-Mottaleb et al., 2008; Corzo et al., 2008; Shijin et al., 2008; Srairi-Abid et al., 2008). 
These peptides are 30-40 amino acids in length, with 3 or 4 disulphide bridges which link 3 
anti-parallel β strands with an α helical region (see Table 2.3 for the sequences of some 
toxin examples). This results in a very compact structure where all the residues are in 
solution, with the exception of the cysteines which are buried in the peptide (Fig. 2.7) 
(Garcia et al., 2001; Garcia et al., 1998). On the whole, scorpion toxins are less specific 
than DTXs as they inhibit other families of Kv channels besides Kv1 such as Ca2+-activated 
(KCa) channels [e.g. Charybdotoxin (ChTX), and NxTX] (some examples are listed in 
Table 4.4). Although divided into sub-families based on sequence homology, toxins across 
these sub-families inhibit Kv1 channels e.g. ChTX (α-KTx1), NxTX (α-KTx2) and the 
agitoxins (AgiTXs) (α-KTx3) (Hopkins et al., 1996).  
 
 
 
 
 
Table 2.3│Comparison of the amino acid sequences of various scorpion toxins, aligned 
with respect to the 6 cysteine residues (bold). The position of the disulphide bonds is 
indicated.  ChTX – carybdotoxin, IbTX – iberiotoxin, Lq2 – L. quinquestriatus toxin 2, 
LbTX – limbatustoxin, NxTX – noxiustoxin, MgTX – margatoxin, C.l.l. I - C. limpidus 
limpidus toxin I, TyKα – tityustoxin-Kα, AgTX1 – agitoxin 1, AgTX2 – agitoxin 2, 
AgTX3 – agitoxin 3, KTX – kaliotoxin, KTX2 – kaliotoxin 2. Taken from (Garcia et al., 
1998) 
α-KTx1 
α-KTx2 
α-KTx3 
1 10 20 30 
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Like the dendrotoxins, several scorpion toxins also block Kv1.1, 1.2 and 1.6 though, 
interestingly, several also target Kv1.3 [e.g. margatoxin (MgTX)] (Hopkins et al., 1996). 
Subunit sensitivities for some of these toxins are given in Table 2.2. While DTXs and 
scorpion toxins interact with many of the same amino acids on Kv1 channels (Imredy and 
MacKinnon, 2000), they bind in slightly different places. Scorpion toxin binding, like DTX, 
is governed by electrostatic interactions between negative residues of the channel and 
positive residues of the toxin, the lysine at position 27 having been identified as crucial for 
binding of several toxins including ChTX and AgiTX-2 (Fig. 2.7) (Garcia et al., 2001). The 
positively charged side chain of the residue lies physically close to the K+ binding site in 
the ion conduction pore and, therefore, its location in the toxin/channel complex is near the 
centre of symmetry in the tetrameric channel structure (Garcia et al., 2001). Therefore, 
scorpion toxins bind in the centre of the pore and physically “plug” it, compared with the 
off-centre interaction of DTXs. AgiTX-2, for example, fits between the channel turrets 
competing for the K+ binding site, thereby, obstructing the pore (Imredy and MacKinnon, 
b a 
Fig 2.7│Backbone and three-dimensional structures of agitoxin-2. Structure showing side 
chains that are vital for binding to the Shaker channel; a, backbone structure and b, three-
dimensional structure. Colours represent residues with the following properties: white, 
hydrophobic; green, polar; red, negatively charged; blue positively charged; gray, aromatic; 
yellow, cysteine. Taken from (Garcia et al., 2001). 
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2000) (see schematic Fig. 2.6). Indeed, the size of the residue at position 425 of the Shaker 
channel can sterically prevent peptides from reaching their binding site (Garcia et al., 2001). 
 
2.7.3 Sea anemone toxins These are rich sources of both voltage-gated Na+ and K+ channel 
toxins (Honma and Shiomi, 2006). The Kv1 channel blockers include Stichodactyla toxin, 
ShK, isolated from the Caribbean sea anemone, Stichodactyla helianthus, BgK from 
Bunodosoma granulifera and HmK from Heteractis magnifica. They are 35 – 37 amino 
acids long with 3 conserved disulphide bridges; 3-35, 12-28 and 17-32. Amino acids serine 
at position 20, lysine at 22 and tyrosine at 23 are completely conserved in all sea anemone 
Kv1 blockers. They are vital for the binding of ShK to both rat brain membranes and Kv1.1, 
1.2, 1.3 and 1.6. The lysine and tyrosine residues have been identified as having particular 
importance, similar to the dyad found in scorpion toxins (e.g. lysine 27 and tyrosine 36 for 
ChTX). Despite a different molecular scaffold, the dyads of both scorpion and sea anemone 
toxins superimpose in the three-dimensional structures (Honma and Shiomi, 2006). ShK, 
like scorpion toxins, binds centrally to the outer vestibule of channels, plugging the pore 
(Lewis and Garcia, 2003).  
 
2.8 Classical K+ channel blockers 
Tetraethylammonium (TEA) and 4-aminopyridine (4-AP) block various families of K+ 
channels and many Kv1 α subunits are sensitive to them. TEA is a quarternary ammonium 
cation consisting of four ethyl groups attached to a central nitrogen atom (Fig. 2.8a). While 
it can bind to both intra- and extracellular sites of a K+ channel (Lenaeus et al., 2005), in 
these experiments it was applied externally. An aromatic amino acid residue at the 
equivalent of position 449 of the Shaker channel is required for extracellular channel block 
by TEA (MacKinnon and Yellen, 1990), and all four subunits of a channel make an 
energetic contribution to the binding of a molecule of TEA (Heginbotham and MacKinnon, 
1992; Kavanaugh et al., 1992). 4-AP is a small molecule (Fig. 2.8b) that requires 
membrane depolarization, i.e. open channels, to block. For a channel to become unblocked, 
depolarization is again required demonstrating that 4-AP becomes trapped in closed 
channels (Armstrong and Loboda, 2001; Choquet and Korn, 1992).  
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While 4-AP does not block channels from the outside, it can block when applied 
extracellulary therefore it must cross the cell membrane. The difference between the extra 
(lower) and intracellular (higher) pH of a cell is a key factor in the potency of 4-AP. 
Therefore it is likely that the molecule crosses the membrane in an unionised form, and 
blocks the channel from the inside once it is re-ionised .(Choquet and Korn, 1992). 
 
2.9 Investigation of relevant channels 
While expression of Kv1 α subunit genes (with or without the accompanying β subunits) 
yields distinct voltage-dependent K+ currents, the biophysical and pharmacological 
properties of these channels rarely matches those of native K+ currents recorded from 
neurons. This highlights the need to establish the subunit compositions of authentic 
neuronal Kv1 channels so that insight into channel structure and function can be obtained 
from the biophysical and pharmacological properties of exact, recombinantly reconstructed 
channels (Dolly and Parcej, 1996). This is especially important given that mutations of 
these channels are implicated in various channelopathies such as Episodic Ataxia 1, some 
epilepsies and even Multiple Sclerosis (Lehmann-Horn and Jurkat-Rott, 1999; Manganas et 
al., 2001; Zuberi et al., 1999), and the development of successful therapeutics depends on 
the availability of an authentic target for drug development. The theoretically possible 
a b 
Figure 2.8│Structures of the classical K+ channel blockers tetraethylammonium (a) 
and 4-aminopyridine (b) 
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number of channels that could be produced from homo- and hetero-tetrameric combinations 
of the 6 α subunit genes alone is manifold. However, only a subset of the potential 
oligomers have been identified (Coleman et al., 1999; Koschak et al., 1998; Scott et al., 
1994a; Shamotienko et al., 1997), most of which are heteromers, suggesting that these 
combinations may confer properties suited to the role of a channel at a particular location. 
This emphasises the importance of studying physiologically-relevant channels unlike 
numerous studies performed solely on homomeric Kv1 channels [e.g. (Garcia et al., 1994; 
Grissmer et al., 1994; Hopkins, 1998; Stuhmer et al., 1989)]. 
As isolating native channels from mammalian brain is not a practical approach for 
supplying adequate material for investigation of blockers, development of recombinant 
technology to produce physiologically relevant channels (detailed later in Chapter 6) is a 
vital step for continued exploration of these proteins. 
 
2.10 Potential utilisation of the specific inhibition of Kv1 channels by peptide toxins  
The value of peptide toxins as blockers of Kv1 channels has already been demonstrated, 
through the use of DTXs and scorpion toxins to purify channels from native tissue and 
determine their specific subunit compositions (Koch et al., 1997; Koschak et al., 1998; 
Wang et al., 1999b). Additionally, scorpion toxins have been used to determine the pore 
region of channels (MacKinnon and Miller, 1989). It is these venom-isolated peptide toxins 
that currently offer the best hope for brain heteromer-specific Kv1 blockers. Understanding 
their interactions with physiologically-relevant oligomers, in contrast to the homomers 
more usually studied, will aid in the pharmacological profiling of Kv1 channels. Finding 
and/or developing blockers specific for defined heteromers would prove particularly useful 
in assigning a molecular basis for K+ currents recorded from neurons. Perhaps most 
importantly, there is potential for such molecules to contribute to future therapeutics.  
There are features of these toxins that in all likelihood would prohibit them from being 
directly used in a clinical situation. For example, such peptides do not cross the blood-brain 
barrier, their bioavailability would preclude oral administration requiring instead 
intravenous, intramuscular or subcutaneous administration, and they are likely to trigger 
immune responses (Lewis and Garcia, 2003). However, using the toxins as templates to 
design small molecules that mimic their action could achieve the hetero-oligomeric specific 
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inhibition required, targeting localised channel populations which would surely decrease 
adverse side effects.  
 
2.11 Rb+ efflux assay for high-throughput screening of specific blockers for Kv1 hetero-
tetramers 
Large scale profiling of a library of peptide toxins requires not only a convenient source of 
native-like targets but also a suitable system for determining channel/toxin interactions. 
Typically, electrophysiological recordings are the gold standard for ion channel 
measurements; these are very accurate but incredibly time consuming and, as such, not 
suitable for screening. Ion channel activity has previously been quantified by flux assays. In 
the case of K+ channels with equal conductivity for Rb+, inhibitors have been tested for 
blockade of the efflux of radioactive 85Rb+. However, the use of such high-energy 
radioisotopes for large scale screens would not be favourable due to their associated 
hazards, especially in large quantities. Moreover, the expense of the isotope, as well as its 
disposal, is of major concern.  
As an alternative, a high-throughput, non-radioactive Rb+ efflux assay has previously been 
described (Terstappen, 1999). Cells expressing the channel of interest are loaded with Rb+ 
and its release upon K+ depolarisation, in the presence and absence of inhibitors, quantified 
by atomic absorption spectroscopy (AAS). The 96-well format of this assay makes it very 
attractive for screening applications. The potential for automation of the assay was 
considered, but analysis of AAS samples was thought to be a limiting step (Terstappen, 
1999). Modifying conventional atomic absorption spectrometers to cope with the smaller 
samples volumes provided by a microplate format, coupled with attached auto-samplers has 
allowed AAS to become a high-throughput technique (Ford et al., 2002). This is, therefore, 
a very practical assay for screening large numbers of compounds in the search for blockers 
of native-like Kv1 channels composed of specific combinations of α subunits. 
 
2.12 Aims of this study 
Many peptide toxins have been shown to block Kv1 channels, mostly through investigation 
of recombinant homomeric channels as it is the α subunit composition that confers 
sensitivity to these blockers (Grissmer et al., 1994; Gutman et al., 2005), and the expression 
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of α subunit cDNAs alone forms active channels (Scott et al., 1994b). In the main, Kv1 
channels from mammalian brain are composed of heteromeric combinations of α subunits 
(Shamotienko et al., 1997). As different compounds require contributions from various 
subunits for binding (Akhtar et al., 2002; Heginbotham and MacKinnon, 1992), it is 
possible that screening heteromeric channels will identify toxins with effects unpredictable 
from looking at parental monomers alone. Such inhibitors could act as useful tools for 
characterising and distinguishing the specific oligomers responsible for K+ currents 
recorded in neurons. Given the many advantages of the Rb+ efflux assay for high-
throughput screening of K+ channel inhibitors, it was highly desirable to establish and 
optimise this technique for determining their effects on concatenated α subunit 
combinations, expressed in mammalian cells. Automation of the efflux assay would expand 
the scope to screen numerous potential blockers against all the available heteromeric 
channels. Electrophysiological recordings and radio-labelled toxin binding experiments 
could confirm results obtained by this newly-established assay and provide functional 
characterisation of such expressed channels. In this way, the effects of many toxins on 
heteromeric channels could be analysed, for the first time, and toxins selective for such 
channels identified.  
Ultimately this research aimed to express channels with compositions mimicking those 
elucidated from mammalian brain, and to characterise them according to their biophysical 
and pharmacological properties. Recreation of such native-like tetramers would provide 
authentic targets for development of future therapeutics.  
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Chapter 3 
Materials and Methods 
 
 
3.1 Materials 
Restriction enzymes were purchased from New England Biolabs, Klenow DNA polymerase 
from Epicentre Biotechnologies, SP6 polymerase and RNase inhibitor from Roche, pSFV 
plasmid, pCR-blunt plasmid, DH5α competent cells, SOC medium and Lipofectamine 2000 
transfection reagent from Invitrogen; 0.5% trypsin/EDTA, L-glutamate, ab/am solution, 
Geneticin, Opti-MEM medium and sterile PBS (for tissue culture) were bought from Gibco. 
HiSpeed plasmid purification kits and Polyfect were from Qiagen. pβUT2 was a gift from 
A. Rodaway, Kings College, London, pIRES2-EGFP plasmid was from Clontech and 
Kv1.X sequences in pAKS plasmid were a gift from Prof. O. Pongs. Calbiochem supplied 
MOWIOL. Protein molecular weight markers were purchased from Biorad. Mouse 
monoclonal anti-Kv1.2 antibody was generated against K+ channels purified from bovine 
brain (Muniz et al., 1992), Kv1.2 antibody directed against external epitopes was a gift 
from Prof. J.S. Trimmer; Kv1.3 and Kv1.6 antibodies were from Santa Cruz and Abcam, 
respectively, and all AF conjugated secondary antibodies from Molecular Probes. Kv1.2 
(clone K14/16), Kv1.4 (clone 13/31) and Kv1.1 (clone 20/78) antibodies for immuno-
labelling total channel populations were bought from Neuromab. α and δDTX and DTXk 
were isolated from the venoms of Dendroaspis angusticeps and polylepis, respectively 
(Dolly, 1992). 4-AP and TEA were purchased from Lancaster Synthesis, Shk and 
Tityustoxin-Kα
 
(TsTX-Kα) from Peptides International; all other toxins tested from 
Alomone Labs. 125Iodine was from Aim Research Company, Rb+ standard for atomic 
absorption spectroscopy from Acro Organics and BCA (bicinchoninic acid) assay kit from 
Pierce. All other chemicals including tissue culture reagents were from Sigma.  
 
3.2 Molecular biology procedures 
3.2.1 Generation of Kv1.1-1.2 cRNA Kv1.1-1.2–pSFV1 cRNA was prepared by Dr. O. 
Shamotienko. DNA, as described previously (Akhtar et al., 2002), was linearised with Spe1 
restrictase and used to generate capped cRNA with SP6 polymerase. This entailed 
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incubating 15 µg of DNA and 20 µl of SP6 polymerase plus 15 µl of RNase inhibitor in a 
total volume of 500 µl at 37°C for 1.5 h, before adding another 10 µl of the enzyme and 
continuing the incubation for 1.5 h. The resultant cRNA (~3.25 mg/ml) was stored in 
aliquots as an ethanol precipitate at -80°C; for reconstitution, the samples were centrifuged, 
ethanol removed and the pellet dissolved in sterile PBS. 
 
3.2.2 Preparation of Kv1.1-1.2 and 1.6-1.2 pIRES2-EGFP constructs These were made by 
Dr O. Shamotienko as described in (Sokolov et al., 2007), including Kv1.1, 1.2 and 1.6 
monomers. pIRES2-EGFP plasmid contains an internal ribosomal entry site (IRES), from 
the encephalomyocarditis virus (ECMV), between a multiple cloning site (MCS) and an 
EGFP cloning region. This allows both the gene of interest (cloned into the MCS) and 
EGFP to be translated from the same mRNA strand. EGFP is a variant of wild-type green 
fluorescent protein (GFP), optimised for brighter fluorescence and enhanced expression in 
mammalian cells; expression simplifies the monitoring of transfection efficiency, channel 
expression and selecting cells for electrophysiological recordings. 
Kv1.1-1.2 Spe I and BamH I restrictases were used simultaneously to digest Kv1.1-
1.2 pSFV (Akhtar et al., 2002) followed by blunting of the 5’-overhangs of the product 
with Klenow DNA polymerase. pIRES2-EGFP was digested with Bgl II and Sma I and 
similar blunting of the 5’-ends was again performed. Both the digested insert and plasmid 
were purified by agarose gel electrophoresis, and the 1.1-1.2 insert was ligated into the 
pIRES2-EGFP plasmid. Restriction mapping with Nhe I and Pst I was used to check the 
orientation of the insert once DNA had been prepared from single colonies of transformed 
DH5α cells. DNA was then purified on a larger scale using a HiSpeed plasmid purification 
kit. 
Kv1.6-1.2 In preparation for assembling the Kv1.6-1.2 pIRES2-EGFP plasmid, the 
following forward and reverse primers were used to amplify Kv1.6 and 1.2 constituents 
from pAKS plasmid: Kv1.6 – forward, TCG ACT CGA GCC GCC ACC ATG AGA TCG 
GAG AAA TCC C and reverse, TCG AGG ATC CGA CCT CCG TGA GCA TTC TTT 
TC (without a stop codon) and Kv1.2 – forward, CGA CTC GAG ATG ACA GTG GCT 
ACC GGA G and reverse, TCG AGG ATC CTC AGA CAT CAG TTA AC, with Xho I 
and BamH I restriction sites underlined on the forward and reverse primers, respectively. 
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The PCR reaction was as follows: 2 min denaturation followed by 22 cycles of: 94°C, 30 s; 
55°C, 45 s; 75°C, 2 min. Following agarose gel electrophoresis purification, PCR products 
were cloned into pβUT2 plasmid after both were digested with Xho I and BamH I. Next, 
Kv1.6 pβUT2 was incubated with BamH I and the 5’-overhangs blunted, as above with 
Klenow DNA polymerase. EcoR I was then used to remove the 3’-untranslated region 
(UTR) flanking the pβUT2 MCS (Akhtar et al., 2002). To remove the Kv1.2 insert with its 
5’ and 3’ UTRs, the Kv1.2 pβUT2 plasmid was incubated with Hind III and 5’-overhangs 
were blunted followed by digestion with EcoR I. After purification, the Kv1.6 pβUT2 
plasmid and Kv1.2 insert were ligated yielding the Kv1.6-1.2 pβUT2 plasmid, with the 
Kv1.6 and 1.2 connected by the 5’-UTR. Confirmation that monomeric constituents were in 
the same open reading frame (ORF) was achieved using a forward primer based on the 3’-
region of Kv1.6 and the reverse based on the 5’-region of Kv1.2. In order to subclone 
Kv1.6-1.2 into pIRES2-EGFP, the 2 plasmids were incubated with Hind III and Xho I, 
respectively, followed by blunt ending of 5’-overhangs, and digestion with EcoR I. The 
insert and plasmid were purified and semi-directionally cloned, and Kv1.6-1.2 pIRES2-
EGFP formed; DNA was prepared from single colonies of transformed DH5α cells, using a 
Qiagen plasmid purification kit. 
 
3.2.3 Cassette cloning system This was developed as described in (Shamotienko et al., 
2008), by Dr O. Shamotienko, Dr J. Wang and Prof J. O. Dolly. Dr O. Shamotienko and Dr 
M. Bodeker prepared the constructs. A modified pβUT2 plasmid was the source of a 
proven inter-subunit linker as above and in (Akhtar et al., 2002). 
3.2.3a PCR amplification of Kv1.X–constituents Rat Kv1.1-, 1.2-, 1.3-, 1.4- and 1.6-pAKS 
plasmids were used as PCR templates; their amplification was achieved using the primers 
detailed in Table 3.1 which incorporated Xba I and Xho I restriction sites at the 5’ and 3’ 
ends, respectively. The conditions for amplification using Pfx high fidelity polymerase 
were: initial denaturation, 95°C for 2 min, then 22 cycles of amplification with each cycle 
comprising denaturation, 94°C for 30 s, annealing at 58°C for 45 s and elongation at 72°C 
for 2 min. PCR-products were purified by electrophoresis on agarose gel and cloned into 
the ‘intermediate’ pCR-blunt plasmid; competent DH5α cells were transformed with the  
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Rat Kv1  
α Subunits 
 
Forward primer  
(with Xba I site underlined) 
 
 
Reverse primer  
(-STOP)* 
(with Xho I site underlined) 
 
 
Kv1.1 
 
G TCTAGA AT GAC GGT GAT GTCAGG 
GGA GAATGC  
 
 
G CTCGAG AA CAT CGG TCA GGA GCT 
TGC TCT TAT TAAC  
 
Kv1.2 
 
GTCTAGAATGACAGTGGCTACCGGAGA
C CCAGTGG 
  
 
G CTCGAG GA CAT CAG TTA ACA TTT 
TGG TAATAT TCAC*  
 
Kv1.3 
 
GTCTAGAATGACCGTGGTGCCCGGGG
AC CACCTG 
 
 
GCTCGAGGACATCAGTGAATATCTTTTT
GATGTTGACAC 
 
Kv1.4 
 
GTCTAGAATGGAGGTGGCAATGGTGAG
TGCC 
 
 
GCTCGAGGACACATCAGTCTCCACAGC
CTTTGCATTAG 
 
Kv1.6 
 
GTCTAGAATGAGATCGGAGAAATCCCT
TACGC 
 
 
GCTCGAGGAGACCTCCGTGAGCATTCT
TTTCTCTGC 
 
Subunit domain in 
pIRES2 plasmids  
(with restriction site) 
 
 
Forward primer 
(restriction site underlined) 
 
 
Reverse primer 
(restriction site underlined) 
 
I (Nhe I – Bgl II) 
 
 
AGCTAGCAGAATAAACGCTCAACTTTG
GCAGATC 
 
GAGATCTCCAGATCCGGTACCAGATCG
ATCTCGAC 
 
II (Bgl II – EcoR I) 
 
 
GAGATCTAGAATAAACGCTCAACTTTGG
CAGATC 
 
CGAATTCCCAGATCCGGTACCAGATCG
ATCTCGAC 
 
III (EcoR I – Sal I) 
 
 
CGAATTCAGAATAAACGCTCAACTTTGG
CAGATC 
 
AGTCGACCCAGATCCGGTACCAGATCG
ATCTCGAC 
 
IV (Sal I – BamH I) 
 
AGTCGACAGAATAAACGCTCAACTTTG
GCAGATC 
 
AGGATCCCCAGATCCGGTACCAGATCG
ATCTCGAC 
 
* Reverse primer for Kv1.2 (+STOP): G CTCGAG TT ATC AGA CAT CAG TTA ACA TTT TGG TAA TAT 
TCAC 
 
Table 3.1│ Cassette cloning primers. Upper panel: specific primers used for amplification of 
Kv1.X subunits, with Xba I and Xho I sites on forward and reverse primers, respectively, to facilitate 
subsequent cloning into pβUT2. Only Kv1.2 was engineered with two STOP codons. Lower panel: 
UTR specific primers for amplifying rat Kv1 subunits, incorporating linker sequences from pβUT2 
and restriction sites allowing position-dependent cloning of individual subunits (with flanking linker) 
into corresponding domain positions within the pIRES2 MCS. The UTR-specific primers differed 
only by domain–specific flanking restriction sites.  
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ligated products. DNA was prepared on a large scale from positive clones; after digestion 
with Xho I and Xba I, inserts were purified by agarose gel electrophoresis and subcloned 
into pβUT2, using Xho I and Xba I sites. 
 
3.2.3b Modification of pβUT2 plasmid and cloning of Kv1.X inserts with flanking half-
linkers Sal I, BamH I and Bg1 II sites of the MCS of pβUT2 plasmid were eliminated by 
sequential in-filling to prevent their interference with subsequent assembly of oligomeric 
constructs into pIRES2-EGFP or-DsRed plasmids. Purified Kv1.X inserts were ligated into 
mutated pβUT2 plasmid and positive clones identified by digestion with Xba I and Xho I 
enzymes. These acted as templates for the subsequent PCR. The forward and reverse 
primers used were based not on the Kv1.X genes but on the first (up to the Xba I site) and 
last (downstream of Xho I site) 30 nucleotides of the UTRs of the Xenopus β-globin gene 
flanking the MCS of pβUT2 (Table 3.1). Restriction sites introduced during this PCR 
allowed positional cloning into the pIRES2-EGFP or-DsRed mammalian expression 
vectors (see later). PCR amplification was performed under the same conditions as before; 
single bands of the expected size were purified by agarose gel electrophoresis, cloned into 
pCR-blunt plasmid and assembled into the pIRES plasmids. All constructs were verified by 
DNA sequencing. 
 
3.2.3c Assembly of Kv1.X tetrameric constructs Paired sites for Nhe I/Bgl II, Bgl II/EcoR I, 
Eco RI/Sal I, and Sal I/BamH I, respectively, were used to individually sub-clone the genes 
from pCR-blunt into domains I to IV of pIRES2-EGFP or -DsRed. In the same way, 
dimeric combinations of channels could be constructed, by sub-cloning only 2 Kv1.X genes 
into the pIRES2 vectors with the ORF still maintained. In these instances, positions 3 and 4 
were occupied. Correct positioning of all the constructs in pIRES2 plasmids were 
confirmed by restriction analysis. Concatenated Kv1 channel constructs were expressed in 
HEK-293 (HEK) cells (except where stated) and experiments performed 48 h after 
transfection.  
 
3.2.4 Transforming competent cells Competent E. coli DH5α cells, stored at -80°C, were 
thawed on ice and 50 µl aliquoted into pre-cooled tubes containing the required DNA. 
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Following a 30 min incubation of the cells and DNA on ice at 4°C, they were heat shocked 
with 20 s in a water bath at 42°C, then returned to ice for a further 20 min; 950 µl of SOC 
medium was added and the mixture transferred to a larger tube for incubation in a shaker 
incubator for 90 min at 220 rpm and 37°C. The resultant culture (100 µl) was spread on a 
kanamycin (50 µg/ml) plate and cultured overnight at 37°C. If individual colonies were not 
visible, a second kanamycin plate was streaked from the first as DNA preparation requires 
individual colonies.    
 
3.2.5 Preparation of DNA This was prepared using HiSpeed plasmid purification kits (midi 
and maxi), according to the manufacturer’s instructions. A single colony was picked from 
plate previously streaked with transformed bacteria and cultured in 50 µg/ml kanamycin LB 
medium (5 ml) for 8 h at 37°C and 300 rpm. Once this starter culture had begun to grow 
(i.e. the medium had become cloudy), it was used to inoculate a 200 ml culture (also 
containing 50 µg/ml kanamycin in LB medium) which was grown overnight under the 
same conditions. The following day, bacteria were pelleted by centrifugation at 6000 g for 
15 min at 4°C. The pellet was resuspended in buffer P1 followed by addition of the alkaline 
lysis buffer P2, thorough mixing, and a 5 min incubation. Buffer P3 was then added, 
neutralising the mixture and precipitating genomic DNA, proteins and cell debris. The 
lysate was incubated in a QIAfilter cartridge for 10 min, during which time a HiSpeed tip 
was equilibrated using Buffer QBT. The cell lysate was then filtered into the prepared tip 
and the resultant cleared lysate left to pass through the tip, before washing with Buffer QC. 
DNA collected in the HiSpeed tip was then eluted with buffer QF, precipitated with 
isopropanol and put through a QIAprecipitator which collects the DNA. Ethanol (70%) was 
passed through the precipitator to wash the DNA following which air was pushed through 
twice to remove any ethanol left over. Finally, the DNA was eluted in TE buffer.  
 
3.3 Cell culture techniques 
3.3.1 Mammalian cell lines CHO, HEK and COS-7 (COS) cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% FCS, ab/am 
solution and L-glutamate, as adherent cultures in a 5% CO2 incubator at 37°C. Once cells 
had grown to 80% confluency, they were harvested by trypsinisation and re-plated. 
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Trypsinisation was performed following removal of culture medium and 2 PBS washes of 
the cell layer; 0.5% trypsin/EDTA solution was then added for approximately 5 min. Once 
the cells were detached, supplemented DMEM was added resulting in inactivation of the 
trypsin by the serum in the medium, which contains trypsin inhibitors. Cells were then 
processed as required.   
 
3.3.2. Electroporation of cells with cRNA (used for expression of the Kv1.1-1.2 channel in 
CHO cells) An 80% confluent 75 cm2 flask was harvested and washed twice by 
centrifugation at 160 g for 5 min followed by re-suspension in sterile PBS. After the final 
wash, cells were resuspended in 0.8 ml PBS containing 75 µg cRNA. This mixture was 
transferred to a 0.4 cm electroporation cuvette and 2 pulses of 850 V, with a capacitance of 
25 uF, were applied. After 1 min, the cells were diluted in supplemented DMEM and plated 
as necessary. Cells were then kept in a 5% CO2 incubator at 37°C for 24 h.  
 
3.3.3 Polyfect transfection of cells Cell densities and quantities of DNA, Polyfect and 
medium were determined from the Handbook supplied by the manufacturer. HEK cells 
were plated in the required flasks one day prior to transfection such that they were 50% 
confluent. DNA was diluted in non-supplemented DMEM, mixed well and Polyfect then 
added. The mixture was left for 10 min for complex formation to occur during which time 
growth medium was replaced on the plated HEK cells. Once the incubation time had 
elapsed, supplemented DMEM was added to the DNA/Polyfect mixture, and the total 
volume transferred to the cells with gentle swirling to ensure even distribution of the 
complexes. Cells were then incubated at 37°C, 5% CO2 for 48 h to allow gene expression.        
 
3.3.4 Transfection of cells using Lipofectamine 2000 HEK cells plated one day previously, 
in the appropriate culture vessel at a density of approximately 40%, were used for 
transfections. DNA, Lipofectamine 2000 and medium volumes for the various size culture 
flasks are given in the manufacturer’s instructions. Quantities for a 75 cm2 flask are given 
in brackets. DNA (30 µg) and Lipofectamine 2000 (75 µl) were separately diluted with 
Opti-MEM (1.9 ml) and left for 5 min, following which they were combined and incubated 
at room temperature for a further 20 min. During this time, growth medium was removed 
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from the cells to be transfected and following 2 washes with non-supplemented DMEM to 
remove any traces of serum or antibiotics, an appropriate amount (19 ml) of the same 
medium was returned to the cells. Following the 20 min incubation, the 
DNA/Lipofectamine 2000 mixture was also added. Cells were replaced at 37°C, 5% CO2 
overnight. The following day, medium was replaced with supplemented DMEM and cells 
were re-plated if necessary. When expression levels were not sufficient for functional 
analysis of channels, the DNA concentration was doubled without altering any other 
parameters. 
 
3.3.5 Lipofectamine 2000 COS cell transfection for K+ channel surface labelling COS cells 
used for surface immuno-staining experiments were plated on poly-l-lysine coated 22x22 
mm coverslips in 35 mm dishes at a density of ~8% in 2 ml supplemented DMEM one day 
prior to transfection. In this instance, 1 µg DNA and 1 µl Lipofectamine 2000 were used for 
each dish, each diluted with 50 µl Opti-MEM. Once the DNA and transfection reagent had 
been mixed and incubated for 20 min, COS cells were placed in 0.5 ml of serum-free 
DMEM after 2 washes in the same. The DNA/Lipofectamine 2000 mixture was added and 
the cells were incubated at 37°C, 5% CO2 for 4 h following which medium was replaced 
with supplemented DMEM and the cells were incubated for a further 2 days.    
 
3.3.6 Establishing Kv1 expressing stable cell lines To prepare HEK cell lines stably 
expressing Kv1 channels, cells were transfected with the relevant pIRES2-EGFP construct 
using Polyfect; 48 h post transfection, Geneticin was added to the culture medium at a final 
concentration of 1 mg/ml. Once the non-transfected cells had died and become detached 
(approx 2 – 3 weeks) and the surviving cells were growing at a healthy rate, they were re-
plated in 24-well plates at a density of 1 cell/well. EGFP expression of the growing cells 
was monitored via fluorescent microscopy and stock cultures were produced from the 
brightest colonies. 
 
3.4 Monitoring expression of recombinant channels 
3.4.1 Immuno-staining of K+ channel proteins expressed in CHO cells Following 
electroporation, CHO cells were plated onto sterile coverslips and incubated in DMEM (as 
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above) for 24 h. Coverslips were washed three times with PBS before the cells were fixed 
with 4% PFA (in the same buffer) for 15 min. Following 3 PBS washes, samples were 
quenched with 50 mM NH4Cl/PBS for 15 min, and washed again. Permeabilisation was 
with 0.1% TX-100/PBS for 5 min and another 3 washes followed. The cells were then 
incubated with a mouse monoclonal antibody specific for Kv1.2 α subunit, diluted in 5% 
FCS/PBS for 4 h at room temperature. Three further PBS washes followed, before 
incubation for 2 h at room temperature with goat anti-mouse IgG-conjugated to AF 488 
diluted 1:1500 in 5% FCS/PBS, washing and staining with DAPI for 5 min. After a final 
wash step, coverslips were mounted onto slides with MOWIOL and, once dried, viewed 
with an Olympus 1X71 microscope using filters appropriate for the fluorophores employed. 
Control experiments were also performed omitting secondary antibody and, in some cases, 
untransfected cells were similarly treated to provide a further control. 
 
3.4.2 Immuno-fluorescent labelling of surface Kv1 channels COS cells plated on poly-l-
lysine coverslips in 35 mm dished and transfected 2 days previously with Lipofectamine 
2000 were processed as described in (Manganas and Trimmer, 2000) with some minor 
modifications (see Appendix A for buffer compositions). Medium was removed from cells 
and replaced with 1 ml ice-cold 3% PFA/PBS for 30 min at 4°C. Following 3x5 min 
washes with chilled PBS, cells were blocked in Tris-buffered milk (blotto) for 30 min. This 
was followed by incubation with primary antibodies directed against an ecto-domain of 
Kv1.2, for 2 h at room temperature (10 µg/ml purified IgG in blotto – 750 µl/dish). After 
3x20 min washes with blotto, cells were permeabilised with 0.1% TX-100/blotto for 30 min 
at room temperature, then incubated with a second cytoplasmically-directed primary 
antibody (used at 10 µg/ml in the same buffer), for 1 h at room temperature. Secondary 
antibody incubation followed 3x10 min washes in 0.1% TX-100/blotto. These AF 
conjugated antibodies were used at 1:1500 dilutions, in 0.1% TX-100/blotto, for 45 – 60 
min at room temperature. The requisite secondary antibodies for both primaries were 
combined in a single incubation and where DAPI staining of nuclei was required, it too was 
included in this step (0.005 µg/ml). Washing with 0.1% TX-100/PBS was the final step 
before coverslips were mounted on slides, sealed with nail varnish and kept at -20°C 
overnight. Slides were viewed as detailed above. All primary antibodies were re-used for 
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further experiments. For controls, primary antibodies were omitted. As fluorescent protein 
genes are present in the pIRES plasmids used for channel expression, their fluorescence 
was also viewed to ensure it did not interfere with signals from antibodies. 
 
3.4.3 Western blot analysis SDS-PAGE and Western blotting were performed as described 
in Section A. Briefly, transiently- and stably-expressing cells were harvested with 0.5 mM 
PBS/EDTA instead of trypsin/EDTA. Detached cells were resuspended in PBS and after 
centrifugation the resultant pellet was dissolved in 1xLDS sample buffer (~4 mg/ml 
protein), heated to 80°C for 10 min, and passed through a 25 G needle. Samples were then 
run on 4-12% pre-cast gels and following transfer, membranes were developed with Kv1 α 
subunit-specific primary antibodies, secondaries conjugated to HRP and SuperSignal West 
Pico Luminol/Enhancer substrate solution.      
 
3.4.4 Biotinylation of surface targeted, expressed channels These experiments were 
performed by Dr O. Shamotienko. For biotinylation of surface proteins, an aqueous 
solution (17 µl) of sulphosuccinimydyl-6-(biotin-amido) hexanoate (60 mg/ml) was added 
to 0.3 ml of cell suspension (5 mg protein/ml) and incubated at 22°C for 1 h. Excess 
reagent was quenched and removed by 3 washes with PBS containing 100 mM glycine 
before resuspending the cells in PBS and extracting with 2% TX-100 for 1 h at 4°C. After 
centrifugation (300 000 g for 1 h), the supernatant was diluted 3-fold and an aliquot (1 ml) 
incubated at 4°C overnight with a 50% slurry of streptavidin-agarose CL-4B. Loosely-
bound unwanted proteins were removed by 3 washes with PBS/0.4 M NaCl and the 
immobilised proteins dissolved in sample buffer (2x). The resultant samples were subjected 
to SDS-PAGE and Western blotting with antibodies specific for Kv1.1 or 1.2 (Shamotienko 
et al., 1999).  
  
3.5 Pharmacological analysis of recombinant Kv1 channels using a Rb+ efflux assay 
3.5.1 Assessment of known K+ channel blockers on Kv1.1-1.2 channels transiently 
expressed in CHO cells Rb+ efflux experiments were performed as described in (Terstappen, 
1999), with some modifications (see Appendix B for buffer compositions). Cells 
electroporated with Kv1.1-1.2-pSFV cRNA were plated in 96-well plates at a density of 
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50,000 cells/well, in 100 µl of DMEM. The following day, Rb+ loading was achieved by 
replacement of culture medium with 300 µl of buffer containing 5.4 mM Rb+  for 4 h. 
Extracellular Rb+ was removed by washing in 25 mM HEPES wash buffer (pH 7.4) using a 
Biotek 405 cw plate washer. Stimulation buffer containing 75 mM K+ (100 µl) was then 
applied to cells for 3 min to activate expressed channels. To measure basal (unstimulated) 
release, some cells were incubated with the wash buffer (containing 0.1 mM K+), also for 3 
min. An aliquot (75 µl) of the supernatants were collected following the stimulation period, 
after which cells were washed again before being lysed with 100 µl 1% TX-100 for 10 min; 
75 µl of lysate was collected and all samples were diluted with 300 µl of ionization 
prevention (IP) buffer. The supernatant and lysate samples were analysed by AAS, using a 
Thermo Solaar S4 atomic absorption spectrometer, attached to a Gilson 222XL auto-
sampler for loading the samples. Rb+ concentration was automatically determined from 
defined standards. The amounts of basal and stimulated release, that is Rb+ concentration in 
the supernatants, were expressed as % of total (supernatant + lysate) Rb+ content.  
To ascertain the optimum time required for Rb+ loading, medium on transfected cells was 
replaced with the appropriate buffer at various time intervals. Once the incubation time had 
elapsed, the test plate was washed and 100 µl 1% TX-100 added for 10 min; lysates (75 µl) 
were collected, diluted and analysed as described above. The optimum concentration of K+ 
required to activate the expressed channels was also determined by measuring supernatant 
[Rb+] after exposure to stimulation buffer with varying [K+] ([NaCl] was altered to 
maintain the isomolar balance). To show that Rb+ release was indeed due to expressed 
channels, untransfected CHO cells and those electroporated in the absence of cRNA were 
similarly analysed. Substances tested for channel blocking ability were either added to the 
stimulation buffer (4-AP and TEA) or included with the cells for the final hour of Rb+ 
loading (αDTX). For experiments on channel blockers, results were expressed as % evoked 
release ± S.E.M. relative to that for the drug-free control; the evoked increment was 
calculated by subtracting basal from the stimulated release value. For all experiments, at 
least eight wells were assayed for every condition and measurements repeated with 3 
different batches of electroporated cells.  
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3.5.2 Characterisation of the pharmacological profiles of Kv1 channels expressed in HEK 
cells, using a modified Rb+ efflux assay Alterations to the assay described above were made 
to suit HEK rather than CHO cells used initially, and to improve application of peptide 
toxins. Buffer compositions are those used routinely for such cells by Xention Ltd. 
(Cambridge, UK). HEK cells stably expressing channels and/or those transiently 
transfected using Lipofectamine 2000, were plated in poly-D-lysine coated 96-well plates 
(Biocoat, BD Falcon), at a density of 50,000 cells/well in a final volume of 100 µl of 
culture medium (1 day post transfection for transients). The following day, cells were 
loaded for 4 h with Rb+ by replacement of medium with 150 µl of Rb+ loading buffer, and 
experiments performed as previously described; however, slightly modified wash and 
stimulation buffers (see Appendix C for compositions) were employed, and stimulation 
time for Rb+ efflux was increased from 3 to 5 min. 
Toxins were tested for blocking ability by addition to the cells of 50 µl of a 2x 
concentration (diluted in 0.01% bovine serum albumin (BSA)/modified wash buffer), 
following washing. After a 10 min incubation, cells were stimulated with 50 µl 150 mM K+ 
modified stimulation buffer (isomolar replacement of NaCl with KCl) resulting in a final 
concentration of toxin and 75 mM K+. The assay was continued as previously described. 
For experiments involving 4-AP and TEA, they were included directly in the stimulation 
buffer (or in wash buffer for some measurements) as described above. Control wells were 
included in each experiment for measurement of basal or unchallenged stimulated release. 
Samples were diluted with 275 µl I.P. buffer before being analysed by AAS as detailed 
above. Fractional inhibition of evoked Rb+ release is plotted ± S.E.M., n = >16 wells from 
measurements made on at least 2 different days. Details of all compounds screened are 
given in Tables 2.2 and 4.3. 
 
3.6 Electrophysiological recordings and data analysis  
3.6.1 Analysis of K+ current evoked from Kv1.1-1.2 channels expressed in CHO (performed 
by Dr M. Sokolov) K+ currents were recorded from CHO cells electroporated with Kv1.1-
1.2-pSFV cRNA in voltage-clamp, whole cell mode (Hamill et al., 1981). Cells were plated 
on glass coverslips immediately after transfection, and currents recorded the next day. The 
extracellular solution contained (in mM): 150 NaCl, 5 KCl, 1.8 CaC12, 1 MgCl2, 10 
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HEPES, 5 NaOH, and 10 D-glucose, adjusted to pH 7.4 with HCl. Patch pipettes were 
pulled from thin-walled borosilicate glass capillaries (1.5 mm OD, 1.2 mm ID); pipette 
resistance was typically between 2 and 5 MΩ. No compensation was made for series 
resistance (ranged from 3-7 MΩ). Patch pipettes were filled with a solution containing (in 
mM) 70 KCl, 70 K-gluconate, 1 MgC12, 5 EGTA, 10 HEPES, and 10 D-glucose, adjusted 
to pH 7.4 with KOH. The osmolarity of all extra- and intra-cellular solutions were in the 
range of 320 ± 7 mOsm. The liquid junction potential was not corrected. The currents were 
filtered at 1 kHz, and sampled at 5 kHz (or 1 kHz for 60 s pulse). Recordings were made at 
room temperature (22-24oC), using a HEKA EPC10 amplifier and Pulse software. 
Pharmacological experiments were performed by applying drugs directly to the recording 
chamber. Currents were recorded in response to repetitive pulses (200 ms, +40 mV); when 
stabilised, drugs were applied and the amplitudes obtained for 10-20 pulses averaged, final 
values for each concentration being taken from at least 3 cells. 
 
3.6.2 Electrophysiological recordings and data analysis from HEK cells stably expressing 
Kv1.1-1.2 and 1.6-1.2 (described in (Sokolov et al., 2007) and performed by Dr M. Sokolov) 
After obtaining stable expression of K+ channels in HEK cells, K+ currents were recorded 
as described above, with some modifications. Currents were filtered at 1 kHz, and sampled 
at 4 kHz (with the exception of 60 s pulses, which were sampled at 50 Hz). P/4 leak 
subtraction was used. The membrane holding potential was -60 mV. To determine voltage 
dependency of activation kinetics after a pre-conditioning pulse to -110 mV for 300 ms, a 
series of depolarisation steps (400 ms duration) from -60 to +50 mV were applied in 10 mV 
increments. Current amplitudes corresponding to 40-90% of the maximum were fitted with 
a single exponential function. Conductance-voltage (G-V) relations were determined from 
averaged current after 200-300 ms of activation, normalised relative to the K+ driving force 
by assuming a reversal potential of -75 mV (measured reversal potential was between -70 
and -80 mV). Kinetics of K+ current deactivation were measured after a 50 ms step to +40 
mV. Inactivation was evaluated during 60 s depolarisation steps to +40 mV. To determine 
steady-state inactivation, cells were maintained at +20 mV for 40 s, followed by 1 s steps to 
the indicated voltage to remove inactivation, and then stepped to +40 mV to determine the 
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extent of K+ current remaining. Time constants were determined by fitting currents with 
single or double exponential functions of the form:  
I =A0+A1 exp(-t/τ1)+ A2 exp(-t/τ2)  (1) 
where A0, A1 and A2  are amplitude coefficients, τ1 and τ2  time constants. 
The voltage-dependence of deactivation was fitted by the equation: 
τ = A
 
exp(-zFE/2.303RT)    (2) 
where A is an amplitude coefficient, z elementary charge, F Faraday’s constant, E 
membrane potential, R gas constant, and T temperature. 
Steady steady-state inactivation and conductance-voltage relationships were fitted by a 
Boltzmann equation of the form:  
 G = Gmax {1 + exp[(V½-V)/k]}-1.  (3) 
 
Drugs were applied directly to the recording chamber and current amplitudes measured 
from the average of 10-20 pulses (200 ms, +20 mV), after current levels stabilised. All data 
shown are mean ± S.E.M. (n>3); where not shown, error bars fall within the data point. 
 
3.6.3 Characterisation of K+ currents elicited from hetero-tetramers (described in 
(Shamotienko et al., 2008) and performed by Dr H. Shaban and Dr J.T. Sack) Membrane 
currents were measured in whole-cell voltage-clamp mode, as outlined in (Sokolov et al., 
2007), except where specified. Borosilicate patch pipettes were filled with an internal 
solution (in mM): 90 KCl, 50 KF, 30 KOH, 10 EGTA, 20 HEPES, pH 7.4. The 
extracellular bath solution contained (in mM) 135 choline chloride, 20 KOH, 1.8 CaCl2, 1 
MgCl2, and 40 HEPES, pH 7.4. Just prior to use, 0.01% (w/v) BSA was added; silanised 
pipette tips and tubes were used for handling toxins. Solutions were exchanged by 
continuous flow with a peristaltic pump or a Cellectricon Dynaflow-16 system. Series 
resistance compensation was applied to minimise the voltage error (<10 mV). Correction 
was made for a calculated liquid junction potential of +8.4 mV. Membrane holding 
potential was -100 mV. Leak subtraction was used to isolate K+ current. Analogue traces 
were filtered at 5 kHz, and sampled at 50 kHz. Non-linear fitting was carried out with 
equations described previously (Sack and Aldrich, 2006).  Data are reported as mean ± 
S.E.M.; n values refer to number of individual cells tested.  
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3.7 125I-αdendrotoxin binding studies 
For all experiments involving 125I-αDTX, HEK cells transfected with the relevant construct 
48 h previously using Lipofectamine 2000 were harvested with 0.5 mM PBS/EDTA instead 
of trypsin. Once cells were dislodged from the flask, they were resuspended in PBS and 
centrifuged as described (see above). Silanised plasticware was also used to minimise toxin 
absorption. 
3.7.1 Iodination of αdendrotoxin Toxin was radiolabelled as previously described (Dolly, 
1992) using the chloramine-T method; 0.98 mg/ml αDTX (10 µl), buffer A (5 µl), 1 mCi 
Na125I (10 µl) and 1 mg/ml chloramine-T (5 µl) were combined for 60 s, then the reaction 
quenched with 970 µl buffer B. At this stage 2x 10 µl aliquots were removed and diluted 
with 990 µl buffer D, for determination of the specific activity. The rest of the reaction 
mixture was loaded onto a column containing 2 ml CM-sepharose CL6B resin. After the 
column was washed with 20 ml buffer B (including washings from the reaction tube) to 
remove free 125I, the labelled toxin was eluted with buffer C (10 ml). Fractions (1 ml) were 
collected and those containing the radio-labelled toxin determined with a Geiger counter. 
Aliquots removed for determination of specific activity were incubated on ice for 20 min 
with 250 µl 40% TCA and 740 µl 1% BSA, with mixing. The pellet resulting from 
centrifugation at 10,000 g for 5 min was washed with 10% TCA and counted in a γ-counter. 
Specific activity was 200 Ci/mmol. 
Buffer A – 0.4 M sodium phosphate, pH 7.4 
Buffer B – 10 mM sodium phosphate, pH 7.4 and 0.02% (w/v) TX-100 
Buffer C – buffer B + 0.6 M NaCl 
Buffer D – buffer B + 2% (w/v) sodium metabisulphite 
 
3.7.2 Saturable binding of 125I-αdendrotoxin to various Kv1 channels and its displacement 
by unlabelled toxins Cells suspended in binding buffer (150 mM NaCl, 5 mM KCl, 1 mM 
SrCl2, 50 mM imidazole-HCl, 1% BSA, pH 7.5) were incubated for 1 h at room 
temperature in a total volume of 200 µl, with increasing concentrations of 125I-αDTX (0.5-
10 nM) in the presence or absence of 1 µM unlabelled αDTX. Aliquots (90 µl) of the 
reaction mixture were filtered through Whatman GF/B filters followed by three washes (0.5 
ml each) with ice-cold TBS-buffer (150 mM NaCl, 5mM KCl, 50 mM Tris-HCl, pH 7.5). 
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For displacement experiments, suspended cells were incubated with 2.5 nM 125I-αDTX, 
with and without increasing concentrations of various unlabelled toxins. Radioactivity 
remaining on washed filters was measured with a γ-counter and resultant data analysed, 
using Graph Pad Prism software. KD and Bmax values were obtained from fitting the 
saturable binding data with a one site binding equation; Y = Bmax.X/KD+X, where X is 
[ligand] and Y is specific binding. Ki values for the peptide toxins investigated were 
calculated as described in Chapter 5. 
 
3.7.3 Determination of protein concentrations in cell suspensions 
The concentration of protein in toxin binding samples (in the absence of added BSA) was 
determined using a BCA assay. It is a detergent compatible method based on the reduction 
of Cu2+ to Cu1+ by protein in an alkaline environment. A Cu1+ ion then chelates with 2 BCA 
molecules producing a complex that absorbs strongly at 562 nm. BSA standards as well as 
reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 
0.1M NaOH) and reagent B (4% cupric sulphate) are provided in the kit. 
Samples of cell suspensions in binding buffer were adjusted to 1% TX-100 to solubilise 
proteins and the same buffer containing 1% TX-100 was used to make up BSA standards 
and, also, served as the blank; 50 parts reagent A and 1 part reagent B, comprised the 
working reagent, 200 µl of which was used to dilute 25 µl of standards, samples and blank, 
in a microplate. After mixing for 30 s, the covered plate was incubated at 37°C for 30 min. 
After cooling to room temperature, absorbance was measured at 562 nm. Protein 
concentrations of the samples were determined from a standard curve produced from 
absorbance readings of the standards after correction for the blank.  
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Chapter 4 
Expression in mammalian cells of 2 concatemers of brain Kv1 channel α 
subunits give similar K+ currents but yield pharmacologically 
distinguishable heteromers: assessment of their suitability for screening 
of inhibitors 
 
 
4.1 Overview 
Synthesis and assembly of Kv1 channels is controlled to yield a limited variety of channels 
as demonstrated by Shamotienko et al (Shamotienko et al., 1997). Presumably, properties 
of these specific channel combinations are suited to different roles according to neuron type 
or location. Channels purified from mammalian brain are predominantly heteromeric in 
composition (Wang et al., 1999b); therefore, it is necessary to characterise oligomers with 
these defined α subunit combinations and stoichiometries. Such heteromeric channels 
contain different proportions of Kv1 α subunits, with Kv1.2 being the most prevalent, 
followed by Kv1.1 (Scott et al., 1994a). Kv1.1 subunits always occur with Kv1.2 
(Shamotienko et al., 1997), with heteromers consisting of these subunits alone present in 
several areas of human brain; cerebral cortical grey matter, cerebral white matter and spinal 
cord (Coleman et al., 1999).  
In a previous study (Akhtar et al., 2002), a Kv1.1-1.2 construct was prepared using a linker 
from the Xenopus β-globin gene and expressed in Xenopus oocytes. Although it gave an 
outward, non-inactivating K+ current whose voltage-dependency of activation differed from 
those of the parental homomers, its other electrophysiological and pharmacological 
properties were not determined. Also to avoid any peculiarities with the amphibian host, it 
was desirable to fully characterise this channel when expressed in mammalian cells. Thus, 
the tandem-linked Kv1.1-1.2 construct was co-expressed with the β2 subunit in BHK cells 
using a Semliki Forest virus (SFV) and found to produce a hetero-oligomer of the expected 
size, indicative of the assembly of two Kv1.1-1.2 dimers (Akhtar et al., 2002). High-affinity 
binding of 125I-labelled αDTX or DTXk observed with the intact cells demonstrated correct 
folding and assembly of the two dimeric constituents to form a tetrameric channel containg 
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two Kv1.1 and two 1.2 subunits in the plasma membrane (Tytgat et al., 1995), but its 
functionality was not analysed electrophysiologically.  
The aims of this study were to profile the biophysical and pharmacological properties of 
this Kv1.1-1.2 containing channel expressed in CHO cells [due to their low content of 
endogenous outward K+ currents (Yu and Kerchner, 1998)], in order to establish its utility 
as a prototypic, authentic target for future screening of drugs capable of selectively 
inhibiting particular subtypes. For this purpose, it was not necessary to co-express auxiliary 
β subunits as in the previous study (Akhtar et al., 2002) because the determinants for 
external binding of channel blockers are provided by the α subunits (Doyle et al., 1998). 
However, biophysical properties could be affected by the absence of β subunits and 
therefore, eventually, constructs consisting of 4 α and 4 β subunits will be desirable for 
such drug development strategies. The transfection procedure was simplified for expressing 
the K+ channel; cells were electroporated with cRNA prepared using the SFV expression 
plasmid (pSFV1) that contained the inserted Kv1.1-1.2 gene (Akhtar et al., 2002), rather 
than using the more time consuming preparation of SFV particles for transfecting the cells. 
Optimisation of the simple, fast and convenient Rb+ efflux assay allowed functional 
analysis of various ion channel blockers on the expressed protein. To validate the results, 
comparisons were made with those obtained from electrophysiological recordings.  
 
Following success with this approach, it was extended to other constructs. First, however, 
modifications to the expression system were required to yield a longer lasting and larger 
quantity of channel-expressing cells, compared to the short-lived and finite number of cells 
provided by electroporation with cRNA described above. To this end, the Kv1.1-1.2-
pSFV1 construct was subcloned into pIRES2-EGFP and a stable cell line developed using 
HEK cells. Kv1.6 is the third most abundant α subunit in brain, like Kv1.1 is found 
complexed with Kv1.2 (Scott et al., 1994a) and in the limited number of instances where 
subunit stoichiometries of neuronal Kv1 tetramers have been identified unambiguously, 
there is evidence of a swap of Kv1.1 with Kv1.6. That is, a Kv1.1 subunit is interchanged 
with Kv1.6 in channels containing the requisite Kv1.2, along with Kv1.3 and 1.4 subunits 
(Coleman et al., 1999; Shamotienko et al., 1997). The functional consequences of this 
single subunit swap are, therefore, of interest. Kv1.2 and 1.6 have also been detected 
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together in auditory neurons from the trapezoid body of Kv1.1 knockout mice (Brew et al., 
2003). Taking these factors into account, the next channel chosen for study was one 
containing Kv1.6 and 1.2 subunits; hence, a Kv1.6-1.2-pIRES2-EGFP construct was 
prepared and a stably expressing HEK cell line developed. The biophysical and 
pharmacological profiles of these channels were ascertained by electrophysiological 
recordings, Rb+ efflux and radiolabelled toxin displacement. Importantly, a ligand capable 
of distinguishing Kv1.1-12 and Kv1.6-1.2 containing channels was identified. These 
findings have been published (Sokolov et al., 2007). 
Having optimised the Rb+ efflux assay for profiling the pharmacology of concatenated K+ 
channels in CHO cells, the establishment of 2 cell lines stably expressing channels 
containing Kv1.1-1.2 and Kv1.6-1.2 provided a ready supply of recombinant channels of 
the defined subunit composition. This facilitated further exploitation of the Rb+ flux assay 
by its automation. The technology not only allowed the screening of a range of peptide 
toxins in the search for further blockers that distinguish these 2 channels, but also allowed 
exploration of the possibility of using Rb+ efflux for more detailed measurements of 
inhibitory constants. 
 
4.2 Optimised expression of Kv1.1-1.2 containing channels resulted in assembly in 
functional form on the plasmalemma of CHO cells 
The effect of altering various electroporation parameters on the percentage of cells 
expressing Kv1.1-1.2 was investigated (Table 4.1). Following electroporation with cRNA 
containing the Kv1.1-1.2 gene in pSFV, cells were plated on sterile coverslips, 24 h later 
fixed and labelled with a monoclonal antibody specific for Kv1.2 (Muniz et al., 1992) to 
asses channel expression (Fig. 4.1a-c). The number of labelled cells was compared with the 
total number of cells in the same field (as determined by DAPI staining of their nuclei) to 
give the fraction expressing K+ channels (Table 4.1, Fig. 4.1a). Two pulses of 850 V with 
capacitance of 25 µF and 75 µg of RNA was decided upon as these conditions resulted in 
~50% of cells being transfected, a level of expression sufficient for Rb+ efflux experiments 
and electrophysiological analysis. The specificity of Kv1.2 labelling was confirmed by 
experiments conducted either on untransfected cells or by omission of the primary antibody 
when labelling transfected cells (Fig. 4.1c); neither of these conditions gave a fluorescent 
 81 
signal. Fig. 4.1b demonstrates the 2 distinct staining patterns observed: uniform staining 
throughout the cell, and punctate staining at the plasma membrane with the majority of 
fluorescence concentrated in the perinuclear region.  
 
Electroporation conditions 
RNA (µg) Volts C (µF) No. of pulses Path length (cm) 
% Transfected 
cells 
 30  210 25 2 0.1 18 
 45  600 50 3 0.4 27 
 45  300 800 1 0.4 35 
 75  420 25 2 0.2 39 
 75  850 25 2 0.4 47 
120  850 25 2 0.4 59 
180  850 25 2 0.4 66 
 
 
 
It was established that storing cRNA at -80°C for >8 weeks was not detrimental to 
transfection efficiency (Fig. 4.2a). There was a decrease in the % of cells expressing 
Kv1.1-1.2 48 h post transfection compared with 24 h (Fig. 4.2a); therefore, all experiments 
were performed 1 day after cells were electroporated. 
Having confirmed the presence of the required protein expressed in transfected cells, it was 
desirable to verify the integrity of the channel on the plasmalemma. This was achieved by 
labelling the surface proteins with a reactive biotin conjugate, affinity-separation of the 
biotinylated derivatives from a detergent-solubilised extract on streptavidin resin, followed 
by SDS-PAGE and Western blotting. The isolated surface K+ channel showed one protein 
band with Mr ~120 kDa that was recognised by antibodies specific for Kv1.1 or Kv1.2 α 
subunits, and corresponds to the size of the dimer (Fig. 4.1d). A notable absence of smaller 
proteins is indicative of the channel in its membrane-bound state containing only intact 
Kv1.1-1.2 protein, where two copies make up the pharmacologically-active oligomer, 
demonstrated by experiments further on. Samples of total protein that were biotinylated 
similarly but not fractionated, gave a broad band of Mr ~ 60 kDa reactive with both 
antibodies, in addition to the larger protein of Mr ~ 120 kDa (Fig. 4.1d). The smaller band 
is approximately the size of one α subunit and may be a result of cleavage of the dimeric  
Table 4.1│ Influence of electroporation conditions on expression of Kv1.1-1.2 
containing channels in CHO cells. 
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Figure 4.1│Expression of Kv1.1-1.2 containing channels: fluorescence microscopy and biotinylation 
of surface proteins reveal expression of the recombinant K+ channel and targeting to the plasmalemma 
of CHO cells. Cells electroporated with cRNA encoding the Kv1.1-1.2 protein were fixed 24 h post-
transfection, permeabilised and labelled with a monoclonal antibody specific for Kv1.2 α subunit. 
Bound IgG was visualised with anti-species IgG conjugated to AF 488 (green) (a,b). a, Cell nuclei 
were stained with DAPI (blue) to demonstrate transfection efficiency (see Materials and Methods). b, 
Two patterns of labelling were observed: uniform throughout the cell (top), and punctate staining at 
the plasma membrane with a concentration of the signal in the perinuclear region (bottom). Omission 
of the primary antibody resulted in absence of the signal (c). d, Transfected cells were solubilised 
with TX-100 after biotinylation of the surface proteins and the soluble extract incubated with 
streptavidin-agarose resin. Immobilised proteins were subjected to SDS-PAGE and Western blotting, 
utilising antibodies specific for Kv1.1 or 1.2. Lanes: 1, eluate from the streptavidin-agarose resin; 2, 
total cell lysate. A single band of Mr ~ 120 kDa, representing intact Kv1.1-1.2 dimer was observed for 
the K+ channels from the surface of biotinylated cells whereas components of lower molecular weight 
also occurred in the total protein sample. 
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protein but as it is not present in the surface expressed channels it will not impact on 
functional studies. Thus, the presence on the plasmalemma of an assembled oligomer 
(composed of a pair of dimers – see 4.5) was demonstrated and expression optimised to 
allow functional characterisation of the surface expressed channel. 
 
4.3 Effects of known Kv1 channel blockers on Kv1.1-1.2 expressed in CHO cells 
determined using a high-throughput Rb+ efflux assay 
Experiments were performed to measure the effect of various Kv1 channel inhibitors on 
Rb+ efflux through the expressed channels. The investigation also established the suitability 
of these transfected cells for employment in a high-throughput assay which can be used for 
screening compounds in search of novel pharmacological agents against these expressed 
targets of pre-defined composition. The necessary time for Rb+ loading was found to be 3 h, 
as beyond this time the concentration of Rb+ in cells stopped increasing (Fig. 4.2b). 
Likewise, 75 and 100 mM K+ evoked the greatest release of Rb+ via the activated 
recombinant channels (Fig. 4.2c), and the lower effective amount was chosen for all 
experiments going forward. In control experiments, basal and stimulated release of Rb+ 
were measured from untransfected as well as transfected CHO cells. Low levels of Rb+ 
were released from untransfected cells under both conditions, similar to basal release from 
transfected cells, the corresponding stimulated Rb+ release being at least twice that from 
these cells (Fig. 4.2d). This 2:1 ratio of stimulated to basal release was applied as a 
necessary criterion for all subsequent experiments [as advised by personnel at Xention Ltd. 
(Cambridge, UK), where the assay is used for high-throughput screening]. A further control 
was included to exclude that electroporation of cells (in the absence of cRNA) affected 
their ability to retain Rb+ under both basal and stimulating conditions (Fig. 4.2d). 4-AP, 
TEA and αDTX were all shown to inhibit evoked Rb+ efflux (Fig. 4.3a-c); 4-AP inhibited 
release with an IC50 roughly estimated at 0.5 mM (Fig. 4.3a). TEA also reduced Rb+ efflux 
though to a lesser extent than 4-AP; the very high, maximum dose (50 mM) used gave only 
a 50% reduction in release (Fig. 4.3b). αDTX blocked Rb+ efflux at nanomolar 
concentrations (Fig. 4.3c) as was expected, with an extrapolated IC50 of ~ 2nM. Basal 
efflux was not affected by the test compounds (Fig. 4.3d) – that is, basal release from cells 
was the same in both the presence and absence of the test compound. The experiments were  
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Figure 4.2│Optimisation of channel expression and Rb+ efflux conditions. a, 
Comparison of transfection efficiency with freshly prepared cRNA and that stored at   
-80°C for >8 weeks at 24 and 48 h post transfection was assessed as described in 
Results. b, [Rb+] in cell lysates (µg/l) was analysed after various loading times (mean 
± S.E.M.; n=>12. c, Both supernatant and lysates were measured following channel 
activation with various concentrations of K+, and Rb+ efflux expressed as % total Rb+ 
in the cells (i.e. content in supernatants and lysates; mean ± S.E.M.; n=≥19). d, 
Transfected, untransfected and mock electroporated CHO cells were loaded with Rb+ 
and release was measured under basal and stimulating conditions (3 min with 75 mM 
K+), using AAS (see Materials and Methods). Supernatant Rb+ levels are expressed 
relative to the total as mean ± S.E.M.; n=15. 
b 
c d 
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Figure 4.3│Sensitivity of Kv1.1-1.2 containing channels expressed in CHO cells to 
various channel blockers as measured by the Rb+ assay. Rb+ efflux from transfected 
cells used for drug testing was calculated as described in Materials and Methods, and 
subtraction of values for basal release from those for stimulation gave the evoked 
increment for each set of cells. The quantities of evoked Rb+ release measured in the 
presence of 4-AP, TEA or αDTX were plotted (mean ± S.E.M.; n=≥24) relative to the 
requisite normalised control. 4-AP or TEA was added to the stimulation buffer (a and 
b) whereas αDTX was included in the Rb+ loading buffer (c). While basal efflux was 
unaffected by the test compounds (d), it differed significantly (in the absence of 
compounds) between different batches of transfected cells (*), as measured by one-
way ANOVA (p=0.0001). 
 
a b c d
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performed on different days using different batches of cells and consequently there were 
significant differences in the amount of basal release measured between different 
compounds (Fig. 4.3d). However, as basal release of Rb+ was measured for each batch of 
cells and only experiments where the stimulated Rb+ release was at least twice the basal 
release were used, this variability in the measurements was accounted for. 
 
4.4 Comparison of the susceptibilities of this expressed K+ channel to 4-aminopyridine, 
tetraethylammonium and αdendrotoxin as revealed by electrophysiological recordings and 
Rb+ efflux 
A fraction of the K+ current (IK) produced by this channel proved very sensitive to 4-AP, 
with a concentration of just 20 µM already exhibiting significant inhibition of the evoked IK, 
and 0.1 mM giving a reduction of 40% compared with the normalised control (Fig. 4.4a). 
However, a component of the current appears to be insensitive to 4-AP as at 10 mM, 45% 
of IK remained. In comparison, at this concentration, evoked release of Rb+ was almost 
completely inhibited. Sensitivity of this IK to TEA was markedly reduced compared with 4-
AP, as 3 mM TEA did not reduce the current significantly. The highest concentration used 
(20 mM) inhibited current by only 34% (Fig. 4.4b), a value which correlates well with Rb+ 
efflux results where the same dose reduced evoked Rb+ release by 42%. 
Electrophysiological recordings revealed αDTX to be more potent at blocking IK than Rb+ 
efflux (Fig. 4.4c), with 80% inhibition requiring 10 and 50 nM, respectively.  
 
4.5 Surface expression of concatenated Kv1 channels stably expressed in HEK cells to a 
level adequate for functional analysis  
Initial experiments on COS, BHK and CHO cells transiently-transfected with Kv1.1-1.2-
pIRES2-EGFP vector showed a protein corresponding in size to the dimer together with 
smaller immuno-reactive bands (data not shown), whereas HEK cells were devoid of such 
fragments (see below). This advantageous feature of HEK cells was exploited for 
successfully creating stable cell lines expressing intact dimer-containing channels. After 2-
3 weeks in geneticin-containing medium, practically all of the surviving cells (~5-10% of 
the original number plated) transfected with Kv1.1-1.2- or Kv1.6-1.2-pIRES2-EGFP 
showed green EGFP fluorescence, which allowed subsequent cell clones to be selected and  
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Figure 4.4│Inhibition of K+ currents from Kv1.1-1.2 containing channels. 
Electrophysiological recordings were performed to compare the effect of K+ 
channel blockers on this recombinantly-expressed channel with that measured by 
Rb+ efflux. K+ currents were elicited in transfected CHO cells with 200 ms 
depolarising pulses (to +40 mV); the amplitudes recorded from 10-20 pulses 
before and after drug application were averaged and normalised. Each point is the 
mean of 3–6 (a) and 2–3 values (b,c) ± S.E.M. 4-AP inhibits the K+ current from 
the Kv1.1-1.2 containing channels significantly at the lowest concentration tested, 
0.02 mM 4-AP (*, p=0.0049, measured by an unpaired t-test). 
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propagated. SDS-PAGE and Western blotting revealed a band of Mr ~120 kDa, recognised 
in these cells by respective anti-Kv1.1, Kv1.2 and Kv1.6 antibodies. It is noteworthy that 
there is an absence of smaller bands corresponding to the size (~ 60 kDa) observed for the 
monomeric constituents (Fig. 4.5). Cell lines chosen for preparing stocks suspensions gave 
satisfactory levels of 125I-αDTX binding (ranged from 0.08 – 0.15 pmoles/mg protein); 
such surface expression of channels is adequate for electrophysiological and Rb+ efflux 
measurements. 
 
4.6 Kv1.1-1.2 and Kv1.6-1.2 channels exhibit similar electrophysiological properties, yet 
are differentiated from their monomeric constituents by their half-activation voltages 
Patch-clamp whole-cell recordings from HEK cells stably expressing the Kv1.6-1.2 or 
Kv1.1-1.2 containing channels gave sigmoidally-activating currents, typically of 1-7 nA 
amplitude, following a depolarisation step from -110 mV to +50 mV (Fig. 4.6a). Likewise, 
deactivation of the IK was found to be similar for both channels. At -40 mV, current 
deactivation occurred incompletely with a time constant of about 20 ms; with more 
negative potentials, the speed of decay increased with a voltage dependence equivalent to 
1.2 elementary charges traversing the transmembrane voltage drop (Fig. 4.6b). This voltage 
dependence is similar to that of the Shaker Kv1 channel (Zagotta et al., 1994).   
To quantify the activation kinetics of these channels, K+ current rise was fitted by a mono-
exponential function (see section 3.6.2, equation 1). Activation rates are similar for Kv1.6-
1.2 and Kv1.1-1.2 (Fig. 4.6c), giving time constants (τ) at 0 mV of approximately 10 ms 
(Table 4.2), and accelerating with increasing command voltage. Also similar to the Shaker 
channel, the steepness of voltage dependence of activation varied with different voltage 
ranges and could not be fitted by equation (2) (see Materials and Methods) as a simple 
elementary charge movement (Fig. 4.6c). Conductance-voltage relations were generated by 
plotting the conductances obtained at different voltages (Fig. 4.6d). This revealed that the 
two channel heteromers activate slightly differently; their half-maximal activation 
potentials are separated by 7 mV, though their slopes are identical (Table 4.2). No 
significant inactivation of the K+ currents from either Kv1.6-1.2 or Kv1.1-1.2 could be 
detected within 400 ms of depolarisation to +50 mV (Fig. 4.7); however, a prolonged step 
revealed slow inactivation of each channel (Fig. 4.7a). Inactivating currents could be fitted  
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Figure 4.5│Expression of Kv1.1-1.2 or Kv1.6-1.2 containing channels and 
monomers in HEK cells via pIRES2-EGFP vectors. Western blotting results confirm 
the correct sizes and subunit compositions. Suspensions of HEK cells stably- and 
transiently-expressing the dimeric and monomeric channels, respectively, were 
subjected to SDS-PAGE, and stained with antibodies specific for Kv1.1, Kv1.2 or 
Kv1.6 using ECL regents (see Materials and Methods).  Lanes: 1, Kv1.1 monomer; 
2,4 Kv1.1-1.2 dimer; 3, Kv1.2 monomer; 5,7 Kv1.6-1.2 dimer and 6, Kv1.6 
monomer. Sizes of the standard markers used are indicated. Note that each dimer 
gave the expected size (), with an absence of any bands corresponding to the 
mobility of the monomers (►). 
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Figure 4.6│Voltage dependence for activation and deactivation of Kv1.1-1.2 and 1.6-1.2 containing 
channels stably expressed in HEK cells. a, Typical K+ current recorded from Kv1.6-1.2 and Kv1.1-1.2 
containing channels during an I–V protocol (depolarising voltage steps of 400 ms from -60 to +50 mV 
in 10 mV increments; records of the initial 80 ms from every second trace are shown). Thick lines 
overlapping the current traces resulted from fitting the data with a mono-exponential function. Note: 
current traces at -30 and -50 mV overlap for Kv1.1-1.2. b, Deactivation observed after returning 
membrane potential from +40 mV to the various voltages specified. Scale bars apply to both channel 
traces (a,b). c, Activation and deactivation kinetics determined by fitting current traces with a mono-
exponential function. The dashed and continuous lines resulted from fitting equation (2) (see Materials 
and Methods) to the calculated τ values for Kv1.6-1.2 and Kv1.1-1.2, respectively. Activation time 
constants at voltages from -20 to +10 mV were used for fitting; data for both channels deviate from fits 
at positive voltages. d, Conductances at various command potentials were normalised and fitted with a 
Boltzmann equation (3); dashed and continuous lines represent the fitted results for Kv1.6-1.2 and 
Kv1.1-1.2, respectively (overlapping for deactivation). A significant difference in the V½ values for 
activation was revealed with two-tailed Mann-Whitney U test (p < 0.03). Error bars show S.E.M.  
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with a double exponential function, revealing similar inactivation constants (Table 4.2). On 
average, at the end of a 60 s depolarisation step to 40 mV, currents had inactivated by more 
than 80% (Table 4.2). On examining the influence of voltage on inactivation of the currents 
with a steady-state inactivation protocol (Fig. 4.7b,c), membrane potentials more negative 
than -60 mV were found to be required to remove inactivation from either channel (Fig. 
4.7d). 
As replacing Kv1.6 with Kv1.1 in a heteromeric channel caused a detectable negative shift 
in its half-activation voltage (see above), a basis for this was sought by studying the 
parental homo-tetrameric channels. Thus, the conductance-voltage relationship of each 
monomer was determined using pIRES2-EGFP constructs expressed in HEK cells (Fig. 
4.8). The Kv1.1 homomeric channel showed half-activations at -24 mV, Kv1.6 at -15 mV 
and Kv1.2 at 7.2 mV.  While Kv1.6 homo-tetramers activate at more positive voltages than 
those made from Kv1.1, replacing Kv1.1 with Kv1.6 in a concatenated construct caused the 
resultant channel to activate at more negative voltages. This indicates that the gating 
differences between Kv1.6 and Kv1.1 are more complex than a simple alteration in the 
midpoint of voltage sensor activation. 
Activation Deactivation 
τ (ms) 
Inactivation 
(step to +40 mV; 60 s) 
Steady-
state 
inactivation 
 
 
HEK stable 
cell lines 
 
V½ (mV); k τ (ms) 
at +0; 20; 50 mV 
at –100 mV at –40 mV % of I τ 1; τ 2 (s) V½ (mV) 
 
Kv1.1-1.2 
-0.7 ± 1.6; 
17 ± 1; 
(n=9) 
10.6 ± 1.3; 
5.1 ± 0.7; 
2.6 ± 0.3;  (n=6) 
2.9 ± 0.4 
(n=6) 
22.2 ± 4.9 82.4 ± 3.6 
(n=6) 
1.6 ± 0.2; 
13.2 ± 2 
-95.7 ± 0.9; 
(n=5) 
 
Kv1.6-1.2 
-7.3 ± 2.3; * 
17 ± 0.5;  
(n=7) 
10 ± 1.5; 
5.8 ± 1.1; 
3.1 ± 0.4; (n=5) 
3.3 ± 0.4 
(n=4) 
23.3 ± 5.7 82.5 ± 2.6 
(n=4) 
2.4 ± 0.7; 
20 ± 6 
-92.5 ± 2.1; 
(n=6) 
Table 4.2│Electrophysiological properties determined for Kv1.1-1.2 and Kv1.6-1.2 channels         
                   * significant difference (p < 0.03, Mann-Whitney U test) 
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Figure 4.7│ Inactivation properties of K+ currents resulting from Kv1.1-1.2 and 1.6-1.2 
channels stably expressed in HEK cells. a, K+ currents show the development of slow 
inactivation in response to a 60 s depolarisation pulse to +40 mV. b, Shows steady-state 
inactivation. c, Cells were held at +20 mV for 40 s to allow channels to undergo significant 
inactivation, then subjected to pre-conditioning pulses of different negative potentials, 
followed by a test pulse to +40 mV. Scale bars apply to both channel traces. d, Conductances 
resulting from the test pulse were plotted against membrane potentials of the pre-pulse; the 
data fitted with a Boltzmann function are shown as dashed and continuous lines for Kv1.6-1.2 
and Kv1.1-1.2, respectively.  
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Figure 4.8│ Voltage dependency of activation of homomeric K+ channels transiently 
expressed in HEK cells. G-V plots of homomeric channels formed by Kv1.1, 1.2 or 1.6 
after transient expressed in HEK cells. Conductance values were fitted with a 
Boltzmann function, equation (3) (see Materials and Methods).  The resultant values for 
half-activation (in mV) and slope were as follows; Kv1.1: -24 ± 1, 11 ± 1 (n=5); Kv1.2: 
7.2 ± 0.6, 15 ± 0.5 (n=6) and Kv1.6: -15 ± 1, 9 ± 1 (n=4). The curves shown for Kv1.6-
1.2 and 1.1-1.2 channels are fitted plots taken from Fig. 4.6d.  
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4.7 Channels composed of Kv1.6-1.2 and Kv1.1-1.2 can be distinguished by their 
susceptibilities to inhibitors   
Different homo-tetrameric Kv1 channels differ to varying extents in their sensitivity to 
pharmacological agents; therefore, the long-term goal of this work is to develop a 
pharmacopoeia capable of identifying different heteromeric Kv1 subtypes. A first step 
along this path is to find ligands that can distinguish between hetero-tetramers that vary in 
some, but not all, α subunits.   
External TEA proved less effective in blocking the K+ current produced by Kv1.6-1.2 than 
Kv1.1-1.2 (Fig. 4.9a). All four K+ channel subunits are known to make an energetic 
contribution to the binding of a single TEA molecule at the external mouth of the 
conduction pore (Heginbotham and MacKinnon, 1992; Kavanaugh et al., 1992). Hence, the 
sensitivity observed is in the expected rank order, as Kv1.1 homo-tetramers are more 
sensitive to TEA than those containing Kv1.6.  In contrast, 4-AP, another classical blocker 
of Kv1 channels, failed to distinguish between the channels made from Kv1.6-1.2 or 
Kv1.1-1.2 (Fig. 4.9b), consistent with very similar 4-AP sensitivities of the parental 
homomers (Grupe et al., 1990; Stuhmer et al., 1989). αDTX binds to homo-tetramers of all 
the Kv1 subunits studied herein (Grupe et al., 1990; Stuhmer et al., 1989) and, accordingly, 
inhibited the K+ currents mediated by Kv1.6-1.2 or Kv1.1-1.2 channels (Fig. 4.9c ) [c.f. 
Rb+ flux, (Fig. 4.10c) and 125I αDTX binding (Fig. 4.11)]. By this electrophysiological 
measurement αDTX is significantly more effective on Kv1.6-1.2 than Kv1.1-1.2, but 
despite the significance of the difference it is insufficient to make this toxin a distinguishing 
ligand. On the other hand, DTXk proved effective in this regard. DTXk is known to block 
any Kv1.1-containing channel in oocytes (Akhtar et al., 2002). Whereas the Kv1.6-1.2, 1.6 
or 1.2 channels proved virtually resistant to DTXk, it inhibited Kv1.1-1.2 or 1.1 (Fig. 4.9d) 
and, thus, the latter toxin can successfully discern the swap of Kv1.6 for Kv1.1 in a 
heteromeric K+ channel.  
Experiments were performed to measure the effects of the same compounds on evoked 
release of Rb+ from the same stable HEK cell lines. The resultant data is plotted as 
fractional inhibition of Rb+ release instead of percentage evoked Rb+ efflux used elsewhere 
in the chapter and thesis, to allow easy comparison with the similarly plotted, 
corresponding electrophysiology data (Fig. 4.9 and 4.10), as published in (Sokolov et al., 
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2007). Thus, in keeping with the paper layout the electrophysiology data has been 
discussed first in the equivalent sections of this chapter (4.6 and 4.7).  
Comparable to results obtained electrophysiologically, TEA preferentially blocked 
depolarisation-elicited efflux of Rb+ through Kv1.1-1.2 containing channels (Fig. 4.10a) 
compared with Kv1.6-1.2, with data for the HEK expressed Kv1.1-1.2 channels 
corresponding to that recorded for TEA inhibition of the same channels expressed in CHO 
cells (Fig. 4.3). While the effect of 4-AP on the two channels was significantly different at 
1 and 10 mM, Kv1.1-1.2 was more inhibited at 1 mM and less at 10 mM (Fig 4.10b), 
demonstrating again that 4-AP does not distinguish these two heteromers produced from α 
subunits with very similar sensitivities to 4-AP (Grupe et al., 1990; Stuhmer et al., 1989). 
αDTX displayed similar efficacy towards both heteromers (Fig. 4.10c), hence the slightly, 
yet significant, enhanced sensitivity of Kv1.6-1.2 compared with Kv1.1-1.2 containing 
channels to αDTX as measured electrophysiologically was not replicated confirming that 
this toxin is not a distinguishing ligand. Importantly, the ability of DTXk to discriminate 
between the heteromers studied was confirmed by Rb+ efflux experiments, where strong 
inhibition of evoked Rb+ release through Kv1.1-1.2 containing channels was in stark 
contrast to the minimal reduction in supernatant Rb+ concentrations observed in wells 
containing channels made up of Kv1.6-1.2 subunits (Fig. 4.10d). Although some studies 
have reported lower potencies for inhibitors when measured by Rb+ efflux than 
electrophysiological recordings (Middleton et al., 2003), this is likely due to the different 
conditions used elsewhere because under the comparable conditions herein both methods 
gave similar results. Individual cells are selected when making electrophysiological 
recordings whereas Rb+ efflux data results from a whole population of cells. Where results 
do differ slightly (e.g. αDTX) this distinction between the 2 assays is likely the reason. It is 
also important to note that channels stably expressed in HEK cells gave more similar results 
with the two methods used than those transiently expressed in CHO cells, likely due to a 
more uniform population of channels. In the case of the peptide toxins, the risk of 
adherence to plasticware was also addressed by silanisation of all relevant assay materials. 
Overall, correspondence to the electrophysiological data again validates the Rb+ efflux 
method to screen K+ channel hetero-multimers for specific ligands.
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Figure 4.9│Pharmacological distinction of Kv1.1-1.2 and 1.6-1.2 containing channels 
through inhibition of their K+ currents. Channels were expressed in HEK cells using Kv1.6-
1.2, Kv1.1-1.2 or their individual constituent subunits. Currents were evoked by 
depolarising pulses (to +40 mV or +20 mV for 4-AP; 200 ms); the amplitudes recorded from 
10-20 pulses before and after drug application (a, TEA; b, 4-AP; c, αDTX; d, DTXk) were 
averaged and normalised. The resultant values for fractional inhibition of the K+ currents are 
presented (mean ± S.E.M) with at least 3 cells tested for every drug concentration. Lines on 
the TEA panel show results fitted with a Langmuir isotherm (a). The difference in inhibition 
of the two channels by αDTX is significant at both 10 (*, p=0.016) and 100 nM (**, 
p=0.048), but not at 1 nM (c). 
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Figure 4.10│Pharmacological inhibition of evoked Rb+ release from HEK cells expressing 
Kv1.1-1.2 or Kv1.6-1.2 containing channels. After loading transfected cells with Rb+, basal 
and stimulated release were measured in the presence and absence of blockers (a,TEA; b,4-
AP; c,αDTX and d,DTXk). Evoked increments were normalised and plotted ± S.E.M. [n = 
>16; in a and b, error bars fall within the data point for 1.1-1.2 and in a, the 1 mM value for 
Kv1.6-1.2 is obscured by that of Kv1.1-1.2]. In b, the effect of 4-AP on the channels differs 
significantly at 1 (*, p=<0.0001) and 10 (**, p=0.0256) mM, as measured by an unpaired t-
test. Basal efflux (as % of total) from untransfected cells and those expressing Kv1.6-1.2 or 
1.1-1.2 was 17.9 ± 0.9%, 8.9 ± 0.3% and 15.4 ± 1.3%, respectively. The slight decrease in 
unstimulated release from transfected cells is likely due to expressed K+ channels lowering 
the resting potential of the cells, thereby, reducing the outward driving force for Rb+. 
Stimulated Rb+ efflux for Kv1.6-1.2 and Kv1.1-1.2 were 69.2 ± 1.0% and 49.4 ± 2.1%, 
compared to 18.2 ± 0.6% for untransfected cells.  
 
a b 
c d 
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The ability of DTXk to discriminate between these two channels was further confirmed by 
displacement with unlabelled αDTX or DTXk of 125I-αDTX bound to intact cells. In the 
case of Kv1.1-1.2 channels, both αDTX and DTXk displaced the labelled toxin with the 
displacement curve for DTXk closely following that for αDTX (Fig. 4.11a). 125I-αDTX 
bound to the Kv1.6-1.2 containing channels was affected by unlabelled αDTX in a similar 
way to the Kv1.1-1.2 channels demonstrating a similar binding of the toxin to the two 
heteromers as demonstrated by electrophysiological and Rb+ efflux measurements (Fig. 
4.11b). However with Kv1.6-1.2 channels, DTXk gave only feeble competition of 125I-
αDTX binding with the highest concentration used displacing less than half of the bound 
toxin (Fig. 4.11b). This much weaker affinity of Kv1.6-1.2 for DTXk (at least 200-fold) is 
consistent with the known requirement for the presence of at least 1 Kv1.1 subunit for avid 
binding, and accords with its inability to block K+ current or Rb+ efflux through this 
channel.   
In summary, both of these channels share susceptibility to 4-AP and αDTX but 
replacement of Kv1.1 by Kv1.6 results in the loss of sensitivity to TEA and DTXk; thus, 
use of such ligands on neuronal preparations may allow pharmacological discernment of 
heteromeric channels with particular subunit compositions. 
 
4.8 Automation of the Rb+ efflux assay  
This was automated using the set up shown in Fig. 4.12. Each individual component can be 
programmed from the central computer (Fig. 4.12g) through individual software drivers 
which allow various protocols to be written for each component. CLARA software is used 
to link all the processes together into a complete assay cycle which can be repeated as many 
times as there are cell plates for analysis. Cell and compound plates, empty assay plates and 
racks of tips start in the Twister II plate racks (Fig. 4.12d). A deep well plate containing 
wash and stimulation buffers and a reservoir containing lysis buffer are placed on the 
Sciclone ALH 500 (Fig. 4.12a). On commencement of the assay cycle, the plate washer 
(Fig. 4.12e) and multidrop (Fig. 4.12f) are initialised, tips moved to the Sciclone and 
loaded onto the 96-well head, a compound plate is also moved to the Sciclone and a cell 
plate moved to the plate washer and washed – all using the Twister II Robotic arm (Fig. 
4.12c).
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Figure 4.11│ Differential displacement by dendrotoxink of 125I-αdendrotoxin bound to Kv1.1-1.2 
and 1.6-1.2 containing channels. HEK cells stably expressing Kv1.1-1.2 (a) or Kv1.6-1.2 (b) were 
incubated with a saturable concentration (2.5 nM) of 125I-αDTX and the indicated concentration of 
unlabelled αDTX or DTXk. Data points are the mean of triplicate measurements (see Materials 
and Methods). Curves represent a Langmuir isotherm fit to the data.  IC50 values from these fits 
were for αDTX: Kv1.1-1.2, 8.0 nM, Kv1.6-1.2, 5.7 nM and for DTXk: Kv1.1-1.2, 13.8 nM; 
Kv1.6-1.2, >3300 nM. The content of sites was calculated by subtracting non-saturable binding of 
125I-αDTX remaining after displacement by unlabelled αDTX from cells stably expressing Kv1.1-
1.2 and Kv.1.6-1.2, which represented 37 and 42% of the respective totals, to yield values of 0.08 
and 0.15 pmoles/mg of total cell protein. It is notable that the higher content of sites obtained for 
the cells expressing Kv1.6-1.2 than Kv1.1-1.2 channels underlies the larger stimulated Rb+ efflux 
from the former.  
a b 
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The cell plate is returned to the Sciclone and compound added. During the compound 
incubation time, the tips on the 96-well head are changed, an assay plate is  
brought to the Sciclone and the compound plate is disposed of (Fig. 4.12h). Wash or 
stimulation buffers are then added to the cell plate and, once the stimulation period has 
elapsed, the supernatants from the cell plate are transferred to the empty assay plate, the 
cell plate is moved to the washer, washed and returned to the Sciclone; tips are changed 
again and the lysis buffer is added. During lysis, the supernatant assay plate is moved to the 
multidrop, the contents diluted and returned to the plate racks. A second empty plate is 
moved to the Sciclone. Once lysates are collected, the second assay plate is diluted with the 
multidrop and it plus the cell plate are returned to the plate racks and the used tips removed. 
The cycle is then repeated for the prescribed number of cell plates. The tips for the 96-well 
head are provided in racks containing 384 tips. Therefore, once 4 sets of tips have been 
used the empty rack is placed in the waste, by being dropped through a hole in the table to 
the waste bin below, and a fresh tip box moved from the plate racks. There is an area on the 
Sciclone through which the used tips are dropped and collected in a container underneath 
(obscured by the plate racks in Fig. 4.12). 
 
4.9 Screening of a small library revealed many additional inhibitors of Kv1.1-1.2 and 1.6-
1.2 containing channels but none that could distinguish them like dendrotoxink 
The capacity of the automated Rb+ efflux assay was utilised for screening a small library of 
potential K+ channel blockers. For the purposes of the screen, these were divided into 
compounds known to block Kv1 containing channels (all peptide toxins), see Table 2.2 for 
details, and those that block other families of K+ channels (Table 4.3). In keeping with the 
screening protocols used in industry (e.g. at Xention Ltd., Cambridge, UK) a single 
concentration was employed for (nearly) all the toxins, for the initial screen. The peptide 
toxins to be screened inhibit channels that are sensitive to them in the low-sub nanomolar 
range, depending on the channel expression system and assays used. Thus, a concentration 
of 10 nM was chosen with the expectation that Rb+ efflux through sensitive channels would 
be substantially inhibited clearly revealing insensitive channels. The only exception was 
MCD peptide. While the published effective doses also differ (Table 2.2, references), they 
tend to be considerably higher than those for the o
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Figure 4.12│Robotic system used for automation of the Rb+ efflux assay. The system 
is composed of a Sciclone ALH 500 automated liquid handling system (a) and a 
Zymark Twister II microplate handler (c) with robotic arm (b) and plate racks (d). A 
Biotek ELX 405 cw plate washer (e) designed for washing plates containing cells was 
used for all washing steps. All large volume dilution steps were performed by a 
Thermo Scientific Multidrop 384 (f). Clara Software, with the appropriate drivers for 
each component, was used to run the system (g). Waste is disposed of through a hole 
in the table under which is a bin (h). 
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concentration of 100 nM was chosen. With a few exceptions, all of the Kv1 inhibitors 
blocked both the heteromers used in this study (Fig. 4.13). As with previous experiments 
(Fig 4.10), DTXk discriminated between the two channels. δDTX, the Dendroaspis 
angusticeps homologue of DTXk differentially inhibited the channels and two-way 
ANOVA analysis of the effect of DTXk and δDTX on the two heteromers revealed that 
there is a significant difference between the reaction of both the channels to both the toxins 
(p=0.0022). Despite the significant difference in inhibition of the channels by δDTX, the 
fact that the toxin blocks Rb+ efflux through both channels by more than 50% makes it an 
inappropriate distinguishing ligand (Fig. 4.13). Hence the startling specificity of DTXk is 
revealed. Reports published previously have shown β and γDTX to inhibit Kv1.1 and 1.2 
homomers expressed in Xenopus oocytes (Hopkins et al., 1996), a result not replicated in 
this study. This could be as a result of differences between the amphibian and mammalian 
expression systems, though more likely is due to discrepancies between the purification and 
identification of these toxins from the native venom.  
Inhibitors active against other families of K+ channels did not attenuate Rb+ efflux through 
the Kv1.1-1.2 and 1.6-1.2 containing channels tested (Fig 4.14), further reassurance for the 
reliability of the assay. This was with the exception of Lq2 (Fig. 4.14a) which blocks the 
inward-rectifier K+ channel, ROMK1 but also Kv1 channels (Lu and MacKinnon, 1997). 
As with the Kv1 channel blockers, 10 nM was used as the screening concentration unless 
available information on inhibition of the target channel type revealed the inhibitor to be 
less potent, in which case 100 nM was used. 
It is important to note that there is some scatter in the efflux data obtained from the screen 
performed. Firstly, a number of compounds block Rb+ efflux resulting in levels less than 
those in unstimulated wells (Fig. 4.13, e.g. MgTX and ShK). Secondly, in some cases, the 
supernatant concentration of Rb+ is not exactly 100% with toxins that do not inhibit the test 
channel (Fig. 4.13, e.g. DTXk on Kv1.6-1.2). Finally, there are instances of Rb+ release 
being greater than the concentrations measured from unchallenged, stimulated cells (Fig. 
4.14, e.g. BeKm I and E4031). As an added control for each 96-well plate of cells tested, 8 
wells were treated with 10 mM 4-AP to ensure that stimulated release was inhibited. There 
was a large amount of scatter in this result also, typically ranging from -10% – +10% of 
normalised evoked efflux (data not shown). As all effux data is normalised to evoked  
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Figure 4.13│Effect of various peptide toxins on Rb+ efflux through recombinant 
Kv1.1-1.2 and 1.6-1.2 channels stably expressed in HEK cells. Rb+ efflux 
experiments were performed, as described in Materials and Methods, to asses the 
activity of various peptide toxins (with know activity against Kv1 channels) towards 
these defined heteromeric channels. Results are expressed as mean ± S.E.M. 
(n=≥16). Two-way ANOVA analysis of the effect of δDTX and DTXk on both 
channels found that the channels were inhibited differently by the toxins and each 
toxin had a different effect (p=<0.0001 in both cases). Test concentrations used were 
derived from effective doses previously published (see section 4.9). Table 2.2 gives 
details of the toxins used and Kv1 homomers they are active against.  
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Table 4.3│Details of compounds known to block various K+ channel families 
Name Type Source Sensitive K+ channel type Refs 
Aa1 Peptide toxin Androctonus australis 
(scorpion) 
Shaker B (A-type) K+ channels 
(IC50 4.5µM) 
(Pisciotta et al., 
1998) 
Apamin Peptide toxin Apis mellifera  
(honey bee) 
Small conductance (SK), Ca2+-
activated K+ channels (IC50 SK1 
3.3 nM, SK2 83 pM) 
(Blatz and 
Magleby, 1986; 
Strobaek et al., 
2000) 
BDS-I Peptide toxin Anemonia sulcata 
(sea anemone) 
Rapidly inactivating (IA) Kv3.4 
K+ channels 
 (IC50 47 nM) 
(Diochot et al., 
1998) 
BDS-II Peptide toxin Anemonia sulcata 
(sea anemone) 
Rapidly inactivating (IA) Kv3.4 
K+ channels 
(IC50 56 nM) 
(Diochot et al., 
1998) 
BeKm-I Peptide toxin Buthus eupeus 
(scorpion) 
ERG1 K+ channels  
(IC50 3.3 nM) 
(Korolkova et 
al., 2001) 
E-4031 Methane- 
sulfonanilide 
class III antiarrhythmic drug Voltage gated (HERG) K+ 
channels (IC50 7.7 nM) 
(Zhou et al., 
1998) 
Ergtoxin Peptide toxin Centruroides noxius 
(scorpion) 
ERG1 K+ channels  (Scaloni et al., 
2000) 
Iberiotoxin Peptide toxin Buthus tamulus 
(scorpion) 
High conductance, Ca2+-activated 
K+ channels (IC50 250 pM) 
(Galvez et al., 
1990) 
Lq2 Peptide toxin Leiurus quinquestriatus var. 
hebraeus (scorpion) 
Voltage- and Ca2+-activated and 
Inward rectifier Kir 1 (ROMK1) 
K+ channels 
(Lu and 
MacKinnon, 
1997; Lucchesi 
et al., 1989) 
Maurotoxin Peptide toxin Maurus palmatus 
(scorpion) 
Voltage- and Ca2+-activated K+ 
channels 
(Castle et al., 
2003) 
Paxilline Tremorgenic 
alkaloid 
mycotoxin 
Penicillium paxilline 
(fungus)  
High conductance (MAXI-K), 
Ca2+-activated K+ channels 
(Knaus et al., 
1994) 
Penitrem A Fungal 
neurotoxin  
Aspergillus, Claviceps, 
Penicillium 
species (fungi) 
High conductance (MAXI-K), 
Ca2+-activated K+ channels 
(Knaus et al., 
1994) 
Scyllatoxin Peptide toxin Leiurus quinquestriatus var. 
hebraeus (scorpion) 
Small conductance (SK), Ca2+-
activated K+ channels 
(IC50 SK1 80 nM, SK2 287 pM) 
(Strobaek et al., 
2000) 
Slotoxin Peptide toxin Centruroides noxius 
(scorpion) 
High conductance (MAXI-K), 
Ca2+-activated K+ channels (Kd 
1.5 nM) 
(Garcia-Valdes 
et al., 2001) 
Tamapin Peptide toxin Mesobuthus tamalus 
(scorpion) 
Small conductance (SK), Ca2+-
activated K+ channels (IC50 24 
pM) 
(Pedarzani et 
al., 2002) 
Tertiapin Peptide toxin Apis mellifera  
(honey bee) 
Inward rectifier (GIRK, Ki 8.6 nM 
and ROMK1, 2.0 nM) K+ 
channels 
(Jin and Lu, 
1998) 
Tertiapin Q Peptide toxin Apis mellifera  
(honey bee) 
Inward rectifier (GIRK) and Ca2+-
activated (BK) K+ channels (IC50 
(Jin and Lu, 
1998; Kanjhan 
et al., 2005) 
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Figure 4.14│Blockers with activity against various families of K+ channels do not 
inhibit Rb+ efflux through Kv1.1-1.2 or 1.6-1.2 containing channels. Details of the 
compounds studied are given in Table 4.3. Doses of 10 nM (a) or 100 nM (b) were 
determined from published concentrations used when these molecules were applied to 
the channel type they are active against. Data plotted is mean ± S.E.M., n≥16. Lq2 
was the one exception that did block. 
a b 
 106 
release calculated from just 16 wells - 8 unstimulated and 8 stimulated - it is not surprising 
that there is some scatter. Increasing the number of wells used for each condition should 
minimise this, but the number of wells used for such controls much be balanced with the 
number of compounds to be tested in each experiment. As the purpose of an initial screen is 
to establish only if a compound inhibits a specific channel or not, the quality of the data 
achieved herein is sufficient to support such conclusions. 
 
4.10 Assessment of the suitability and accuracy of Rb+ efflux for determining inhibitory 
constants of blockers  
Having ascertained that at a fixed concentration, 10 nM, a number of peptide toxins block 
both channels used in this study, the IC50 values were determined for some of the more 
potent inhibitors [AgiTXs, ChTX (with Lq2 included for comparison), MgTX and ShK]. 
Inhibition of evoked Rb+ efflux in the presence of various concentrations of each toxin 
(0.025–10 nM) was plotted using GraphPad Prism and the % evoked release remaining was 
fit with the Hill equation. IC50 values and Hill coefficients of the resultant slopes were 
determined from the line fit. Results obtained with the 2 channels were remarkably similar 
(Fig 4.15a-e and Table 4.4). All 3 AgiTXs inhibited K+ elicited Rb+ efflux with similar 
potencies; IC50 values were in the low nanomolar range with AgiTX-1 being the most 
potent and AgiTX-2 the least, with all values within a 10-fold concentration range. ChTX 
and Lq2 blocked the channels with potencies comparable to the AgiTXs. While Lq2 was 
more potent than ChTX, the difference was not sufficient to distinguish them. While none 
of these toxins proved able to distinguish the heteromers, these experiments demonstrate 
the suitability of Rb+ efflux for the determination of inhibitory constants of toxins that 
block in the nanomolar range, thereby, offering a much faster alternative to the more labour 
intensive electrophysiology techniques. The Hill coefficient values are close to 1 (Table 
4.4), demonstrating the expected independent binding of the toxin to the channel. 
For some toxins though, the lowest concentrations used were already blocking both 
channels and Hill coefficient values were greater than 1 (Fig. 4.16 and Table 4.4). MgTX 
and ShK potently inhibited Rb+ efflux through both the Kv1.1-1.2 and 1.6-1.2 containing 
channels with IC50s in the picomolar range. A minimum number of cells must be used in 
each well for Rb+ efflux to give a sufficient signal:noise ratio. In the case of these very 
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potent toxins, the smallest possible cell number could still be too high for the number of 
toxin molecules in a µl volume of a picomolar solution, based on the following estimated 
calculations: 
• ~8 nA current/cell x 1 pA predicted current/channel (Gutman et al., 2003a) = 8,000 
channels/cell 
• *100,000 cells/well x 8,000 channels/cell = 800 million channels /well 
• 1.3 femtomole channel/well in **80 µl solution = 16 pM channel concentration 
(* 50,000 cells/well left overnight; therefore, assume each cell divides once, ** 50 µl of 
compound added to well, plus a small amount of wash buffer remaining in each well) 
Toxin is added to cells for 10 min and even assuming that all toxin molecules are available 
for binding to the channels where there is a small or no excess of toxin, an infinitely longer 
incubation time would be required for such a process to occur. 
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Figure 4.15│Concentration response curves showing the effects of various toxins on 
Kv1.1-1.2 and 1.6-1.2 containing channels, as measured by Rb+ efflux. Curves were fit 
using a Hill plot allowing an unconstrained Hill slope. IC50 and Hill coefficients are 
shown in Table 4.4; values plotted are an average of n >16 ± S.E.M. 
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Table 4.4│IC50 and Hill coefficient values determined by Rb+ efflux 
for several toxins’ inhibition of Kv1.1-1.2 and 1.6-1.2 containing 
channels 
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Figure 4.16│Toxins that block Kv1.1-1.2 and 1.6-1.2 containing channels in the sub-
nanomolar range are too potent for accurate determination of inhibitory constants by the 
Rb+ efflux assay. Values plotted are an average of n >16 ± S.E.M. See Table 4.4 for IC50 
and Hill coefficient values.  
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4.11 Discussion 
4.11.1 Kv1.1-1.2 containing channels expressed in CHO cells are susceptible to various 
blockers as measured electrophysiologically and by Rb+ efflux 
To develop inhibitors of therapeutic value, it is necessary to determine the functional 
properties of Kv1 channels in neurons, as related to their structures. These channels are 
present in neurons as oligomers of 4 α subunits (Parcej et al., 1992), in most instances as a 
combination of more than 1 α subunit type (Shamotienko et al., 1997). It is, therefore, 
necessary to study such physiologically-relevant heteromers in order to identify their 
individual characteristics and profiles as distinct from the homomers usually studied e.g. 
(Grissmer et al., 1994; Gutman et al., 2005). Given that Kv1.2 and Kv1.1 are the most 
prevalent α subunits in brain (Scott et al., 1994a), Kv1.1 is always associated with Kv1.2 
(Shamotienko et al., 1997) and channels composed of only Kv1.1 and Kv1.2 α subunits 
have been identified in human brain (Coleman et al., 1999), this channel was chosen for 
study. Furthermore, several mutations have been reported in the Kv1.1 gene from patients 
with channelopathies (Lehmann-Horn and Jurkat-Rott, 1999). Recreation of this naturally-
occurring heteromer was achieved through linkage of the α subunit genes as described 
previously (Akhtar et al., 2002). cRNA generated from the Kv1.1-1.2-pSFV1 plasmid was 
electroporated into CHO cells, resulting in good transfection efficiency and surface 
expressed channels; this was demonstrated by immuno-staining with an antibody specific 
for Kv1.2 (Muniz et al., 1992) and biotinylation followed by Western blotting of the 
surface-expressed channels. Electroporation conditions were optimised such that ~50% of 
cells were transfected, this being sufficient expression for electrophysiological recordings, 
enabling functional characterisation of these mammalian-expressed channels, experiments 
not conducted in the earlier study (Akhtar et al., 2002). The channel expression level was 
also such that Rb+ efflux experiments could be conducted. The Rb+ efflux assay as 
described by (Terstappen, 1999) is non-radioactive, high capacity (due to the 96-well plate 
format) and capable of functional analysis of both native and recombinant channels. It 
allows robust and reproducible characterisation of ion channel modulating compounds. 
Employment of this assay for use with recombinant heteromeric channels offers a 
convenient method in the search for specific blockers, especially in comparison to labour 
intensive and costly electrophysiology techniques. In this study, the assay was optimised 
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for use with the Kv1.1-1.2 expressing CHO cells and the effects of various inhibitors were 
measured and compared to those obtained from electrophysiological recordings.  
The recombinant channel generally behaved as expected in response to blockers. However, 
there were some minor differences observed between the assay systems. 4-AP (10 mM) 
gave a more complete block of Rb+ efflux than K+ current, presumably due to dissimilar 
experimental conditions used, based on the reasoning detailed in (Armstrong and Loboda, 
2001). For example, the membrane potential was discharged with 75 mM K+ rather than by 
the more extensive depolarisation used electrophysiologically. Incomplete block as 
measured by the latter has been attributed to the use of very negative holding potentials and 
a partial relief of inhibition by large depolarisation (Armstrong and Loboda, 2001). 
Conversely, low concentrations of 4-AP (<1 mM) inhibited IK more than Rb+ efflux, 
perhaps due to a reduced effectiveness of this compound in the presence of Rb+ compared 
to K+ (Kirsch et al., 1986).  
The inhibition by TEA of Rb+ efflux resembles that seen electrophysiologically. In both 
instances, the expressed channel showed low susceptibility to TEA, with 20 mM giving 
only ~40% inhibition; this is likely due to the presence of 2 TEA-insensitive Kv1.2 
subunits (Gutman et al., 2005). While αDTX blocked the K+ current potently and almost 
completely as would be expected from the sensitivities of Kv1.1 and 1.2 homomeric 
channels to the toxin (Grissmer et al., 1994), equivalent levels of blockade required higher 
concentrations in the flux assay. This could be due to restricted diffusion of the toxin to 
cells, but as the cell number in each well was balanced between maintaining a monolayer 
while still providing sufficient channels for Rb+ efflux measurements, this possibility 
should be minimised. Perhaps, more likely, the effect is due to the adherence of some toxin 
to the cell plate and other plastics used during the course of the assay. 
Despite these limited discrepancies, this study has confirmed that Rb+ efflux can be used to 
determine the pharmacological profiles of recombinant K+ channels of defined subunit 
composition expressed in mammalian cells. The ability to investigate several blockers in a 
single experiment, conferred by the 96-well format, is particularly attractive for 
pharmacological applications. This, coupled with the recombinant technology validated 
herein for creating Kv1 channels of specific α subunit composition, should facilitate 
research into the pharmacological characteristics of native channels, thereby, revealing 
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heteromer-specific blockers. However, given the short useful life-span of the electroporated 
CHO cells (24 h) and the large numbers of cells that would be required for screening even a 
minimal library of potential blockers, a larger source of channels and longer lasting cells 
were necessary for harnessing the full potential of this technology. 
 
4.11.2 Heteromers composed of Kv1.1-1.2 and 1.6-1.2 stably expressed in HEK cells 
provide a plentiful source of channels for extensive biophysical and pharmacological 
characterisation  
To this end, stable cell lines were developed expressing Kv1.1-1.2 and 1.6-1.2 containing 
channels. The resultant channels, composed of the 3 most prevalent Kv1 subunits in brain, 
were profiled and revealed similar biophysical properties. There was, however, a change in 
activation when Kv1.1 was substituted with Kv1.6, resulting in Kv1.6-1.2 containing 
channels activating at somewhat more negative potentials. As Kv1.6 monomers activated at 
more positive potentials than Kv1.1, this result is unexpected. It illustrates the point that 
assumptions cannot be made as to the properties of heteromeric channels based on those of 
homomers. The pharmacology of these channels was of particular interest given the 
ultimate aim of this research - to find specific blockers of hetero-tetrameric combinations of 
Kv1 α subunits. Therefore, the effects of TEA, 4-AP, αDTX and DTXk were investigated. 
4-AP and αDTX had similar effects on both channels, consistent with the published effects 
of these blockers on the parental Kv1.1, 1.2 and 1.6 homomeric channels (Gutman et al., 
2005; Harvey, 1997). TEA was less effective at blocking Kv1.6-1.2 than Kv1.1-1.2 
containing channels as expected given the increased susceptibility of Kv1.1 subunits 
compared with Kv1.6. When measured electrophysiologically, this difference was 
sufficient to distinguish the 2 channels. However, while Rb+ efflux results revealed a 
difference in sensitivities, it was not as pronounced as found with the former. DTXk proved 
to be the most effective discriminating ligand, from both electrophysiological recordings 
and Rb+ efflux results. Furthermore, while DTXk displaced 125I-αDTX from Kv1.1-1.2 
containing channels, this was not the case with those containing Kv1.6-1.2. This data 
clearly establishes the distinguishing properties of DTXk. Taken together, these results 
demonstrate the unique properties of the 2 heteromeric channels studied and emphasise the 
 113 
importance of investigating K+ channels composed of α subunit combinations mimicking 
those found in neuronal channels. 
The agreement between Rb+ efflux and the more conventional electrophysiology results 
demonstrated with HEK-expressed channels, and the provision of large numbers of 
channels with this expression system, led to automation of the assay resulting in a truly 
high-throughput screening system. Such added capacity was utilised to perform a small 
scale screen of some blockers known to inhibit some Kv1 and other families of K+ channels. 
Examination of the Kv1 α subunits sensitivities of the known Kv1 blockers demonstrated 
some predictability for effects on Kv1.1-1.2 and Kv1.6-1.2 containing channels. However, 
despite previously reported action of β and γDTX on both Kv1.1 and Kv1.2 homomers 
expressed in oocytes, no inhibition was seen herein. While differences in post-translational 
modifications between amphibian and mammalian expression systems could contribute to 
this, or inconsistencies in the identification of these toxins when purified from venom, this 
discrepancy demonstrates yet again the importance of studying physiologically-relevant 
heteromeric channels and not extrapolating from homomers. Inhibitors that block other 
families of K+ channels did not affect the Kv1 channels used in this study. In this case Lq2, 
a blocker of ROMK1 channels (Lu and MacKinnon, 1997), was an exception. However, 
Lq2 is purified from the same venom of ChTX and has close sequence homology, differing 
at only 8 positions (Lucchesi et al., 1989). It is, therefore, not surprising that both these 
toxins exhibit similar effects on the expressed channels.   
Having performed a successful screen, the quantitative potential of Rb+ efflux was 
deciphered by examining inhibitory constants from concentration response measurements. 
While toxins that block at picomolar concentrations are too potent for such measurements, 
requiring instead electrophysiological analysis, toxins that block these channels with IC50 
values in the nanomolar range are ideal for such analysis. The outcome demonstrates the 
value of Rb+ efflux as a means of decreasing the number of samples to be tested using more 
time consuming techniques, and its potential for quantitative analysis in some situations. 
This validated approach can now be applied to more Kv1 constructs to determine 
pharmacological profiles and garner further information in the search for heteromer- 
specific ligands. 
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Chapter 5 
Comparison of the pharmacological profiles of channels composed of a 
Kv1.X-1.2 series of dimers 
 
 
5.1 Overview 
In the search for blockers with specificity for neuronally-expressed Kv1 channel 
heteromers, it is important to understand the influence of combinations of α subunits within 
tetramers, on their inhibitory activities. To achieve this, Kv1.1-1.2, 1.2-1.2, 1.3-1.2, 1.4-1.2 
and 1.6-1.2 containing channels were expressed in HEK cells, their surface targeting 
confirmed by immuno-fluorescence and pharmacological profiles determined using Rb+ 
efflux. Saturable binding of 125I-αDTX to cells expressing the recombinant proteins further 
established the presence of intact channels on the plasmalemma; abilities of various other 
toxins to antagonise the binding of the radioactive probe were found to be comparable with 
Rb+ efflux results. 
 
This study explored the effects of heteromeric combinations of α subunits on blockade of 
channels by various peptide toxins, results that cannot be determined solely by examining 
the previously reported interactions of relevant parental homomers with the requisite 
inhibitor. It is clear that a heteromeric channel consisting of some toxin-sensitive subunits 
cannot be assumed to be inhibited by that compound. Indeed, the presence of some 
insensitive subunits in a heteromer can reduce or prevent inhibition despite inclusion in the 
channel of subunits sensitive to the toxin in question. Identifying the effects of heteromeric 
α subunit compositions on peptide toxin inhibition is an important step in the design of 
blockers specific for oligomeric channel subtypes.  
 
5.2 Plasma membrane targeting of Kv1.X-1.2 containing channels revealed by immuno-
staining 
COS cells transfected with Kv1.X-1.2-pIRES2-EGFP plasmids, prepared using the cassette 
cloning system (see Materials and Methods and Chapter 6), were labelled with IgGs 
specific to external epitopes of Kv1.2 (Tiffany et al., 2000) (Fig. 5.1 left hand panels).  
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Figure 5.1│ Fluorescent micrographs showing surface expression of channels containing 5 
different Kv1.X-1.2 dimers. COS cells, transfected with Kv1.1-1.2- (a), Kv1.2-1.2- (b), 
Kv1.3-1.2- (c), Kv1.4-1.2- (d) or Kv1.6-1.2-pIRES2-EGFP (e) were double labelled using an 
antibody reactive with external epitopes of Kv1.2 (Tiffany et al., 2000) (left panels) and a 
monoclonal antibody specific for an intracellular epitope of Kv1.2 (right panels). The surface 
labelling visualised (red) was distinguished from the total (green) using anti-species IgGs 
coupled to AF 594 or 488, respectively (a-e). f, Only background signals were seen upon 
omission of primary antibodies, representing the signal resulting from EGFP expression in 
transfected cells. Top panel shows DAPI stained nuclei, the bottom panel, EGFP signal from 
a transfected cell. With these exposure conditions, the EGFP fluorescence visible is 
concentrated mainly around the nucleus of the cell and clearly does not interfere with the 
specific signals resulting from antibody labelling. 
a 
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After cell permeabilisation, a monoclonal Kv1.2 antibody directed against a cytoplasmic 
domain was used to label the total channel population (Fig. 5.1 right hand panels). 
Secondary antibodies conjugated to AF 594 and 488, respectively, were used. Despite a 
large population of internal channels for each construct, a significant proportion of each of 
the channels was targeted to the cell surface. Different patterns of staining resulted from the 
2 antibodies used. While surface channels are labelled all over the plasma membrane, in the 
total field there is a strong signal from the internal channels, concentrated around the 
nucleus. Omission of the primary antibodies resulted in an absence of signals at this 
exposure, and in doing so revealed the EGFP signal due to the pIRES2-EGFP constructs 
(Fig. 5.1f). This result shows clearly that such fluorescence does not interfere with the 
antibody labelling. 
 
5.3 Saturable binding of 125I-αdendrotoxin demonstrates that the surface expressed 
channels are correctly assembled 
Suspensions of cells expressing the Kv1.X-1.2 constructs were incubated with increasing 
concentrations of iodinated toxin in the presence and absence of unlabelled αDTX. 
Subtraction of the non-specific binding from the total generated the saturable component. 
Thus, 125I-αDTX was shown to bind to the channels tested in a saturable manner (Fig. 5.2), 
evidence that correctly folded and assembled tetrameric channels are present on the cell 
surface (Tytgat et al., 1995). The KD and Bmax values for the five constructs are listed in 
Table 5.1. The KD value (0.6 nM) obtained for Kv1.1-1.2 containing channels (Fig. 5.2a) 
was comparable with results previously obtained for concatenated Kv1.1 and 1.2 subunits 
(0.5 nM) (Akhtar et al., 2002). Kv1.6-1.2 containing channels behaved similarly (KD = 0.6 
nM), as might be expected due to the presence of 4 αDTX-sensitive α subunits (Fig. 5.2e). 
Surprisingly, toxin interaction with Kv1.2-1.2 heteromers resulted in a higher KD (1.7 nM), 
perhaps as a result of the transient nature of the channel expression (Fig. 5.2b). The KD of 5 
nM for Kv1.3-1.2 containing channels could be attributed to the presence of αDTX 
insensitive Kv1.3 subunits in the channels (Fig. 5.2c). Likewise, this was also the case for 
Kv1.4-1.2 containing channels (KD = 4.3 nM) (Fig 5.2d). The presence of a positively 
charged lysine residue in the pore region of the 1.4 subunits obviously electrostatically 
reduces the toxin’s affinity. The low unsaturable binding levels are likely due to enhanced  
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Channel KD (nM) Bmax (pmol/mg) 
Kv1.1-1.2 0.6 0.04 
Kv1.2-1.2 1.7 0.2 
Kv1.3-1.2 5.0 0.2 
Kv1.4-1.2 4.3 0.3 
Kv1.6-1.2 0.6 0.05 
 
 
 
 
surface expression of these channels, imbued by the presence of Kv1.4 subunits (Manganas 
and Trimmer, 2000). This is supported by a higher Bmax value than the other constructs 
(Table 5.1). It should be noted that both Kv1.2-1.2 and Kv1.3-1.2 channels had a much 
higher level of surface expressed channels, presumably due to the larger quantities of DNA 
required to achieve saturable toxin binding when expressing these constructs compared 
with Kv1.1-1.2 and 1.6-1.2 containing channels. 
 
 
 
Figure 5.2│ Saturable binding of 125I-αdendrotoxin to intact HEK cells transfected with 
various heteromeric Kv1 channel constructs. a, Stably expressed Kv1.1-1.2 containing 
channels, b, c and d, transiently expressed Kv1.2-1.2, 1.3-1.2 and 1.4-1.2 containing 
channels respectively. e, Kv1.6-1.2 heteromers stably expressed. Total binding 
(resulting from increasing concentrations of 125I-αDTX) was quantified with a filtration 
assay; non-saturable binding was measured in the presence of 1 µM unlabelled αDTX; 
substraction of the 2 values yields the saturable component. Insets show a Scatchard plot 
of the saturable binding. Data was analysed using GraphPad Prism nonlinear regression 
to yield KD values. 
Table 5.1│ KD and Bmax values for saturable binding of 125I-αdendrotoxin to 
HEK cells expressing Kv1.X-1.2 containing channels 
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5.4 Effects of various Kv1 inhibitors on the functionality of Kv1.X-1.2 heteromeric channels 
cannot be predicted from inhibition of their parental homomers 
Rb+ efflux experiments were performed on HEK cells transiently transfected with Kv1.2-
1.2- and 1.3-1.2-pIRES2-EGFP and a stable cell line expressing Kv1.4-1.2-pIRES2-EGFP. 
The 3 constructs were prepared by the modular cloning described in Materials and Methods 
and Chapter 6. Stable cell lines expressing Kv1.2-1.2 and 1.3-1.2 containing channels were 
also developed but the level of expression was insufficient to give an adequate signal:noise 
ratio in the Rb+ efflux assay. The effects of peptide toxin inhibitors with known activity on 
Kv1 channels (Table 2.2) were investigated and combined with results obtained previously 
for Kv1.1-1.2 and 1.6-1.2 containing channels (Fig. 4.3, 4.13, 4.14) but this screen also 
included ShK-Dap22, a derivative of the sea anemone toxin ShK, described in (Kalman et 
al., 1998; Middleton et al., 2003). β and γDTX failed to inhibit flux through any of the 
recombinant channels at the concentration tested despite the presence of Kv1.2 subunits, 
contrary to their previously attributed activity on Kv1.1 and 1.2 containing channels 
(Hopkins et al., 1996). DTXk, which only blocks channels containing Kv1.1 (Akhtar et al., 
2002), inhibited Rb+ efflux only through Kv1.1-1.2. Notably, its homologue δDTX from 
Dendroaspis angusticeps behaved similarly, not attenuating Rb+ release through Kv1.2-1.2, 
1.3-1.2 or 1.4-1.2 containing channels. However, in contrast to DTXk, it blocked Kv1.6-1.2 
channels significantly more (p<0.0001). Both these toxins were isolated from venom in-
house and are very pure, giving single peaks on ion-exchange and reverse phase 
chromatography. Although the peptide sequences of these toxins differ in only 3 places 
(Table 2.1), these residues are on the channel-binding face of the toxin and this clearly has 
a marked effect on the activity (Harvey, 1997; Imredy and MacKinnon, 2000).  
Literature to date reports kaliotoxin (KTX) to have inhibitory activity on IK through 
channels possessing Kv1.1 or 1.3 (Grissmer et al., 1994). The inhibition of Rb+ efflux 
through Kv1.1-1.2 and 1.3-1.2 containing channels in this screen is, therefore, to be 
expected; however, efflux via Kv1.6-1.2 was also reduced. Given that Kv1.2-1.2 is not 
similarly affected, it can be presumed that this effect is due to Kv1.6 subunits being 
sensitive to this toxin, an observation not previously recorded. However, it would be 
worthwhile to try higher concentrations of KTX on Kv1.2-1.2 containing channels to 
ascertain if the small amount of block seen in these measurements is real or more likely due 
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Figure 5.3 │Inhibition of Rb+ efflux through channels made up from the Kv1.X-1.2 
dimer series expressed in HEK cells. The effects of various peptide toxin blockers of 
Kv1 channels on Rb+ efflux from HEK cells expressing Kv1.1-1.2-, Kv1.2-1.2-, Kv1.3-
1.2-, Kv1.4-1.2- and Kv1.6-1.2-pIRES2-EGFP constructs, were quantified by AAS. 
Evoked (stimulated-basal) efflux was normalised to that for an unchallenged control 
and data plotted as average (n = 16) ± S.E.M., with measurements performed on at least 
2 different days. All toxins were tested at 10 nM with the exception of MCD peptide 
where a 100 nM dose was used - in line with previously reported effective doses 
(Grissmer et al., 1994). Rb+ efflux through Kv1.6-1.2 containing channels was inhibited 
significantly more by δDTX compared with DTXk (p<0.001) as measured by an 
unpaired t-test. 
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to data scatter; experiments not performed herein due to the large amounts of toxin required 
and the associated expense. The other toxins tested inhibited channels in accordance with 
known α subunit sensitivies with the exception of the toxins described in-depth in the 
coming sections. Across all the toxins tested, Kv1.4-1.2 containing channels gave unusual 
results. While in most cases the presence of insensitive subunits does not prevent channel 
inhibition, this is not the case for Kv1.4-1.2 containing channels. Kv1.4 homomers are not 
blocked by any known peptide toxin (see below) and their presence in a heteromeric 
channel appears to greatly reduce or prevent blockade of the sensitive subunits. TsTX-Kα is 
a potent blocker of Kv1.2 channels (Hopkins, 1998) [as well as Kv1.3 (Rodrigues et al., 
2003)] but while it inhibited all the other Kv1.X-1.2 containing channels, it proved 
relatively ineffective towards Kv1.4-1.2, blocking less that 20% of the Rb+ efflux. This 
effect is seen with all toxins tested including ShK which was once reported to block Kv1.4 
channels (Kalman et al., 1998) although that result has not been replicated elsewhere. 
Prevention of expected channel inhibition by the presence of Kv1.4 is less pronounced with 
some toxins e.g. MgTX, HgTX and DTXI. Further investigations are necessary to 
determine the extent to which the binding of these toxins are affected by the presence of 
Kv1.4 subunits. Overall though, it appears that Kv1.4 subunits act, to a greater or lesser 
extent, in a “repulsive” manner in the inhibitory actions of toxins on heteromeric channels.  
 
5.5 Inhibitors of other families of K+ channels do not inhibit these Kv1 channels, with a few 
exceptions    
In the main, the K+ channel inhibitors used in this screen (see Table 4.3 for details) did not 
attenuate Rb+ efflux (Fig. 5.4a,b). As observed in other screening experiments there was 
some scatter in the data (see Chapter 4), in many cases with Rb+ concentrations in 
supernatants being higher than in the unchallenged control wells; this resulted in evoked 
release greater than 100%. Generally, this was more pronounced for transiently-expressed 
channels, reinforcing the notion that this is likely due to data variability rather than 
measured channel modulatory effects of the compounds in question. However in some 
more extreme cases, e.g. Penitrem on Kv1.2-1.2, the potential of channel opening activity 
could be investigated. As was observed with Kv1.1-1.2 and 1.6-1.2 containing channels 
(Fig. 4.14), Lq2 blocked other members of the Kv1.X-1.2 family with the exception of 
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Kv1.4-1.2 (Fig. 5.4a) where less than 20% inhibition of Rb+ efflux was observed. This 
corresponds to the actions of the related ChTX, raising the assumption that these toxins 
target the same Kv1 α subunits. Given that the 2 toxins are isolated from the same venom 
and have significant sequence homology differing at only 8 positions (Lucchesi et al., 
1989), this is not unlikely. Experiments on Kv1.4-1.2 containing channels with ChTX and 
Lq2 using a range of concentrations, would determine if Lq2 more potently inhibits Kv1.4 
containing channels – a result suggested from this initial screening data. Maurotoxin 
(MoTX) is a potent blocker of the intermediate-conductance Ca2+-activated K+ channel, 
hIKCa1 (Visan et al., 2004), but there have also been reports of its ability to block Kv1.1, 
1.2 and 1.3 homomers (Kharrat et al., 1996). This toxin was initially screened against 
Kv1.1-1.2 and 1.6-1.2 containing channels (Fig. 4.14). However, no inhibition of Rb+ 
efflux was observed, even in the case of Kv1.1-1.2 where only reportedly sensitive subunits 
were present in the channel. The same result was observed with Kv1.3-1.2 containing 
channels and, not surprisingly, Kv1.4-1.2. However, Rb+ efflux was attenuated through 
channels consisting of only Kv1.2 subunits (Kv1.2-1.2), highlighting the sometimes 
unexpected interaction between peptide toxins and heteromeric Kv1 channels.    
 
5.6 Screening agitoxins against the Kv1.X-1.2 series reveals previously unknown 
sensitivities of Kv1 α subunits 
Three AgiTXs have been isolated from the venom of the scorpion Leiurus quinquestriatus 
var. hebraeus (Garcia et al., 1994). To date, AgiTXs -1 and -2 have been shown to be 
active on Kv1.1, 1.3 and 1.6 and AgiTX-3 inhibits Kv1.3 channels (Cayabyab et al., 2000; 
Garcia et al., 1994; Suarez-Kurtz et al., 1999). In this study, AgiTX-1 inhibited Rb+ efflux 
through Kv1.2-1.2 containing channels (Fig. 5.5a). Given that this is a homomeric Kv1.2 
channel, the result suggests that the toxin also has activity against Kv1.2 subunits. This was 
not the case for AgiTXs 2 and 3 which did considerably inhibit Rb+ efflux through the 
Kv1.2-1.2 channels. While there appears to be some decrease in Rb+ efflux through Kv1.2-
1.2 channels with these toxins, this is likely due to data scatter as the channel is transiently 
expressed and the error bars are considerable. Likewise, AgiTX-3 was shown to have the 
same effects as AgiTX-2 on the heteromeric channels investigated, implying the same  
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Figure 5.4│Effects of various blockers of other K+ channel families on Rb+ efflux through the 
Kv1.X-1.2 channels. MoTX was found to be an interesting blocker of Kv1.2-1.2. Evoked Rb+ 
release in the presence of 10 nM (a) or 100 nM (b) test compound (detailed in Table 4.3), was 
normalised to unchallenged efflux. Data plotted are average (n = 16) ± S.E.M.   
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range of α subunit targets (Fig. 5.5a). It is clear that the presence of Kv1.4 subunits in the 
heteromers examined proves repulsive to these toxins, as there was no inhibition of Rb+ 
efflux by AgiTX-2 or -3 through Kv1.4-1.2 containing channels. In the presence of AgiTX-
1, flux was inhibited by ~20%. While this is possibly due to scatter in the data, it could also 
be a result of a limited effect of this toxin imbued by its action on the Kv1.2 subunits in the 
channel. As these results were obtained with just a single concentration of the respective 
toxins (10 nM), 125I-αDTX displacement experiments were performed to further evaluate 
this result (Fig. 5.5b). Inhibitory constants (Ki) of the various peptide toxins investigated 
were calculated according to the equation: Ki = (IC50)/{1+ [L*]/KD}, where the IC50 value 
was taken from the sigmoidal concentration-response curves for the displacement of 125I-
αDTX, drawn and analysed using GraphPad Prism and [L*] is concentration of radioactive 
ligand, in this case 2.5 nM. Ki values are listed in the figure legend and in Table 5.2. 
Kv1.1-1.2 and 1.6-1.2 containing channels are most potently blocked by all 3 AgiTXs, with 
Kis less than 1 nM. Though Kv1.3-1.2 heteromers were less sensitive to the toxins, they 
were still inhibited in the low nanomolar range. While knowledge of the interaction of these 
toxins with channels possessing various α subunits was expanded, these toxins do not fulfil 
the criterion set for this search; that is ability to distinguish the heteromers examined. 
 
5.7 Noxiustoxin gives a similar displacement of 125I-αdendrotoxin from Kv1.2-1.2 and 1.3-
1.2 containing channels in contrast to Rb+ efflux results 
NxTX has been shown to block Kv1.2 and Kv1.3 elicited IKs with a KD of 2 and 1 nM, 
respectively (Grissmer et al., 1994). However in this study, while Rb+ efflux through 
Kv1.2-1.2 channels was inhibited completely by 10 nM toxin, the same was not the case for 
Kv1.3-1.2 containing channels, where only 35% block was observed (Fig. 5.6a). As both 
homomeric channels have very similar sensitivities to NxTX, this result was unexpected 
and, therefore, 125I-αDTX displacement experiments were performed and inhibitory 
constants determined (Fig. 5.6b). Under these experimental conditions, however, the toxin 
potency was virtually identical for both channels (Kv1.2-1.2, Ki = 0.1 nM; Kv1.3-1.2, Ki = 
0.2 nM, see Table 5.2).    
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Figure 5.5│Comparison of the influences of agitoxins on the series of Kv1.X-1.2 
containing channels expressed in HEK cells. Results obtained for the inhibition of Rb+ 
efflux (a) (taken from Fig. 5.3), were confirmed by displacement of bound 125I-αDTX 
(b). b, Averages (n = 4) are plotted ± S.D. Kis are as follows, for AgiTX-1: 1.1-1.2 
(0.8 nM), 1.2-1.2 (1.6 nM), 1.3-1.2 (6.9 nM), 1.6-1.2 (0.9 nM); for AgiTX-2: 1.1-1.2 
(0.6 nM), 1.3-1.2 (1.6 nM), 1.6-1.2 (0.1 nM) and for AgiTX-3: 1.1-1.2 (0.3 nM), 1.3-
1.2 (16.2 nM), 1.6-1.2 (0.2 nM). 
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Figure 5.6│Contrary to Rb+ efflux results, noxiustoxin inhibits 125I-αdendrotoxin 
binding to Kv1.2-1.2 and 1.3-1.2 containing channels with very similar potency. While 
blockade of evoked Rb+ release through Kv1.3-1.2 channels was only 35% compared 
with 100% for 1.2-1.2 (a), displacement of 125I-αDTX by the toxin from both channels 
was almost identical (b). Toxin displacement data is plotted as mean ± S.D., n = 4.   
a b 
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 Kv1.1-1.2 Kv1.2-1.2 Kv1.3-1.2 Kv1.4-1.2 Kv1.6-1.2 
Agitoxin-1 0.8 1.6 6.9  0.9 
Agitoxin-2 0.6  1.6  0.1 
Agitoxin-3 0.3  16.6  0.2 
Noxiustoxin  0.1 0.2   
ShK-Dap22 2.3    38.0 
Maurotoxin  0.9 0.1   
αdendrotoxin    1.9  
Hongotoxin    0.8  
Margatoxin    0.6  
 
 
 
 
5.8 ShK and its derivative ShK-Dap22 have different potencies and selectivities for channels 
comprising the Kv1.X-1.2 series 
As described above (Fig. 5.7a), 10 nM ShK gave a 100% inhibition of Rb+ efflux through 
all Kv1.X-1.2 channels with the exception of Kv1.4-1.2, due presumably to the presence of 
“inhibitory” Kv1.4 subunits. While the derivative ShK-Dap22 blocked Kv1.1-1.2, 1.3-1.2 
and 1.6-1.2 containing channels (Fig. 5.7b), it showed a reduced potency compared with 
wild type ShK at the same concentration. This was expected given the results from previous 
studies (Kalman et al., 1998; Middleton et al., 2003). Both toxins failed to significantly 
block Rb+ efflux through Kv1.4-1.2 containing channels (Fig 5.7a,b), suggesting that these 
toxins are also “repelled” by the presence of Kv1.4 subunits in a channel. Once again, the 
small (~10%) reduction of flux seen with ShK on these channels (Fig. 5.7a) could be due to 
data scatter or the presence of Kv1.2 subunits, which ShK inhibits. Most interestingly, 
ShK-Dap22 did not attenuate evoked Rb+ release (Fig. 5.7b) from Kv1.2-1.2 channels in 
agreement with published data showing the low affinity of Kv1.2 homomers to this toxin 
(Middleton et al., 2003). This result was confirmed by its inability to displace 125I-αDTX 
bound to the same channels (Fig. 5.7c). This was not the case for displacement of 125I-
αDTX from Kv1.1-1.2 or 1.6-1.2 containing channels, though the potency of the toxin was  
Table 5.2│Ki values (nM) for the displacement of 125I-αdendrotoxin from various Kv1.X-1.2 
containing channels expressed on the surface of HEK cells 
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less than has been seen with other peptide toxins (Ki = 2.3 and 38.0 nM for Kv1.1-1.2 and 
1.6-1.2 containing channels respectively, Table 5.2), resulting in large amounts of non-
displaceable binding even with 1 µM ShK-Dap22 (Fig. 5.7c). Taken together this data 
demonstrates the lower potency of the ShK derivative, but its selectivity for Kv1.1-1.2 (and 
to a lesser extent Kv1.6-1.2) containing channels over Kv1.2 homomers is in agreement 
with previous reports (Middleton et al., 2003). 
 
5.9 Maurotoxin is distinct from other venom-derived peptide toxins studied herein in its 
effects on heteromeric compared to homomeric channels 
Given reports that MoTX inhibits IK through Kv1.1, 1.2 and 1.3 channels expressed in 
Xenopus oocytes (Kharrat et al., 1996), it was surprising that only Rb+ efflux through 
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Figure 5.7│ShK-Dap22 is less potent but more selective than the wild type ShK. The 
different potencies and selectivities of ShK and ShK-Dap22 were measured by 
inhibition of Rb+ efflux through Kv1.X-1.2 containing channels (a and b; data from 
Fig. 5.3). The selectivity of ShK-Dap22 is confirmed with 125I-αDTX displacement 
experiments (c). Average values are plotted ± S.D.; n = 4.  
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Kv1.2-1.2 and not Kv1.1-1.2 and 1.3-1.2 channels was inhibited by this toxin, as 4 sensitive 
subunits are present in the latter (Fig. 5.4a/5.8a). Displacement by 1 µM MoTX of 125I-
αDTX bound to these channels was quantified to asses this result (Fig. 5.8b). As expected, 
this very large dose of toxin did not displace appreciable amounts of labelled αDTX from 
Kv1.1-1.2 (or Kv1.6-1.2) containing channels. However, this was not the case for those 
containing Kv1.3-1.2 (and 1.2-1.2 as expected from the Rb+ efflux results). Therefore, 
experiments were performed to compare the Kis of displacement (Fig. 5.8c). While MoTX 
more potently displaced 125I-αDTX from Kv1.3-1.2 compared with Kv1.2-1.2 containing 
channels, there was less than a 10-fold difference between them (Kv1.2-1.2, 0.9 nM and  
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Figure 5.8│Inhibition by maurotoxin of Kv1.2 containing heteromeric channels is 
influenced by the presence of other subunits. Rb+ efflux data shows MoTX blocks 
Kv1.2 homomeric channels and not those containing Kv1.2 with other subunits (a – 
taken from Fig. 5.4). b, An excess (1 µM) of MoTX (□) does not substantaially 
displace 125I-αDTX (■) bound to the Kv1.1-1.2 and 1.6-1.2 containing channels (mean 
± S.D., n = 4). Ki values for Kv1.2-1.2 and 1.3-1.2, the 2 MoTX sensitive channels, 
were compared (0.9 and 0.1 nM respectively); averages are plotted ± S.D., n=4 (c). 
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Kv1.3-1.2, 0.1 nM, Table 5.2). Furthermore, the total amount of radio-labelled toxin 
displaced for Kv1.3-1.2 heteromers was limited, with high levels of non-displaceable 
binding remaining. Taken together, this data demonstrates that MoTX inhibition of 
heteromeric combinations of channels differs from that of other Kv1 blockers examined. 
 
5.10 αdendrotoxin does not attenuate Rb+ efflux through the Kv1.4-1.2 channel, but the 
expressed protein binds 125I-αdendrotoxin and this is displaced by several toxins 
Despite the lack of substantial inhibition of Kv1.4-1.2 containing channels by various 
Kv1.2 inhibiting toxins in Rb+ efflux experiments, 125I-αDTX bound saturably to this 
channel with low levels of non-specific binding (Fig. 5.2d,). In the presence of some toxins 
(HgTX and MgTX), however, there did appear to be some reduction in Rb+ efflux, found to 
be statistically significant (Fig. 5.9). To test the consistency of these results, displacement 
of 125I-αDTX by these toxins was quantified (Fig. 5.9b). The resultant Ki values reflect the 
degree of inhibition of Rb+ efflux (in nM; αDTX, 1.9; HgTX, 0.8; MgTX, 0.6, Table 5.2). 
These results not only demonstrate the possibility of using αDTX as a radio-ligand for 
Kv1.4 containing channels when sensitive subunits are present, but also suggest that MgTX 
and HgTX may have some properties that render them less susceptible to “repulsion” by 
Kv1.4 than other peptide toxins examined. 
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Figure 5.9│ Comparison of 125I-αdendrotoxin displacement from Kv1.4-1.2 
containing channels by 3 peptide toxins. Kv1.4-1.2 containing channels proved 
insensitive to several Kv1.2 blocking toxin when measured by Rb+ efflux (a). 
Increased inhibition of Rb+ efflux by both HgTX and MgTX was statistically 
significant compared with block by αDTX; HgTX, p=0.0216 (*), MgTX, 
p=0.0001 (**), as measured by an unpaired t-test. b, Displacement of radio-
labelled αDTX by the same unlabelled, HgTX and MgTX are expressed as 
averages (n = 4) ± S.D. 
αDTX HgTX MgTX
0
20
40
60
80
100
Toxin (10 nM)
N
o
rm
a
lis
e
d 
e
v
o
ke
d 
R
b+
 
e
fflu
x 
(%
)
-6 -4 -2 0 2 4
0
20
40
60
80
100
120
HgTX
MgTX
αDTX
log [Toxin] (nM)
12
5 I-
α
D
TX
 
bi
n
di
n
g 
(%
)
a b 
* 
** 
 132 
5.11 Discussion 
Potential future therapeutics for the treatment of the many conditions involving hypo-
excitability of subtypes of Kv1 channels require absolute specificity for their target, given 
the wide expression of these channels. As the majority of Kv1 channels isolated from 
mammalian brain are heteromeric combinations of α subunits, it is these channel 
compositions that need to be mimicked when considering targets for drug screening. 
Understanding the interaction of blockers with heteromeric as opposed to homomeric 
channel combinations, provides necessary insights for the design of these important 
inhibitors. 
Kv1.2 is the most prevalent subunit in brain (Scott et al., 1994a) and is present in most 
heteromers whose compositions have been determined (Coleman et al., 1999; Shamotienko 
et al., 1997). Therefore, different subunits were combined with it, to produce the interesting 
Kv1.X-1.2 series. The cassette cloning system described in Chapter 6 and (Shamotienko et 
al., 2008) was used to make the constructs (Kv1.2-1.2, 1.3-1.2 and 1.4-1.2) which had not 
been investigated in previous studies. The extensive characterisation of channels resulting 
from these constructs confirms the efficacy of the modular cloning system for expressing 
constructs with any number of positions filled, as the constructs used here had only 2 
positions filled and expressed functional channels, confirming that the ORF was maintained.  
In an attempt to understand the interactions of the peptide toxins used in this study with 
heteromeric channels, screening of numerous Kv1 blocking peptide toxins was performed 
using a Rb+ efflux assay. Inhibition of Rb+ efflux was monitored in channels composed of 
subunits not previously shown to be sensitive to the toxins in question. In this way, the 
study served to increase the number of Kv1 α subunits known to be susceptible to some of 
the inhibitors screened. Of course, this assumes that sensitivities of homomeric Kv1.X 
channels can be extrapolated from results achieved with heteromeric combinations of Kv1 
α subunits. While such conclusions are likely correct, it is important that the same 
assumptions are not made to predict heteromer pharmacology from examining homomeric 
combinations of channels alone. Nevertheless, in this study further target subunits for the 
AgiTXs, KTX and the ChTX homologue Lq2 have been putatively identified. 
The “repulsive” effect of the Kv1.4 subunit on peptide toxin binding to channels containing 
it was also clearly demonstrated. That is, Rb+ efflux through the Kv1.4-1.2 containing 
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channels was reduced to a far lesser extent than the other channels examined. Based on 
results obtained from the other members of the Kv1.X-1.2 series, toxins with activity 
against Kv1.2 subunits including but not limited to αDTX, ChTX, ShK and TsTX-Kα, 
would have been expected to block Rb+ efflux. However, this was not the case as these 
toxins (10 nM) inhibited release by no more than 20%. Interestingly, some toxins did have 
a more pronounced effect and these were investigated further. When performing 125I-αDTX 
binding experiments on the Kv1.X-1.2 containing channel series, Kv1.4-1.2 was also 
included despite the fact that αDTX did not inhibit flux. Surprisingly, the 125I-αDTX bound 
specifically (KD=4.3 nM) to the expressed channel, albeit with reduced affinity. This 
allowed displacement experiments to be performed confirming the Rb+ efflux result that 
MgTX and HgTX have some inhibitory activity towards this channel. The interaction of 
αDTX as measured with Rb+ efflux compared to toxin displacement experiments is 
surprising. Perhaps, the presence of Kv1.4 subunits increases the time required for toxin 
binding and, therefore, the 10 min toxin incubation used for Rb+ efflux experiments is not 
sufficient but the 1 h incubation time used for radio-labelled toxin experiments is. An 
interesting next step is to see if the “repulsive” effect of Kv1.4 is altered in relation to the 
number of subunits present in a channel.  
Importantly, there were several instances where the specificity of a toxin for a particular 
heteromer could not be predicted from published sensitivities of the relevant parental 
homomers. The selectivity of the ShK derivative ShK-Dap22 for Kv1.1 and 1.2 containing 
heteromeric channels compared with either of the homomers, as previously reported 
(Middleton et al., 2003), was reproduced in this study for Kv1.1-1.2 compared with Kv1.2-
1.2 containing channels (i.e. Kv1.2) homomers. Most surprising and truly unique though, 
was MoTX. Only Rb+ efflux through Kv1.2-1.2 channels was blocked despite the fact that 
Kv1.1 and 1.3 subunits have also been shown to be sensitive to this toxin (Kharrat et al., 
1996). Kv1.2 is the most sensitive of the 3 subunits, perhaps explaining why Rb+ efflux 
through channels composed solely of this subunit (the Kv1.2-1.2 heteromers) was blocked. 
While of the remaining subunits, previously published data (Kharrat et al., 1996) suggests 
IK through Kv1.1 is more sensitive to block by MoTX than K+ current through Kv1.3 
channels, when 125I-αDTX displacement experiments were performed the opposite result 
was obtained. That is, while toxin binding to Kv1.1-1.2 was very poorly displaced by 
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MoTX, the toxin was more effective on Kv1.3-1.2 containing channels. The unusual 
features of this toxin certainly warrant further investigation. Perhaps it is more effective on 
homomeric as compared with heteromeric combinations of channels. Identification of the 
structures and residues responsible for this surprising selectivity could provide vital 
information for the manipulation of other more promiscuous but potent blockers.  
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Chapter 6 
Concatenating tetramers of Kv1 α subunits to mimic those expressed 
neuronally unveils novel K+ channel characteristics of authentic 
therapeutic targets 
 
 
6.1 Overview 
Many ion-channels, receptors, transporters and enzymes are heteromeric proteins, some of 
which are composed of structurally-related subunits. In most cases, specific channel 
subtypes or combinations are localised to particular tissues (Coleman et al., 1999), 
presumably to fulfill a defined function imbued by such controlled composition. When 
looking for new therapeutics, development of blockers specific for such localised oligomers 
should decrease side effects. The versatile and novel methodology described herein for 
concatenating subunits allows expression and functional characterisation of such proteins, 
providing native-like targets for drug screening. 
This technology was developed for the study of hetero-tetrameric Kv1 channels with 
subunit compositions mimicking those identified in mammalian brain (Coleman et al., 1999; 
Koch et al., 1997; Koschak et al., 1998; Shamotienko et al., 1997). Functional analysis of 
such recombinant channels facilitated determination of the characteristic profiles of these 
channels which can be used to elucidate the molecular entities responsible for K+ currents 
recorded from neurons.  
 
This chapter describes the generation of 4 concatenated tetrameric combinations of Kv1 α 
subunits. Initially, three of these channels were extensively characterised and shown to 
traffic to the surface of HEK cells and yield functionally uniform channels whose K+ 
currents could be distinguished by inactivation profiles and responses to selective blockers. 
This work has been submitted for publication in (Shamotienko et al., 2008). Experiments 
further investigating the effect of various toxins on Kv1.4 containing channels, begun in the 
previous chapter, involved the use of a fourth tetrameric channel. 
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6.2 The modular cloning system 
This was designed to prepare concatenated constructs of Kv1.X genes, encoding any pre-
determined stoichiometry and composition of α subunits. It involved linking constituents in 
the same ORF, using a proven inter-subunit linker originating from the Xenopus β-globin 
gene (Akhtar et al., 2002), making this approach potentially applicable to any multi-protein 
complex. 
 
6.2.1 Generation and engineering of a bank of α subunit genes Initial PCR of Kv1.1, 1.2, 
1.3 and 1.6 DNAs yielded single bands of the expected molecular mass of 1.5 kbp with 
Kv1.4 giving a larger size of 2.0 kbp. Amplified products were individually cloned into the 
polylinker of pβUT2 situated between the 5’ and 3’ UTRs of the Xenopus β-globin gene. 
Subsequent amplification of individual subunits within pβUT2 was carried out using 
primers designed against these flanking UTRs (Table 3.1); additionally, pairs of restriction 
sites were introduced to allow positional cloning of individual subunits (with flanking UTR 
elements) into the MCS of the pIRES expression plasmids (Fig. 6.1a). The first gene of 
each tetramer was inserted as domain I between Nhe I and Bgl II sites, with cloning being 
achieved using UTR-specific primers that encompass their sequences. Similarly, cloning of 
each of the constituent sequences into the remaining three domains could be accomplished, 
utilising the requisite pairs of restriction sites (Fig. 6.1a). Unlike the genes in domains I-III, 
the occupant of the last slot contained two stop codons. Thus, all four groups of UTR-
specific primers differed only by domain–specific flanking restriction sites. Since each half-
linker contained 30 nucleotides plus 3 (after assembly) for restriction sites, each two 
neighbouring subunits in the assembled oligomers (regardless of their domain) were 
separated by 78 nucleotides, including 6 each for Xba I and Xho I sites. Each product from 
the second round of PCR showed single DNA bands of the expected sizes when subjected 
to agarose electrophoresis. 
 
6.2.2 Domain-specific assembly of gene cassettes into pIRES plasmids and expression of 
concatenated Kv1 channels Assembly of cassettes containing α subunit genes can be started 
from any of the 4 cloning domains. Similarly, any constituent can be cut-out and replaced  
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: Common linkers pre-attached to 5’ and 3’ sides of Kv1.X keep 
neighbouring genes in the same ORF
Kv1.X(-s)
Nhe I Bgl II EcoR I Sal I BamH I
Kv1.X(+s)Kv1.X(-s)Kv1.X(-s)
I II III IVDomain:
Anti-Kv1.2  -Kv1.1  
100
250
150
75
37
50
-Kv1.2 -Kv1.2-Kv1.3-Kv1.6-Kv1.4 -Kv1.1
k 1   2    3  4 1   2 1   2    3   4    5   6   7   8    9  10
b c d
Figure 6.1│ Concatenation of Kv1.X genes, expression and surface targeting in HEK cells of 
intact tetrameric Kv1 channels. a, Schematic - attachment to Kv1 genes of half-linkers and 
restriction sites for assembly of concatemers in pIRES2-EGFP or -DsRed. UTRs of Xenopus β 
globin gene and restriction sites for the enzymes specified were added to the ends of the Kv1.X 
inserts by PCR to allow position-specific cloning into the plasmids. Complete linkers form during 
the assembly of concatemers retaining all the sequences in the same ORF. b, HEK cells were 
transfected with pIRES2 reporter plasmids containing the Kv1 inserts specified and after 48 h 
subjected to SDS-PAGE followed by Western blotting with the antibodies specified, and 
visualisation using ECL reagents. Samples from cells transfected with pIRES2-EGFP containing 
the following constructs are shown in lanes: 1, Kv1.2; 2 Kv1.2-1.2; 3 & 4, Kv1.1-1.1-1.2-1.2. c, 
Biotinylation of surface proteins. Lanes: 2, surface biotinylated and affinity-isolated Kv1.1-1.1-
1.2-1.2; 1, total protein from the non-biotinylated cells. d, Western blots of cells transfected with 
tetrameric constructs in pIRES2-DsRed; Kv1.4-1.6-1.1-1.2, (lanes 1, 3, 5, 7, 9), Kv1.4-1.6-1.3-1.2 
(lanes 2, 4, 6, 8, 10). Lysates prepared from untransfected cells showed no reactivity against the 
antibodies used for the blotting (data not shown). Mobilities of standard proteins are indicated (b-
d). 
a 
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with another desirable Kv1.X gene; in fact, the structures of all the constructs were easily 
verified by restriction mapping (Fig. 6.2). For convenience, assembly was started at domain 
IV by incorporating the Kv1.2 gene (+ stop codons) into pIRES2-EGFP; upon expression, 
this gave a band with a Mr ~ 60-65 kDa, as revealed by SDS-PAGE and Western blotting 
(Fig. 6.1b), a size expected for this partially-glycosylated subunit. A homo-dimeric 
expressed protein with a Mr ~ 120 kDa (Fig. 6.1b) resulted from placing Kv1.2 (-stop 
codon) into domain III of the plasmid. Insertion of Kv1.1 (- stop codon) into domain II of 
Kv1.2-1.2, followed by incorporation of Kv1.1 (-stop codon) into domain I produced a full 
Kv1.X tetramer. After expression, this yielded a protein of Mr ~ 240 kDa detected by 
antibodies specific for Kv1.1 and 1.2 (Fig. 6.1b). Likewise, direct immuno-blotting of 
lysates from HEK cells transfected with pIRES2-DsRed containing Kv1.4-1.6-1.1-1.2 or 
Kv1.4-1.6-1.3-1.2 visualised a major band in each case corresponding to Mr ~ 240 kDa, 
when probed with antibodies specific for each of the constituent subunits (Fig. 6.1d). Some 
immuno-blots detected double bands corresponding, perhaps, to glycosylated forms 
characteristic of Kv1.4-containing channels (Shi and Trimmer, 1999). The successful 
generation of 3 hetero-tetrameric channels (the fourth is described later) exemplifies the 
usefulness of this strategy for assembling multi-component constructs which, in turn, 
allowed new structure-activity studies.  
 
6.3 Intact and active tetrameric channels are targeted to the plasma membrane of HEK 
cells 
For utilising recombinant Kv1 channels as targets for future drug screening, it was 
important to establish whether the concatenated oligomers traffic intact to the plasma 
membrane in active form when expressed in mammalian cells. Labelling of COS cells 
expressing Kv1.1-1.1-1.2-1.2 with IgGs specific for external epitopes of Kv1.2, followed 
by fluorescent microscopy, demonstrated clear staining on the cell surface (Fig. 6.3a,b – 
left hand panels). When the same cells were then permeabilised and incubated with a 
monoclonal antibody specific for a cytosolic epitope of Kv1.2, all the channels became 
stained (Fig. 6.3a). Repeating this with a monoclonal antibody specific for an intracellular 
epitope of Kv1.1 confirmed the presence of both subunits in the expressed channels  
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Kv1.1-1.1-1.2-1.2 Kv1.4-1.6-1.1-1.2   Kv1.4-1.6-1.3-1.2
M   1    2    3   4 M    5    6    7   8   M    9   10  11  12 
 
 
Figure 6.2│Restriction mapping of Kv1.X tetrameric constructs and intermediates 
formed during the concatenation. a, Sequential release from pIRES2-EGFP Kv1.1-1.1-
1.2-1.2 of Kv1.1, Kv1.1-1.1, Kv1.1-1.1-1.2 or Kv1.1-1.1-1.2-1.2 inserts by digestion 
with Nhe l and Bgl II, EcoR I, Sal I or BamH I, as seen in lanes 1-4 from an agarose 
(1%) gel electrophoretogram. b, Sequential release of Kv1.4, Kv1.4-1.6, Kv1.4-1.6-
1.1 or Kv1.4-1.6-1.1-1.2 inserts from the final pIRES2-DsRed Kv1.4-1.6-1.1.-1.2, and, 
Kv1.4, Kv1.4-1.6, Kv1.4-1.6-1.3 or Kv1.4-1.6-1.3-1.2 inserts from Kv1.4-1.6-1.3-1.2-
pIRES2-DsRed by digestion with Nhe l and Bgl II, EcoR I, Sal I or BamH I, as seen in 
lanes 5-8 and 9-12 respectively also from an agarose (1%) gel electrophoretogram. M, 
kbp markers, from the top; 10.0, 8.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.5, (in a and b). Note 
tetramer band is larger than vector band in lanes 4, 8 and 12. 
 
a b 
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Surface Kv1.2 Total Kv1.2 Surface Kv1.2 Total Kv1.1 
Surface Kv1.2 Total Kv1.4 Surface Kv1.2 Total Kv1.4 
Surface Kv1.2 Total Kv1.1 
t l v .  
d 
a 
c 
b 
Figure 6.3│Surface expression of 3 hetero-tetrameric Kv1 channels in COS cells. 48 h 
post transfection with Kv1.1-1.1-1.2-1.2-pIRES2-EGFP (a,b), Kv1.4-1.6-1.1-1.2- (c) 
or Kv1.4-1.6-1.3-1.2-pIRES2-DsRed (d), COS cells were labelled using an antibody 
reactive with external epitopes of Kv1.2 (Tiffany et al., 2000), visualised with anti-
rabbit AF 594 (left panels). Following permeabilisation of the same cells, monoclonal 
antibodies specific for intracellular epitopes of Kv1.2 (a), 1.1 (b) or Kv1.4 (c,d) and 
anti-mouse AF 488 (right panels) were used to reveal the total channel population. 
Only background signals were seen upon omitting the primary antibodies; in the case 
of pIRES2-DsRed constructs (c,d), no background fluorescent signal from the DsRed 
was visible under these conditions.   
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(Fig. 6.3b). As the majority of staining occurred intracellularly in each case (Fig. 6.3a.b), it 
was necessary to biochemically analyse the minority of channels on the surface to ascertain 
whether their protein profile differed from that of the total population (Fig. 6.1b,c). This 
was accomplished by biotinylation of the surface components in intact transfected HEK 
cells. Precipitation of the solubilised biotinylated proteins with streptavidin agarose, SDS-
PAGE and Western blotting revealed that only the intact tetrameric channel (Kv1.1-1.1-1.2-
1.2) was expressed on the surface (Fig. 6.1c). With the other two hetero-tetramers used in 
this study, surface expression was also demonstrated by fluorescent microscopy (Fig. 
6.3c,d). Evidence for a correctly-folded and assembled tetrameric channel on the 
plasmalemma was provided by the avid binding of αDTX to the intact cells (Fig. 6.4a). 
Intact HEK cells expressing Kv1.1-1.1-1.2-1.2 displayed saturable interaction with 125I-
labelled αDTX (KD = 0.74 nM); in view of this affinity corresponding to that (0.5 nM) 
previously reported for channels composed of tandem-linked Kv1.1-1.2 in (Akhtar et al., 
2002) and in Chapter 5 (0.6 nM), binding is not affected by this concatenation. The content 
of sites (0.13 pmoles/mg protein) (Fig. 6.4a) reflects a similar level of expression of 
tetramer compared to that observed for cells stably expressing dimeric constructs (Sokolov 
et al., 2007). This is considerably lower than the 1.22 pmoles/mg observed for the same 
combination of subunits in a previous study (Akhtar et al., 2002), however in that instance 
the construct was expressed via electroporation with viral particles and co-expressed with 
Kvβ2.1 which both increase the surface expression of channels. Saturable interaction of 
125I-αDTX with cells expressing Kv1.4-containing constructs, Kv1.4-1.6-1.1-1.2 or Kv1.4-
1.6-1.3-1.2, could not be reliably detected by this method with minimal specific binding 
observed (Fig. 6.4d), consistent with a rapid dissociation observed for αDTX from Kv1.4-
containing channels (see below). This is surprising, however, given the measurable binding 
of the toxin to Kv(1.4-1.2)2 described in Chapter 5. 
 
6.4 Hetero-tetrameric constructs express uniform populations of Kv1 channels  
Functional properties of concatenated Kv1 heteromers were examined by whole-cell 
voltage-clamped recordings from transfected HEK cells. The resultant currents indicated 
proper assembly of the recombinant channels. Kv1.1-1.1-1.2-1.2 gave an IK consistent with 
a single population of channels; depolarising voltage steps from a holding potential of -100  
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Figure 6.4│ Radiolabelled αdendrotoxin binding to tetrameric channels expressed on HEK 
cells. Saturable binding (▼) of 125I-αDTX to intact HEK cells, expressing Kv1.1-1.1-1.2-
1.2, quantified with a filtration assay (a); relatively low values were recorded for non-
saturable (▲) binding compared with the total (■). Inset shows a Scatchard plot of the 
saturable binding. b, Competition of 2.5 nM 125I-αDTX binding (mean ± SD; n = 4) to 
transfected cells as in (a) by αDTX, DTXk or TsTX-Kα. c, Representative plot showing the 
relative potencies of ShK and ShK-Dap22  in antagonising 2.5 nM 125I-αDTX binding to the 
K+ channels as in (b). d, Binding of 2.5 nM 125I-αDTX to cells expressing Kv1.4-1.6-1.1-
1.2 or Kv1.4-1.6-1.3-1.2 was measured in the absence (total, ■) and presence (αDTX, □; 
DTXk ■) of 1 µM competing unlabelled toxins (mean ± SD; n = 4). Very little specific 
binding was observed, probably due to the fast dissociation of the radio-ligand from these 
channels. 
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mV triggered outward delayed-rectifying IK typical of Kv1 channels. Sigmoidally-shaped 
activation currents were observed which could be fit by the power of a single exponential 
function (Fig. 6.5a, Table 6.1), indicative of channels undergoing multiple conformational 
transitions at similar rates before their opening (Hodgkin and Huxley, 1952). The observed 
slow inactivation of IK (Fig. 6.5b) accords with a lack of an N-type, fast inactivation 
domain (Jan and Jan, 1997). Upon return to negative voltage, IK decayed with a mono-
exponential time-course (Fig. 6.5c, Table 6.1), again, consistent with a uniform population 
of underlying channels. Activation-gating accelerated as the voltage step was increased, 
and at values positive to +20 mV increased with a voltage dependence of 0.24 elementary 
charges (Fig. 6.5d). Likewise, upon release of membrane potentials to less than -60 mV,  
  
Kv1.1-1.1-1.2-1.2 
 
 
Kv1.4-1.6-1.1-1.2 
 
Kv1.4-1.6-1.3-1.2 
 
τ-Activation at 0 mV (ms) 
 
 
1.9 ± 0.1 
(n=3) 
 
1.5 ± 0.1 
(n=5) 
 
1.8 ± 0.1 
(n=7) 
 
τ-Inactivation at 0 mV, fast (ms)  
 
 
540 ± 20 
(n=5) 
 
45 ± 8 
(n=7) 
 
47 ± 0.1 
(n=5) 
 
τ-Inactivation at 0 mV, slow (ms) 
 
 
6200 ± 500 
(n=5) 
 
260 ± 20 
(n=7) 
 
270 ± 6 
(n=5) 
 
V½ (mV) 
 
 
-12 ± 1 
(n=13) 
 
-19 ± 0.8 
(n=10) 
 
-23 ± 0.6 
(n=10) 
 
Slope (k) (mV) 
 
 
15 ± 0.8 
(n=13) 
 
11 ± 0.7 
(n=10) 
 
10 ± 0.5 
(n=10) 
 
Table 6.1│Biophysical and pharmacological properties of 3 hetero-tetrameric K+ channels.  
Values for activation and inactivation were calculated by fitting power and double-exponential 
functions, respectively. Values for V½ and slope k were calculated from Boltzmann equation 
fitting of the gk–V relations from peak outward currents. 
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Figure 6.5│ Kv1.1-1.1-1.2-1.2 construct expresses functionally uniform channels on HEK 
cells. a, K+ currents (IK) in response to depolarising steps (grey traces) from -40 to 80 mV in 20 
mV increments fit with the power of an exponential function (black lines). b, Inactivation of IK 
during a pulse to 0 mV (grey traces), fit with a double exponential function (black line). c, 
Deactivation of IK at -80, -100 or -120 mV (grey traces) after 50 ms at +60 mV, fit with mono-
exponential functions (black lines). d, Time constants (n=3) associated with activation (>-50 
mV) or deactivation (<-50 mV); lines are fits of exponential functions. e, Conductance-voltage 
relationship of outward K+ peak currents (n=15) after 100 ms at indicated voltage; dashed line 
is a Boltzmann fit. f, Concentration dependence of TEA inhibition of IK (n=4) during voltage 
steps to +60 mV for 50 ms. Inhibition in each cell was normalised (○) to a saturating value of a  
a b c 
d e 
f g
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the deactivation became progressively faster with a voltage dependence of -0.81 elementary 
charges. Analysis of the steady-state conductance-voltage relation (gK-V) revealed a 
conductance profile well-fitted by a single Boltzmann function (Fig. 6.5e), with an 
activation midpoint and slope (Table 6.1) intermediate to those for homomers of the 
parental Kv1.1 or Kv1.2 subunits (Sokolov et al., 2007). 
 
6.5 Biophysical profiles and susceptibilities to inhibitors can be used to distinguish these 
heteromeric channels 
The sensitivities of IK to various blockers were examined. TEA, a characterised K+ channel 
blocker, binds just external to the K+ conduction pore with all 4 subunits contributing to 
this interaction (Lenaeus et al., 2005). The TEA dose-response of IK from Kv1.1-1.1-1.2-
1.2 was well fit by a Langmuir binding isotherm (Fig. 6.5f) giving a dissociation constant 
of 8.4 mM, a value intermediate to that of Kv1.1 and 1.2 homo-tetramers (Sokolov et al., 
2007). Similarly αDTX, DTXk, 4-AP, TsTX-Kα and ShK-Dap22 inhibited this IK (Fig. 
6.5g), in accord with their known interactions with Kv1.1- and 1.2-containing channels 
(Middleton et al., 2003; Sokolov et al., 2007).  Congruently, 125I-αDTX was readily 
displaced from this channel by DTXk, αDTX, TsTX-Kα (Fig. 6.4b) (Kis = 2.0, 0.6 and 0.1 
nM, respectively) or ShK-Dap22 (Fig. 6.4c). The greater potency of ShK than its derivative 
ShK-Dap22 (Ki = 0.04 compared with 4.0 nM) is consistent with their abilities to inhibit 
homomeric Kv1 channels (Middleton et al., 2003), and the results obtained in Chapter 5 for 
the displacement of radio-labelled αDTX by ShK-Dap22 from Kv1.1-1.2 heteromers (2.3 
nM). A reported pattern (Middleton et al., 2003) of ShK-Dap22 binding to Kv1.1/1.2 
concatemers was indicative of a mixture of channels being expressed; in contrast, 
displacement herein of 125I-αDTX from Kv1.1-1.1-1.2-1.2 indicates that this concatemer is 
fit with Langmuir isotherm (dashed line). g, Reduction by various agents of IK from Kv1.1-1.1- 
1.2-1.2 (open bar), homomeric Kv1.1 (grey bar) or Kv1.2 (black bar) during voltage steps to +60 
mV for 50 ms (n ≥ 5). ShK-Dap22 measurements were conducted in a solution used previously 
(Sokolov et al., 2007). Greater inhibition by ShK-Dap22 of the hetero-tetramer compared to the 
homomers was statistically significant [Kv1.1, p=0.01 (*); Kv1.2, p=0.001 (**) – measured by a 
Student’s t-test]. 
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more uniform (Fig. 6.4c). One subpopulation of Kv1.1/1.2 hetero-tetramers is known to 
bind ShK-Dap22 with an unexpectedly high affinity (Middleton et al., 2003). Accordingly, 
30 pM ShK-Dap22 substantially blocked IK from Kv1.1-1.1-1.2-1.2 yet proved ineffective at 
this low concentration against either Kv1.1 or 1.2 homomers (Fig. 6.5g), mirroring the 
displacement by this toxin of 125I-αDTX bound to Kv1.1-1.2 and Kv1.2-1.2 containing 
channels (see Chapter 5). This pronounced selectivity for the hetero-oligomer illustrates the 
potential utility of ShK-Dap22 in differentiating K+ currents.  
Unlike Kv1.1-1.1-1.2-1.2, IK mediated by Kv1.4-1.6-1.1-1.2 and Kv1.4-1.6-1.3-1.2 
channels displayed fast inactivation over tens of ms (Fig. 6.6a-c, Table 6.1) imbued by the 
free N-terminus of the leading Kv1.4 subunit (Rettig et al., 1994). Surprisingly, this rapid 
decay occurred in the presence of one Kv1.6 subunit, which possesses a domain known to 
disallow N-type fast inactivation in heteromers containing Kv1.4 (Roeper et al., 1998). It is 
possible that the functionality of this domain was attenuated due to its N-terminus being 
constrained in the second concatenated domain. Analysis of the currents elicited by 
depolarising voltage steps revealed similar gK-V relations for these channels (Fig. 6.6d, 
Table 6.1), well fitted by a single Boltzmann function, consistent with a uniform 
population of expressed channels. The dose responses for inhibition of these two channels 
by TEA showed somewhat different sensitivities (Fig. 6.6e); both sets of data were well-
described by a Hill slope of 1 with KD values for Kv1.4-1.6-1.1-1.2 and Kv1.4-1.6-1.3-1.2 
of 36 and 78 mM, respectively. Despite Kv1.3 and 1.4 homo-tetramers being insensitive to 
αDTX (Stuhmer et al., 1989), these heteromeric channels retained some sensitivity to 100 
nM of this toxin with 78% block (± 5%; n = 8) of IK from Kv1.4-1.6-1.1-1.2 and 70% block 
(± 2%; n = 9) of IK from Kv1.4-1.6-1.3-1.2. However, these 2 currents recovered rapidly 
upon toxin washout with respective τdissociation values of 12 s (± 3; n = 4) and 9 s (± 2; n = 8). 
Notably, DTXk discriminated between the two Kv1.4 containing tetramers even though the 
sole difference between them is the replacement of Kv1.1 with Kv1.3 in domain III. 
Consistent with the exclusive inhibition by DTXk of channels containing Kv1.1 (Akhtar et 
al., 2002), its inclusion was shown to greatly enhance susceptibility of IK to this toxin (Fig. 
6.6a,b,f). Indeed, DTXk at low concentrations (≤ 10 nM) almost exclusively blocked IK 
mediated via the Kv1.1-containing tetramer while, at 100 nM, this toxin gave only partial  
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Figure 6.6│Similar Kv1.4-containing hetero-tetrameric channels are distinguishable by 
dendrotoxink and tetraethylammonium. a and b, The effect of 10 nM DTXk on IK from Kv1.4-
1.6-1.1-1.2 and Kv1.4-1.6-1.3-1.2 induced by 500 ms voltage steps from -100 to 0 mV. Control 
trace in black; drug effect in gray. c, Representative current traces of Kv1.4-1.6-1.1-1.2 in 
response to depolarising steps from -100 to +80 mV in 20 mV increments; for clarity, similar 
data from Kv1.4-1.6-1.3-1.2 is not shown. d, gk-V relations assembled from peak outward 
currents from Kv1.4-1.6-1.1-1.2 (●) and Kv1.4-1.6-1.3-1.2 (○). e, Concentration dependence for 
TEA inhibition of IK from Kv1.4-1.6-1.1-1.2 (●) or Kv1.4-1.6-1.3-1.2 (○) assayed by pulses to  
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inhibition of IK from Kv1.1-free hetero-oligomer (Fig. 6.6f). Hence, DTXk can clearly 
differentiate between these otherwise indistinguishable channel subtypes. 
 
6.6 Increasing the number of Kv1.4 α subunits in a channel heightens the resistance to 
inhibition by peptide toxins  
A fourth tetramer, Kv1.4-1.2-1.2-1.2, was also expressed to provide a comparison with 
Kv(1.4-1.2)2 in examining the effect of the number of Kv1.4 subunits on a channel’s 
pharmacology. HEK cells were transiently transfected with Kv1.4-1.2-1.2-1.2-pIRES2-
EGFP using Lipofectamine 2000, and for Kv(1.4-1.2)2 channels, a HEK stable cell line was 
used. Inhibition of Rb+ efflux through these 2 channels was quantified in the presence of 
several concentrations of various toxins (Fig. 6.7). In earlier studies (see Chapter 5), Kv1.4-
1.2 containing channels were found to be virtually insensitive to most toxins at 10 nM. 
Therefore, the dose of toxins used for these experiments was increased. KTX, which blocks 
neither Kv1.4 nor Kv1.2 homomers was also used to ensure that any attenuation of Rb+ 
efflux observed was not due to non-specific effects resulting from high toxin doses. As was 
expected, neither channel was blocked by 500 nM of this toxin (Fig. 6.7). As αDTX, HgTX 
and MgTX have been most extensively characterised on Kv1.4-1.2 channels in experiments 
so far (Chapter 5), they were tested here. Also included was the Dendroaspis polylepis 
homologue of αDTX, DTXI. In all cases, channels containing only 1 copy of Kv1.4 were 
more sensitive to inhibition than those containing 2, the extent of which varied depending 
on the toxin used (Fig. 6.7). Consistent with MgTX and HgTX being the most potent 
blockers of Kv1.4-1.2 channels, they also inhibited Kv1.4-1.2-1.2-1.2 to a greater extent. 
Most interesting was the difference between the homologues αDTX and DTXI. At 10 nM, 
αDTX had little effect on Rb+ efflux through either channel, whereas at this concentration, 
DTXI clearly distinguished them. A ten-fold increase in concentration of this toxin saw any  
0 mV (n=5) and fit by the Langmuir isotherm as in Fig 6.5f. f, Inhibition by 3 DTXk 
concentrations of IK from Kv1.4-1.6-1.1-1.2 (open bar) or Kv1.4-1.6-1.3-1.2 (grey bars), 
assayed at ≤ 0 mV showed a significant sensitivity difference, measured by a Student’s t-tet [1 
nM, p=0.00029 (*); 10 nM, p=0.0002 (**); 100 nM, p=0.00034 (***)]. 
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Figure 6.7│A comparison of the effect of Kv1.4 subunits on the inhibition of Rb+ efflux through 
Kv1.4- and 1.2-containing channels by various peptide toxins. Averages (n=16) are plotted ± 
S.E.M. KTX, which is unable to block either Kv1.4 or Kv1.2 is included to ensure that 
attenuation of evoked Rb+ efflux by high concentrations of other toxins is specific. 
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“repulsive” effect of Kv1.4 abolished with the channel containing only 1 copy; complete 
block was observed - a result not achieved by MgTX nor HgTX. While 
electrophysiological refinement of these results will be needed, it appears that toxins are 
affected differently both by the presence of Kv1.4 and the number of subunits. It could be 
argued that differences observed between the 2 channels could be as much a result of an 
increase in the sensitive Kv1.2 subunits, as a decrease in “repulsive” Kv1.4. However, a 
demonstration previously that the presence of only 1 sensitive subunit in a channel confers 
near maximal activity of DTXk (Akhtar et al., 2002), makes this unlikely. 
 
6.7 Discussion 
A long-term aim of re-creating native Kv channel heteromers is to understand their 
pharmacology and, eventually, develop drugs to aid identification of subtypes in vivo; 
control of α subunit stoichiometry is crucial for this. The extensive validation of 3 ‘native-
like’ Kv1 heteromers demonstrated that the concatenation can generate uniform populations 
of channels, allowing measurement of their biophysical and pharmacological parameters 
for the first time. The successful expression of these representative channels, containing 
combinations of 5 neuronally-predominant α subunits, highlights that this technology 
should be able to recreate any subtype of the numerous K+ channel families found in 
various tissues (Gutman et al., 2003b). As extensive future developments are required to 
generate these Kv1 channels associated with the requisite β subunit partners (Rettig et al., 
1994; Shamotienko et al., 1997), criteria adopted herein for the purpose of subtype 
identification rely largely on pharmacological characteristics known to be unaffected by 
these cytoplasmically-located auxiliary proteins.  
It was clearly demonstrated here that the properties of hetero-tetramers are not necessarily 
predictable from the parental homo-tetramers; by showing that Kv1.1-1.1-1.2-1.2 displays 
greater susceptibility to ShK-Dap22 than the respective homomers. Despite the fact that the 
selectivity of peptide toxins for heteromeric channels has been largely unknown, these 
toxins have been widely used to dissect native currents. For example, Kv1.1 and 1.2 
subunits have been shown to have a role in µ opioid receptor-mediated inhibition of 
GABAergic inputs into basolateral amygdala neurons (Finnegan et al., 2006). αDTX, DTXk 
and TsTX-Kα inhibited the effect of the µ opioid receptor agonist D-Ala2, N-MePhe4, Gly-
 151 
ol-enkephalin (DAMGO), on miniature inhibitory post synaptic currents, decreasing their 
frequency (Finnegan et al., 2006). Given that all 3 toxins proved effective, it seems likely 
that they are acting on Kv1 hetero-tetramers containing at least one Kv1.1 and one Kv1.2 α 
subunit. 
Although Kv1.4 and Kv1.3 homo-tetramers are insensitive to αDTX and DTXk (Grissmer 
et al., 1994; Hopkins, 1998), the native-like heteromers containing these subunits were 
found to be blocked by either toxin, provided subunit(s) from sensitive homomers were 
present. This newly-revealed pharmacology makes Kv1.4-containing heteromers candidates 
for native, rapidly-inactivating DTX-sensitive currents, such as those found to shape the 
action potentials in the axon initial segment of layer 5 pyramidal neurons (Kole et al., 2007), 
or the low-threshold IK of the medial nucleus of the trapezoid body of the calyx of Held 
(Dodson et al., 2002). In particular, similar biophysical and pharmacological properties 
make Kv1.4-1.6-1.1-1.2 a candidate to shape temporal precision in octopus cells of the 
mammalian cochlear nucleus (Dolganiuc et al., 2000). Improved interpretation of these and 
other attempts to establish the molecular identity of native channels will be greatly aided by 
empirical determination of the pharmacology of physiologically-relevant heteromers, a 
process initiated by the advances achieved here. 
Examining the pharmacological influence of Kv1.4 subunits in heteromeric channels (in 
this and Chapter 5) revealed MgTX and HgTX to be more potent than the other toxins 
investigated on Kv1.4-1.2 containing channels. However, at low (10 nM) doses on Kv1.4-
1.2-1.2-1.2 channels, DTXI was as effective as MgTX and HgTX and more so at higher 
concentrations. While Kv1 blockers isolated from scorpion toxins (including MgTX and 
HgTX) inhibit channels by physically occluding the pore, the DTXs are hypothesised to 
bind off-centre, interacting predominantly with 3 subunits (Imredy and MacKinnon, 2000). 
This could be an advantageous feature for DTXs when blocking channels containing only 1 
Kv1.4 subunit, as this “repulsive” element could be avoided, perhaps explaining the potent 
block of Kv1.4-1.2-1.2-1.2 by DTXI. However, αDTX did not have the same effect 
suggesting that the nature of DTX binding to Kv1 channels is not the sole factor. That said, 
proportionally the αDTX elicited attenuation of Rb+ efflux through Kv1.4-1.2-1.2-1.2 was 
more so than Kv1.4-1.2 with increased toxin concentration. While DTXI and αDTX, differ 
by only five residues, studies to date have shown that three of these changes occur in a 
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region important for DTXI binding to channels [see Table 2.1, Fig. 2.5, (Katoh et al., 2000; 
Wang et al., 1999a)]. While this is used explain the increased binding of DTXI to rat brain 
membranes compared with αDTX, it does not explain the potency of DTXI binding to 
channels containing one Kv1.4 subunit. Presumably, the smaller the area that contacts with 
a channel, the easier it would be to avoid the repellent lysine residue present in Kv1.4 
subunits. Future site-directed mutagenesis studies of the DTXI Lys19/Tyr/17/Trp37 triad of 
residues would be necessary to determine whether this extra binding site is in fact 
responsible for the enhanced inhibition of Kv1.4-1.2-1.2-1.2 channels by DTXI. The 
construction of concatemers consisting of one Kv1.4 subunit and various combinations of 
other α subunits would answer questions as to the role of other subunits in this enhanced 
inhibition. 
The new cassette cloning methodology described in this Chapter allows quick and easy 
generation of constructs to address technical questions, such as the influence of the number 
of Kv1.4 subunits in a channel on peptide toxin binding, as examined here with the 
expression of a fourth tetramer. It is now possible to design and produce a series of 
constructs which would allow specific questions to be answered, thereby, increasing 
understanding of the interactions of brain Kv1 channels with their inhibitors. Furthermore, 
this technology could be applied to examine the biophysical properties of such channels, for 
example investigating the effect on inactivation kinetics, of various combinations of Kv1.4 
and 1.6 subunits in heteromers. 
To date, no neuronal currents produced by heteromeric Kv1 channels have had their 
underlying subunit compositions unambiguously identified. The large number of selective 
Kv1 toxins now available, in combination with this new concatenation technology, 
provides a route towards that long-sought goal. Here, the successful expression of 
tetrameric combinations of 5 α subunits, and trafficking to the surface as single proteins 
such that their distinguishing characteristics were measurable, represents a major first step. 
Moreover, these recombinant channels now serve as authentic drug targets for therapeutics 
to control neuronal excitability and synaptic transmission. 
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Chapter 7 
General Conclusions 
 
 
Developing tools for studying Kv1 channels, and finding inhibitors of therapeutic value, 
require determination of the functional properties of structurally-defined channels. The 
necessity for investigating neuronally-occurring heteromeric α subunit combinations is 
clearly demonstrated in this study. Recombinant expression of oligomers with the requisite 
defined stoichiometry requires concatenation of α subunit genes. Such channels provide 
authentic targets for drug discovery, and heteromer-specific blockers can be used for 
elucidating the molecular basis of neuronal K+ currents.  
 
In this study, expression of Kv1.1-1.2 α subunit containing channels via electroporation of 
CHO cells with cRNA prepared from pSFV1-Kv1.1-1.2 provided the necessary proof of 
concept for such an approach. Previous studies had demonstrated that when expressing 
such dimeric constructs 2 copies of the resultant protein combine to form a tetrameric 
channel of the expected size (Akhtar et al., 2002). Binding of radio-labelled αDTX to the 
channels in this study further confirms the tetrameric assembly, as 4 α subunits are required 
for binding of the toxin (Tytgat et al., 1995). The most selective blockers identified, thus far, 
for the Kv1 channel family are pore-blocking peptide toxins isolated from venoms. As 
these bind to the external surface of channels provided by α subunits, the internally-acting 
auxiliary β subunits which do not affect the pharmacological properties were not included. 
Expression levels of surface targeted, intact proteins in mammalian cells proved adequate 
for functional characterisation of the resultant channels via electrophysiological recordings, 
experiments not performed in the previous study (Akhtar et al., 2002). A source of 
recombinant channels for setting up and optimising a non-radioactive Rb+ efflux assay was 
also provided by this method. Results achieved with this and the more time-consuming 
electrophysiological protocols were generally in agreement but with some inconsistencies 
likely due to inherent differences in the assays (see below). Despite this, both assays 
identified the blocking ability of the same compounds.  
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Development of HEK cell lines stably expressing the Kv1.1-1.2 construct and other Kv1.X-
1.2 containing channels provided a more convenient and plentiful source of targets for 
screening potential inhibitors. Initially, biophysical and pharmacological properties of 
Kv1.1-1.2 and 1.6-1.2 containing channels were compared identifying DTXk as a 
distinguishing ligand. With more similar protocols employed, and a more consistent source 
of channels provided by stable cell lines, there was greater consistency between the data 
from electrophysiological and Rb+ efflux assays (see below). The improved source of 
recombinant channels, coupled with further Rb+ efflux assay validation, facilitated the 
setting-up of an automated system for Rb+ efflux measurements of these and the other 
Kv1.X-1.2 containing channels resulting in a truly high-throughput assay platform.  
 
When designing protocols for high-throughput screening measurements, several factors 
must be taken into consideration depending on the experiment priorities. The purpose of 
such a screen is to test as many compounds as possible in the search for inhibitors and, in 
doing so, only analyse promising leads by more time-consuming methods. To achieve this 
aim, the protocol employed must be balanced between getting maximum information on a 
particular compound, with the possibility of missing potential blockers but having a more 
time/cost effective assay and, therefore, screening more compounds. With these 
considerations in mind, a single concentration of toxin was applied initially in this study, 
determined from previously established effective ranges. In some instances, this may have 
resulted in distinguishing toxins not being identified but in these cases the degree of 
distinction is likely not sufficient for future therapeutic consideration. For example, some 
toxins may block all channels at the selected dose, but distinguish between them at much 
lower concentrations. The considerations detailed above were also taken into account when 
dealing with variations in the data obtained. In an initial screen, a yes or no answer is 
required as to whether the test compound inhibits the channel in question. Some scatter in 
the data is acceptable as long as this decisive outcome can be achieved. Therefore, the 
numbers of wells used in the plate for control and each toxin are chosen on this basis. 
Increasing the number of wells for each condition should reduce data scatter but that will 
reduce the quantity of compounds that can be screened per plate. The use of stable cell lines 
for these experiments gave more consistent results with smaller error bars, thereby, 
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reducing the scatter in the data. Having performed the initial screen, the automated assay 
can be exploited further both to clarify any unusual results and to obtain additional 
information about channel inhibition by the compounds in question. In this study, the Rb+ 
efflux assay was validated for determining inhibitory constants for interesting blockers, 
information which can confirm their discrimination of different channels, refining the pool 
of toxins chosen for further analysis. Likewise, the action of toxins that appeared to inhibit 
Kv1.4 containing channels was confirmed simply by increasing the number of 
concentrations of toxin tested (the cost of toxin is prohibitive for full dose response curves). 
 
In the main, results achieved from Rb+ efflux experiments were consistent with those 
determined by electrophysiological and radio-labelled toxin binding techniques. There were 
some exceptions which are important to note and address. In experiments conducted with 
CHO cells, differences existed in the sensitivities measured by the various methods for the 
Kv1.1-1.2 containing channels when inhibited by 4-AP and αDTX. While Rb+ efflux 
through these channels was almost completely blocked by 4-AP IK was not, with a 
component of the current seemingly insensitive. Some possible reasons for this are 
addressed in the Chapter 4 Discussion. Reassuringly, these dissimilarities were not evident 
upon repeating these experiments with channels stably expressed in HEK cells. Likewise, 
discrepancies in sensitivity of the CHO-expressed channel to αDTX when measured by the 
2 techniques were not evident in the HEK expressed channels. Use of BSA in solutions and 
silanised plastic for Rb+ efflux experiments in HEK cells may have reduced adherence of 
the toxin to plasticware used, thereby increasing the amount available for binding to the 
channels. There were also some differences between Rb+ efflux and radio-labelled toxin 
results. For example, MoTX did not block Rb+ efflux through Kv1.3-1.2 channels but did 
displace 125I-αDTX bound to the same channels; NxTX displaced the labelled toxin bound 
to both Kv1.2-1.2 and 1.3-1.2 with same efficacy but Rb+ flux through the latter was 
inhibited to a much lesser extent. Displacement but not inhibition of flux by a toxin could 
be attributed to the use of higher concentrations in the former but this does not explain the 
observed binding of 125I-αDTX to Kv1.4-1.2 containing channels where little flux inhibition 
was achieved, even at increased concentrations, or the fact that the same labelled toxin did 
not bind specifically to tetramers containing just 1 copy of Kv1.4 (Kv1.4-1.6-1.1-1.2 and 
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Kv1.4-1.6-1.3-1.2). While it is possible that the longer incubation with toxin in the 
displacement experiments compared with the flux assay could help to overcome the 
“repulsive” action of Kv1.4 subunits, the lack of binding to channels containing only 1 
copy of this subunit is confusing. Given the increased size of the tetrameric construct 
compared with that of the dimer and the subsequent reduction in expression levels (data not 
shown), it is possible that there was not sufficient channel expression to bind appreciable 
amounts of toxin. The fast dissociation constant of the unlabelled toxin from these channels, 
as measured electrophysiologically, could also contribute but this would be expected to be a 
factor when measuring binding to the channels made from dimers, evidence of which was 
not clear from the results obtained. 
 
The pharmacological characterisation of 5 Kv1.X-1.2 containing oligomers was an 
important step in elucidating the interactions of peptide toxins with heteromeric rather than 
homomeric channels. The Rb+ efflux data obtained from experiments performed with many 
peptide toxins on this channel series, gave some insight into the contribution to toxin 
inhibition of the various α subunits within the channel. It is, thus, deduced that the 
composite subunits can be termed necessary, permissive or repulsive. In many instances, 
the presence of only one copy of a subunit with sensitivity for a toxin will result in block of 
the channel; such subunits are deemed “necessary”. Also, in the majority of cases, any 
other α subunits in the channel that are insensitive to the toxin in question do not have a 
negative effect on the block, and, therefore, could be described as “permissive”. One 
exception to this is Kv1.4. No known toxins inhibit Kv1.4 monomers. Furthermore, the 
presence of even one copy of this subunit in a channel can negate the effects of three 
sensitive or “necessary” subunits. Thus, in such instances Kv1.4 can be termed “repulsive”. 
It was also revealed that the peptide toxins investigated can behave in an unexpected 
fashion highlighting the importance of screening heteromeric combinations of α subunits. 
MoTX for example, has been shown to inhibit IK from Kv1.2, and to a lesser extent 1.1 and 
1.3 homomers expressed in Xenopus oocytes (Kharrat et al., 1996). It could, therefore, be 
hypothesised that at least one of these three subunits would be “necessary” in a heteromer, 
that any Kv1.6 subunits present would be “permissive” and presumably any Kv1.4 subunits, 
“repulsive”. However, MoTX blocked Rb+ efflux through Kv1.2 homo-tetramers only and 
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did not inhibit Kv1.1-1.2 or 1.3-1.2 containing channels despite the presence of 2 pairs of 
sensitive subunits in each. This could be attributed to potency. However, in radio-ligand 
displacement studies, MoTX displaced 125I-αDTX from Kv1.3-1.2 containing channels 
(albeit with high levels of non-specific binding remaining) as well as channels containing 
only Kv1.2 subunits, but not channels composed of two copies of Kv1.1-1.2. This suggests 
that the toxin may be more sensitive to homomeric combinations of channels. An important 
next step would be to investigate inhibition by MoTX of Kv1.1 and 1.3 homomers in the 
same assay to confirm the homomeric selectivity of the toxin. Taken together this 
demonstrates, again, the necessity of working with physiologically relevant α subunit 
combinations when studying the interactions between channels and their inhibitors. 
 
While concatenating 2 α subunit genes provides channels composed of two copies of each 
subunit, many heteromers isolated from mammalian brain are composed of three or four 
different α subunits. The next step in studying native-like Kv1 channels, therefore, was the 
concatenation and expression of four α subunit genes in a single construct. The cassette 
cloning system described herein is a simple and convenient system for achieving this goal. 
Its modular nature allows easy swapping of one or more subunits, potentially with those 
found to be mutated in diseased states, and the strategy of holding all the domains in the 
same ORF means constructs can be expressed with any number of the positions filled – 
demonstrated by expression of some of the dimeric channels. The tetramers produced to 
date were biophysically and pharmacologically characterised and proved distinguishable 
based on the resultant profiles. For the first time, these novel properties allowed putative 
definition of the molecular basis of several K+ currents recorded from neurons (see Chapter 
6 Discussion). Profiling of more native combinations will no doubt aid in this task.   
 
This thesis sought to define the pharmacology of heteromeric Kv1 channels mimicking 
those in mammalian brain, to progress towards the ultimate goal of finding specific 
blockers of channels as a source of potential therapeutics. Selective inhibition of channel 
subtypes would also lead to a better understanding of their role in neurons. To date the 
inhibitory activites of peptide toxins have been studied mainly on homomeric Kv1 channels. 
It was therefore necessary to understand the interaction of these blockers with channels 
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composed of heteromeric combinations of α subunits. Recombinant expression of various 
dimeric combinations of α subunits provided a source of channels and a Rb+ efflux assay 
was validated for the quantitive and qualitative analysis of the pharmacological properties 
of the proteins. Generation of stable cell lines and automation of the Rb+ efflux assay made 
large scale screening of potential blockers a possibility. Following proof of concept studies, 
the pharmacology of the Kv1.X-1.2 dimer series was extensively characterised. This 
process increased the known number of Kv1 α subunits sensitive to some of the toxins 
investigated. Furthermore, the contributions of the various subunits in a channel to toxin 
inhibition were described and toxins identified that did not fit the pattern. Identification of 
the features responsible for these unusual characteristics could prove useful in the design of 
heteromer-specific blockers. Development of a modular cloning system for the expression 
of all four α subunits of a Kv1 heteromer allows the expression of any neuronally isolated 
channel, thereby providing an invaluable range of authentic targets for the development of 
therapeutics. Characterisation of the biophysical and pharmacological profiles of three such 
channels allowed putative identification of the α subunit combinations responsible for 
recorded neuronal currents, an important step forward in K+ channel research. 
 
Going forward, this novel cloning system must be exploited fully to produce a range of 
targets for further studies. While investigation of externally binding pore blocking peptides 
only requires the expression of α subunit genes, it is desirable to improve the recombinant 
technology to express the associated β subunits, thereby fully recreating native channels. 
The development of stably expressing cell lines would allow the employment of more, high 
throughput techniques such as automated patch-clamp (Qpatch) for biophysical and 
pharmacological profiling. In continuing the work described herein the first step would be 
to use the new cloning system to produce constructs that once expressed as stable cells lines 
could be used to answer questions raised in this thesis. Investigating the interaction of Kv1 
homomers (especially Kv1.1 and 1.3) with MoTX, would confirm or reject the hypothesis 
that MoTX preferentially inhibits channels composed of homomeric rather than 
heteromeric combinations of subunits. In a similar way, constructs containing one Kv1.4 
subunit and various combinations of other subunits could be used to examine the influence 
of subunits other than Kv1.4 on the inhibition of Kv1.4 containing channels by, for 
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example, HgTX, MgTX, αDTX and DTXI. With as many constructs as possible expressed 
stably, the scope for the techniques that can be used to profile them is increased.  
Site-directed mutagenesis is a logical next step to build on the information gained during 
the course of this study. A possible approach for investigating the potency of DTXI on 
channels containing one Kv1.4 subunit is given in the discussion of Chapter 6. When 
profiling the pharmacology of the Kv1.X-1.2 series of dimers the most unexpected results 
came from MoTX. This was the one toxin that does not fit with the “necessary”, 
“permissive” and “repulsive” model for predicting the pharmacology of Kv1 channels 
composed of heteromeric combinations of α subunits. Scorpion toxins that block ion 
channels contain three or four disulphide bridges with most K+ channel blockers containing 
three. The position of these bonds is highly conserved: for three disulphide-bridged toxins; 
C1-C4, C2-C5, C3-C6 and for four bridged toxins; C1-C5, C2-C6, C3-C7, C4-C8. 
However, MoTX not only has 4 disulphide bridges but they are also in different places; C1-
C5, C2-C6, C3-C4 and C7-C8. This results in the α helix being connected to different 
strands of the β-sheet instead of the same strand. This affects the position of some residues 
and therefore could affect the pharmacological properties of the toxin (Fajloun et al., 2000). 
While mutagenesis studies to return the disulphide bridges to the conserved positions 
resulted in less potent inhibition of Kv1.2 and 1.3 homomers (Fajloun et al., 2000), there is 
no evidence as to the effect this would have on heteromeric combinations of channels. 
Perhaps the altered bridging is what confers the toxin with its unusual pharmacological 
profile and similar alterations to other more potent but less selective blockers could result in 
greater selectivity perhaps combined with enhanced potency. The high-throughput assay 
described in this thesis together with the cloning strategy for the quick and easy assembly 
of tetrameric combinations of α subunits will allow the screening of large numbers of 
mutants against many combinations of Kv1 channels. While a peptide toxin is unikely to be 
used in a clinical situation, it could act as a template for the design of a small molecule with 
the same key functional groups. Alternatively, the channel expression and screening 
technologies described herein could be used to search compound libraries from a variety of 
sources in the search for lead compounds for future therapeutics.        
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Appendix A: Composition of buffers for K+ channel surface labelling 
 
 
         PBS      Blotto  
 
138 mM NaCl     10 mM Tris - pH 8.0 
26.7 mM KCl     0.15 M NaCl 
14.7 mM KH2PO4    4% non-fat milk powder 
81 mM Na2HPO4 
       
pH 7.4        
 
 
 
Mounting Medium 
  
p-Phenylenediamine (10 mg/ml) in PBS, pH 9.0, diluted 1:10 in glycerol, mixed in the dark, 
aliquoted and stored at -20°C. 
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Appendix B: Composition of buffers for the Rb+ flux assay when using 
CHO cells 
 
 
          Rb+ Loading Buffer        25 mM Hepes Wash Buffer 
  
5.4 mM RbCl      0.1 mM KCl 
 150 mM NaCl      155.3 mM NaCl 
 2 mM CaCl2      2 mM CaCl2 
 0.8 mM NaH2PO4     0.8 mM NaH2PO4 
 1 mM MgCl2      1 mM MgCl2 
 5 mM Glucose     5 mM Glucose 
 25 mM Hepes      25 mM Hepes 
 
 pH 7.4       pH 7.4 
 
 
     75 mM K+ Stimulation Buffer   Ionization Prevention Buffer 
 
 75 mM KCl      1 % HNO3 
 80.4 mM NaCl     0.1% CsCl 
 2 mM CaCl2 
 0.8 mM NaH2PO4 
 1 mM MgCl2 
 5 mM Glucose 
 25 mM Hepes 
 
 pH 7.4 
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Appendix C: Composition of buffers for the Rb+ flux assay when using 
HEK cells 
 
 
        Modified Wash Buffer    Modified Stimulation Buffer  
 
 0.1 mM KCl      75 mM NaCl 
149.9 mM NaCl     75 mM KCl 
2 mM CaCl2      2 mM CaCl2 
1 mM MgSO4      1 mM MgSO4 
5 mM Glucose     5 mM Glucose 
10 mM Hepes      10 mM Hepes 
 
pH 7.4       pH 7.4 
 
 
150 mM K+ Modified Stimulation Buffer                       Ionization Prevention Buffer 
  
150 mM KCl                                                                   0.1 % CsCl  
0 mM NaCl 
2 mM CaCl2                                                                                         
1 mM MgSO4 
5 mM Glucose 
10 mM Hepes 
 
pH 7.4 
 
 
 
